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PREFACE 
 
 
This text is taken from the postgraduate thesis, which one of the authors (A.B.) 
developed for the degree of Medical Physicist in the School on Medical Physics of the 
University of Florence. 
The text explores the feasibility of quantitative Magnetic Resonance 
Spectroscopy as a tool for daily clinical routine use. The results and analysis comes from 
two types of hyper spectral images: the first set are hyper spectral images coming from 
a standard phantom (reference images); and hyper spectral images obtained from a 
group of patients who have undergone MRI examinations at the Santa Maria Nuova 
Hospital. 
This interdisciplinary work stems from the IFAC-CNR know how in terms of data 
analysis and nanomedicine, and the clinical expertise of Radiologists and Medical 
Physicists. 
The results reported here, which were the subject of the thesis, are original, 
unpublished, and represent independent work. 
 
   
Chapter 1 
 
INTRODUCTION 
 
Proton magnetic resonance spectroscopy (MRS) is provided as an option by most 
manufacturers and is becoming more common in clinical practice, particularly for prostate 
and neurological applications. Although MRS can be performed on nuclei such as 31P and 13C, 
proton (1H) MRS is the easiest and least expensive spectroscopy for all MRI system because 
requires only a test phantom and a common software package which automate acquisition 
sequences and post-processing for metabolites quantification. Non-proton spectroscopy 
indeed requires radio frequency (RF) coils tuned to the Larmor frequency of other nuclei 
plus matching preamplifiers, hybrids, and a broadband power amplifier. Sometimes 
however, the efficient implementation of MRS acquisition protocols is beyond the 
expectations for most MR technologists, therefore MR physicists are often called in to 
perform MRS procedures to evaluate whether problems with proton MRS are due to 
equipment malfunctions, software problems, or operator errors.  
In this thesis we focus on some of these problems. 
 
1.1 - Single Voxel Spectroscopy 
 
Techniques for quantitative localized in vivo magnetic resonance spectroscopy 
(qMRS) have been available for 30 years and were used in countless research projects [Ref. 
91, 136, 218 - 219]. The potential value of qMRS in a clinical setting has especially been 
demonstrated in the characterization of pathologic tissue changes, where the diagnosis is 
not evident in MR imaging and in tissues that are not readily available to biopsy (e.g., 
intracerebral tumors) [Ref. 220]. Despite the fact that localized in vivo MR spectroscopy is 
noninvasive, and produces quantitative biochemical information [Ref. 137], its use in clinical 
routine examinations is still very limited. There are several reasons for this.  
First, as MR images are closely linked to anatomical structures, their interpretation 
is for clinical radiologists much more intuitive than that of MR spectra. To interpret MR 
spectra correctly, knowledge about the signal acquisition and signal artifacts is mandatory. 
To obtain this knowledge, training is required with experienced spectroscopists, which is 
not possible in most clinical centers. Furthermore, background knowledge about cellular 
metabolism is also necessary in order to meaningfully interpret the limited number of 
metabolites in MR spectra. Compared to the immense amount of different structural 
proteins, enzymes, and metabolites of a human cell, the very few substances that can be 
measured using MR spectroscopy yield a low specificity and sensitivity in the context of 
pathologic tissue changes.  
Second, clinical MR scanners and manufacturer’s spectroscopy postprocessing 
software have greatly improved and became user-friendly in the recent years. However, 
most of them do not offer the possibility to quantify the measured metabolites in units of 
amount (expressed in mole) per unit volume. This implies that the user can only interpret 
peak area ratios, which is for some applications sufficient, but not for all. The inherent 
weaknesses of using peak area ratios [Ref. 137], is that the total number of quantifiable 
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metabolites decreases by one, and alterations in the peak ratio cannot be assigned 
unambiguously to changes in the concentration of the numerator or denominator. More 
serious are the indications that peak area ratios may introduce larger errors than qMRS 
[Ref. 221, 222]. In order to calculate ‘‘absolute’’ quantities of measured substances in a 
clinical setting, freely available quantification methods like AMARES, AQSES, QUEST, 
TDFDFIT [Ref. 74, 128, 149, 150, 223, 224], the free software package jMRUI [Ref. 145], or 
commercially available software like LC-Model can be used [Ref. 75]. Most of these 
applications have no, or only very rudimentary image display possibilities, preventing the 
study of MR spectra together with MR images of the same examination. As the currently 
available offline applications for qMRS do not support DICOM network transfer 
functionality, the acquired spectral data need to be exported manually from the main MR 
console (or satellite workstation), to a computer for quantification having one of the above 
mentioned programs installed. Additionally, none of the applications for qMRS offer any 
DICOM-typed reporting functionality, and therefore, reporting of quantitative results is 
normally done by the creation of text/html files and/or images (e.g., jpg, gif), or by manual 
insertion of screenshots of reports into a picture archiving and commu- nication system 
(PACS). Overall, in order to do clinical qMRS, most data handling has to be done manually, 
which is time consuming, and prone to errors. The time and financial cost of additional 
personnel makes qMRS unattractive in centers with intense workload, and prevents its use 
on a larger scale.  
Third, qMRS of pathologic tissues requires the availability of normal values for 
comparison. Normal values, even within an organ (e.g., brain tissue), depend on voxel 
localization and subject age [Ref. 225 - 227]. Moreover, as large voxel sizes are needed for 
qMRS due to low signal-to-noise ratio, there is always partial volume effect of tissues with 
different MR spectroscopic profiles. The high variability of MR spectroscopic results further 
decrease the specificity and sensitivity of this method for the use in clinical routine. To 
minimize this variability, patient MRS results have to be compared to valid reference 
concentrations, and multiple databases per organ and age must be available. The currently 
available software packages do not offer any possibility of building up and using normal 
value databases, which prevents simple and easy to use comparison of patient data with 
reference data.  
 
1.2 - Aim of this thesis 
 
The aim of this thesis is to make quantitative MRS a more valuable and attractive 
tool for daily clinical routine use. 
In the first part of this thesis we will give a brief overview of clinical proton MRS, 
discussing some common clinical MRS problems. In the second part we will focus on 
developing a standard protocol to confront the accuracy of different MR scanners from 
different vendors, analyzing water signals with the open source software package jMRUI – 
v5.0.  
Then we will discuss some examples of T1, T2 estimation of water and metabolites 
at the 3T MR scanner of A.O.U. Meyer using the Siemens phantom aimed to quantitation of 
metabolites concentration. Some examples of quantitation coming from S.G.D. and S.M.N. 
hospital will be described too.  
In the final part some examples of in vivo prostate cancer spectroscopic data analysis 
will be described, illustrating the potential of MRS, the differences between Philips data 
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analysis software and jMRUI-v5.0, and showing the problems in the daily clinical routine 
acquisitions too. These MRS data have been acquired at Philips Achieva 1.5 T (S.M.N. 
hospital). 
As a future development we will describe an interesting application of PMMA and 
gold nanoparticles to MR, using the know-how coming from biophotonics research at IFAC-
CNR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
MAGNETIC RESONANCE SPECTROSCOPY 
 
 
Usually the principal application of MR is imaging, but a very important and 
promising application is the Magnetic Resonance Spectroscopy. This section is a short 
review of proton magnetic resonance spectroscopy based on the Report of AAPM MR Task 
Group #9 [Ref. 13]. More details about the theory and principles of MRI can be found in [Ref. 
9, 10, 11, 12].  
 
2.1 - Larmor equation 
 
If all the proton nuclei in a mixture of molecules had the same Larmor frequency, 
magnetic resonance spectra would be limited to a single peak. However, the magnetic B0 
field ‘‘seen’’ by a nucleus is shielded by the covalent electron structure surrounding the 
nucleus. Therefore, nuclei with different chemical neighbors will have slightly different 
resonance frequencies (f) given by 
  
𝑓 = 𝛾𝐵0(1 − 𝜎cs) 
 
where σcs is a screening constant (σcs ≪ 1). This small change in the resonance frequency is 
the basis for magnetic resonance spectroscopy. Note that both the overall molecular 
structure and the proton(s) position within the molecule will determine σcs or f.  
 
2.2 - Magnetic resonance signal  
 
In spectroscopy, the strength of the MR signal is proportional to the number of 
protons at that frequency. While spectroscopy can be described in the time domain, MRS 
data are usually displayed in the frequency domain. In the frequency domain, the area under 
a specific peak is proportional to the number of protons precessing at that frequency.  
2.2.1 - Parts per million (ppm) scale  
 
Although one could use a frequency axis to display spectra, two problems arise with 
this type of display. One, the axis is proportional to B0 which means that peak locations on 
an axis will depend on the B0 field used for the measurement. Second, there is no natural 
material to represent zero frequency. To overcome these problems, NMR chemists mix the 
substance to be measured with a reference, then express the frequency difference between 
the substance and the reference as a dimensionless quality, δcs (in parts per million), given 
by  
𝛿cs =
𝑓s − 𝑓ref
𝑓ref × 10−6
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where fs is the frequency of the substance (laboratory frame) and fref is the frequency of the 
reference (laboratory frame). The reference used in proton spectroscopy is TMS 
(tetramethyl-silane, (CH3)4Si), and its single peak is assigned a chemical shift of 0.0 ppm. 
Another reference used is DSS (2,2-dimethyl-2-silapentane-5-sulfonate), and its major peak 
is at 0.0 ppm.  
Since TMS and DSS are toxic, they are not used in in vivo spectroscopy. When spectra 
are acquired without TMS or DSS, another equation for δcs is as follows: 
𝛿cs =
𝑓s
𝑓transmitter
106 + offset     
where fs is the frequency of the sample (rotating frame), ftransmitter is the frequency of the 
transmitter (laboratory frame), and offset is a constant that references the ppm scale to an in 
vivo standard, which for 1H brain spectroscopy, is usually the CH3 peak of N-acetyl aspartate 
(NAA) with a chemical shift value of 2.01 ppm. Knowing the chemical shift of a peak, the 
value for offset can be determined by using the measured frequency (fs) of the peak, the 
chemical shift of the peak (δcs), and the transmitter frequency. Once determined, this offset 
can be used to change all frequencies in a spectrum from Hz to ppm. For example with δcs = 
2.01 ppm, fs =71.8 Hz, and ftransmitter = 63 863 375 Hz, the offset is equal to 4.700 ppm. In 
this example the transmitter frequency was centered on water. Note that the resonance 
frequency of water is dependent on temperature, with frequency increasing as temperature 
decreases (Δppm/Δ°C = ―0.01 ppm/°C) [Ref. 14] At  37°C, δcs of water is 4.70 ppm; at 20°C, 
δcs of water is 4.87  ppm. Therefore water is not a good internal standard for the ppm scale.  
2.2.2 -  J coupling  
 
Another feature of spectra is peak splitting or multiplets, caused by J coupling (spin–
spin)[Ref. 15 -18]. With J coupling, the nuclear magnetic energy levels are split by quantum 
interactions, via covalent bond electrons, with other nuclei whose magnetic moments may 
be parallel or antiparallel to the main magnetic field. J coupling can be homonuclear (e.g., 1H 
- 1H) or heteronuclear (e.g. 1H – 13C).  
A more intuitive classical explanation of J coupling can be given as follows. Suppose 
nucleus A is coupled to nucleus X and nucleus X has an equal probability of being in a 
parallel or an antiparallel spin state. Nucleus A will be split into two equal peaks. The peak 
of nucleus A that is coupled to nucleus X parallel to the main field will have higher 
frequency; the peak of nucleus A that is coupled to nucleus X antiparallel to the main field 
will have lower frequency. For lactate, the CH3 nucleus at 1.31 ppm is coupled to the CH 
nucleus at 4.10 ppm, and the CH3 nucleus is split into two equal peaks (doublet) separated 
by 6.93 Hz [Ref. 15]. Peak splitting from J coupling has the same absolute value in Hz, 
regardless of the main magnetic field strength. 
In [Ref. 15, 19] have a list of J coupling constants for other metabolites. J coupling 
also causes phase evolutions that cause peak and baseline distortions that vary with echo 
time (TE, Ref. 16 -18) and field strength. J coupling explains the wellknown observation that 
the lactate doublet has negative peaks (180° out of phase) at TE 140 ms for a PRESS 
sequence. Less known is that J coupling also causes overlapping multiplet peaks within 
individual metabolites and between metabolites to cancel each other due to dephasing at 
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later echo times under typical in vivo field homogeneities. For this reason, metabolites such 
as glutamine (Gln), glutamate (Glu), and gamma-Aminobutyric acid (GABA) cannot be 
measured using long echo times (TE > 50 ms) with in vivo proton spectroscopy [Ref. 19],
 
although Ref. 20 uses a CPMG type sequence to overcome this problem. Some spectroscopy 
techniques use J coupling to eliminate overlapping peaks, in order to quantify concentra-
tions of an underlying peak allowing the in vivo measurement of metabolites such as GABA 
[Ref. 21-23].  
 
2.2.3 - Spectral resolution 
 
The acquisition time depends on spectral resolution: 
 
∆𝑓 =
1
𝑇Acq
=
𝐵𝑊
𝑛𝑠
 
 
where 𝑇Acq is the acquisition time, BW the bandwidth and ns the number of samples. 
 
2.2.4 - Brain metabolites  
 
Metabolites containing protons that can be measured in the brain at 1.5 Tesla 
include N-acetyl aspartate (NAA), considered to be present only in neurons and dendrites; 
N-acetylaspartylglutamate (NAAG), suggested to be involved in excitatory 
neurotransmission; creatine/phosphocreatine (Cr), a reservoir for high energy phosphate 
for generation of adenosine triphosphate (ATP);  
choline/phosphocholine/glycerophosphorylcholine (Cho), associated with glial cell 
membrane integrity; GABA, glutamate, and glutamine, important in neurotransmission, but 
very difficult to quantify in vivo due to multiplets and J coupling effects; myo-inositol (M-
Ins), important in cell growth and possibly a glial cell marker; and sometimes lactate, 
indicative of anaerobic metabolism. Although NAA is considered a neuronal marker, changes 
in NAA from normal may reflect reversible changes in neuronal metabolism rather than 
irreversible changes in neuronal density. Ross et al. have a good discussion on 
neurometabolism and the clinical application of in vivo 1H MRS [Ref. 24, 25].  
 
2.2.5 - Prostate metabolites  
 
Prostate cancer is the most prevalent non-cutaneous cancer in men and the second 
leading cause of cancer-related death in western countries [Ref. 26]. The use of MR in 
prostate cancer management is emerging, and the demand from patients and clinicians is 
increasing as a result of the growing number of men suspected of having prostate cancer 
due to the uptake of blood tests for prostate-specific antigen.  
In vivo the detection of molecules is limited to those present at tissue levels of more 
than 0.5–1 mM. The first metabolite studied with in vivo was citrate, and a decrease in its 
resonances’ amplitude was observed in prostate cancer patients compared with healthy 
controls [Ref. 27]. Next, the choline methyl resonance gained attention as an increase in this 
signal in prostate cancer was observed [Ref. 28, 29]. Due to frequency-selective water and 
lipid suppression, only signals of major metabolites between approximately 2.2 and 3.8 ppm 
8                                                                                                                MAGNETIC RESONANCE SPECTROSCOPY -  DATA ANALYSIS FOR CLINICAL APPLICATIONS 
 
  
remain in prostate spectra, which also includes those of creatine and polyamines. Because 
the choline and creatine methyl signals are only separated by a relatively small chemical 
shift difference, a non-optimal B0 homogeneity, causing line broadening, will lead to signal 
overlap. The presence of polyamine signals between these two metabolite signals further 
complicate their separation. This potential overlap led to the introduction of the signal ratio 
of choline plus creatine divided by citrate (Cho+Cr)/Cit [Ref. 28, 30] and its inverted 
counterpart [Ref. 29] as a marker for prostate cancer.  
In this thesis, the major variables that can influence the (Cho+Cr)/Cit ratio are 
discussed. An overview of the main metabolites detectable in the commonly obtained MR 
spectra of the prostate, their function, and the acquisition parameters that influence their 
appearance in the spectrum will be provided. These metabolites form the basis for the 
(Cho+Cr)/Cit ratio, of which the intensity not only depends on the underlying physiology, 
metabolism, and anatomy, but also on the acquisition parameters. This latter aspect is 
particularly relevant for the citrate and polyamine signals.  
Although 1H-MRSI has great potential in prostate cancer management, its use in 
routine clinical practice is limited. A major hurdle toward clinical use is that several 
acquisition and processing steps still rely on manual procedures, in particular post-
processing of the data, including quality control, and displaying easily visualized and 
interpretable results [Ref. 31]. A generalized classification scheme for prostate MRS to assist 
in prostate cancer management is not available. In the last part of this thesis some examples 
of in vivo measurements ratio will be discussed, looking for the introduction of a protocol-
dependent classification scheme that could increase the clinical usability of the metabolite 
ratio for prostate cancer management. 
The main metabolite signals in commonly obtained 1H-MRSI spectra of the prostate 
are choline, creatine, polyamines and citrate. 
Choline 
Different compounds containing a choline moiety can contribute to the main peak at 
about 3.2 ppm in in vivo 1H-MR spectra. These are free choline, glycerophosphocholine, and 
phosphocholine, but also contributions from protons in taurine, ethanolamines and myo-
inositol may be present at this spectral position [Ref. 32]. As convenient shorthand, we refer 
to this composite resonance as the “choline” signal. Choline-containing metabolites are 
precursors and breakdown products of the phospholipid phosphatidylcholine, a major cell 
membrane compound [Ref. 33]. In prostate cancer cell lines, an increase in choline is 
observed due to an altered phospholipid metabolism [Ref. 34]. This alteration is probably 
due to an increased expression and activity of choline-kinase, a higher rate of choline 
transport, and an increased phospholipase activity [Ref. 33, 34].  
The choline moiety has nine chemically equivalent protons of three methyl groups 
resonating as a singlet around 3.19 ppm and two methylene groups, resulting in two 
multiplets at 4.05 and 3.50 ppm [Ref. 15]. Because the intensity of these multiplets is very 
low in in vivo MR spectra of the prostate, it is common to only evaluate the nine-proton 
singlet at 3.19 ppm.  
Creatine  
 
Both creatine and phosphocreatine contribute to the methyl resonance observed at 
about 3.0 ppm in 1H-MRS of the prostate (referred to, in combination, as the creatine signal 
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in this thesis). Creatine plays a crucial role in the energy metabolism of tissues [Ref. 35], as 
phosphocreatine acts as a spatial and temporal buffer to maintain constant adenosine 
triphosphate levels in tissue through the creatine-kinase reaction. The stromal cells consist 
predominantly of smooth muscle cells [Ref. 36], which are expected to contribute most to 
the creatine and phosphocreatine signals.  
Creatine has five non exchanging protons: a methyl group resonating at 3.03 ppm 
and the methylene group at 3.93 ppm. The protons in each group are chemically equivalent 
and uncoupled, resulting in two singlets with a ratio of 3:2. The concentration of creatine 
was estimated with in vivo MRS at 4.4±0.8 mM [Ref. 30] and with ex vivo high-resolution 
magic angle spinning spectroscopy as being between 7.6±2.7 and 9.7 ± 4.4 mmol/kg for 
normal and cancer tissue (no significant differences) [Ref. 37].  
Citrate  
 
The production and storage of citrate is one of the main functions of the prostate. 
Citrate is an intermediate in the tricarboxylic acid cycle. In most organs, citrate is quickly 
oxidized in the tricarboxylic acid cycle and is therefore only present in low concentrations. 
In contrast, prostate epithelial cells actively produce citrate and store it in the luminal space, 
where it is one of the main components of the prostatic fluid [Ref. 38]. Prostate tissue has 
high levels of zinc, which inhibits mitochondrial (m-)aconitase activity. This leads to the 
buildup of a high concentration of citrate [Ref. 39]. In prostate cancer, a decrease in zinc 
levels is observed that leads to activation of m-aconitase and the consequential oxidation of 
citrate [Ref. 39]. At the same time, the morphology of the prostate gland changes, leading to 
a loss of luminal space, which might also cause a decrease in the observed (or total) citrate 
levels.  
Citrate contains two methylene groups that are magnetically equivalent. The four 
protons of these groups form a strongly coupled AB spin system. The difference in chemical 
shifts, the midpoint of the chemical shifts, and the scalar coupling (J) of this spin system 
depend on pH [Ref. 40, 41] and cation concentration [Ref. 41] and are approximately 0.15 
ppm, 2.61 ppm, and 16.3 Hz, respectively. Because citrate is a strongly coupled spin system, 
its shape depends on interpulse timing, pulse shape, TE, and field strength [Ref. 40 - 46].  
In the first in vivo prostate studies at 1.5T, stimulated echo acquisition mode 
(STEAM) and point resolved spectroscopy (PRESS) techniques were used for volume 
localization [Ref. 28, 47]. One advantage of the STEAM for these data is its ability to use a 
very short TE (at the expense of the general loss of half of the signal in a stimulated echo). In 
this way, the strongly coupled protons of citrate will have limited phase evolution, which 
will result in an almost completely in-phase citrate signal. Integration of the area of the 
citrate peak(s) will then result in maximal signal intensity. For the PRESS sequence, 
generally longer TE ̓s are used for prostate MRS, and dispersive parts can be present in the 
spectrum that affect the peak area by cancellation with absorptive parts in simple 
integration. Several studies have been performed to determine the PRESS pulse timing with 
maximum absorptive signal at the central lines of the citrate signal [Ref. 42, 45, 48-51].  
In the physiological range of pH (6.8 -7.4), variations in chemical shifts of 3.2 Hz and 
variations in the midpoint of the chemical shifts of 0.025 ppm were observed using a 400-
MHz magnet [Ref. 40]. The changes in J are minimal in this pH range [Ref. 40, 41], but the 
concentrations of zinc, calcium, and magnesium also influence the value of this coupling 
[Ref. 41], which may have significant effects on the in vivo resonances. Ref. 52 shows that 
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small changes in chemical shifts and J can have substantial influences on the spectral shape 
of citrate. Although a relation was found in vitro between the spectral shape of citrate and 
the ion concentration or pH, variations in the spectral citrate shape in vivo are difficult to 
relate to ion concentrations or pH, as these are difficult to measure. For a good fitting, it is 
necessary to use a model signal that is based on values that closely resemble those present 
in vivo.  
The RF pulses that are used to suppress the large lipid and water signals may 
adversely affect the citrate signals. Often dual frequency-selective pulses are used to 
suppress both these signals simultaneously, mainly by Mescher-Garwood (MEGA) [Ref. 53] 
or double band-selective inversion with gradient dephasing (BASING) [Ref. 54, 55] pulses. 
These pulses selectively invert the lipid and water resonances and are surrounded by 
crusher gradients. Their bandwidth and position in the frequency domain should be 
sufficient to invert all lipid signals, but distant enough from the chemical shift of citrate. 
When the bandwidth of the lipid inversion pulse is too broad, this will cause a decreased 
signal intensity of citrate. As a consequence, healthy spectra may get a “cancerous” profile. 
Therefore, a good adjustment of the dual frequency pulses is essential for obtaining 
consistent results. Spectrally selective refocusing pulses may be used instead of signal 
suppression pulses, which prevent refocusing of lipids by simultaneous volume and 
frequency selection [Ref. 56, 57]. Care should be taken that these pulses fully excite or 
refocus the citrate spins and leave the lipid signals untouched.  
For proper selective suppression or spectral excitation, the homogeneity of the B0 
field is critical. Poor homogeneity will not only negatively affect spectral quality as it causes 
broadening of the spectral lines, it will also decrease the effectiveness of frequency selective 
pulses. Broadened or shifted fat and water signals can suffer from diminished suppression 
and components of these signals may overlap with the resonances of interest. In addition, in 
the case of shifted or broadened spectral lines of citrate, the metabolite can be influenced by 
the frequency selective pulses for lipid and water suppression leading to decreased citrate 
intensities.  
The dependence of the citrate signals on interpulse timing can also be exploited for 
spectral editing. By varying this timing (at a constant TE) in such a way that citrate is 
inverted in one measurement and in phase in the next measurement, uncoupled resonances 
can be removed from the spectrum by subtraction [Ref. 58, 59]. In this way, rapid citrate 
imaging without lipid suppression is possible.  
Polyamines - Spermine  
The tissue concentration of polyamines in the prostate is relatively high. Because 
spermine is the dominant polyamine in the prostate, we focus on this compound. Like 
citrate, polyamines are stored in the luminal space, and a very strong correlation between 
the citrate and spermine concentration is reported for prostatic fluid specimens [Ref. 60]. A 
hypothesis for the strong correlation is the formation of complexes between citrate and 
spermine since citrate is negatively charged, whereas spermine is positively charged. In this 
way ionic neutrality can be achieved [Ref. 60]. Polyamines play a role in prostatic growth 
and differentiation [Ref. 61]. A decrease in spermine has been suggested as a marker for 
prostatic malignancy [Ref. 61, 62]. In prostate cancer, a decrease in spermine or polyamine 
levels is observed compared with benign tissue using MRS [Ref. 62]. The incorporation of 
polyamine levels measured with MRS to improve detection of prostate cancer has been 
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proposed and has yielded an increased sensitivity at the same specificity [Ref. 63].  
Spermine is a coupled spin system and, in addition to its amine groups, contains 10 
methylene groups. These methylene protons consist of symmetrical pairs, giving a total of 
four protons that resonate approximately at 1.81 ppm with further groups of four at 2.11 
ppm, 3.13 ppm, 3.12 ppm, and 3.18 ppm [Ref. 64]. These chemical shifts are pH-dependent 
[Ref. 65] and these quoted chemical shifts were measured at pH 7. At a higher pH, the amine 
groups are more protonated, and the chemical shifts are therefore more downfield [Ref. 65]. 
Protons near a nitrogen atom show the largest pH dependence. Spermine proton chemical 
shifts are also sensitive to temperature differences. For that reason, when one wants 
perform a phantom measurement to determine the shape of spermine (with a certain 
sequence), the phantom should be measured at body temperature and have a pH in the 
physiological range. Local chemical shift correction to improve the separation between 
choline and spermine is hindered by the dependence of the chemical shift of spermine on 
the environment. Also, usually no water reference measurement is done that could be used 
for this purpose. The metabolites in the prostate spectrum are unsuitable for this purpose, 
as the chemical shift of citrate is environment-dependent and choline is not always well 
separable from spermine.  
As with citrate, TE and interpulse timing influence the spectral shape of spermine 
and leading to dispersive components in the resonances. If dispersive parts are present in 
the 3.1-ppm region, this can negatively affect the apparent intensity of choline and/or 
creatine resonances. Furthermore, BASING and MEGA pulses that are used for simultaneous 
water and lipid suppression invert the 2.1- and 1.8-ppm resonances of spermine [Ref. 66]. 
Without these pulses and crushers, the 2.1- and 1.8- ppm resonances could be helpful for 
decomposition of spermine from the 3.1-ppm region. These measured spermine shapes can 
be used as prior knowledge for spectral fitting of the metabolites [Ref. 66]. T1 and T2 values 
of spermine reported in the literature are obtained in vitro and the T2 values were rather 
short and dependent on the presence of ions and proteins [Ref. 65]. No in vivo data of 
relaxation times of spermine spins is available yet.  
 
2.3 - Quantitative spectroscopy: evaluation of the metabolite ratio 
 
Prostate spectra can be evaluated qualitatively or (semi-)quantitatively. Qualitative 
guidelines are based on visual inspection of the height of choline compared with the citrate 
height [Ref. 67, 68]. A more quantitative approach is the determination of metabolite 
concentrations in prostate spectra with the help of a reference compound. If the tissue 
water concentration is known in the volume of interest and the individual metabolites are 
fitted reliably, water can be used as an internal reference to obtain absolute prostate 
metabolite concentrations [e.g., Ref. 30, 69]. This requires additional time for a water 
reference measurement, which is often not available.  
More practical, and sufficient for diagnostic purposes, is the use of the (Cho+Cr)/Cit 
ratio for classification. The usability of this ratio for prostate cancer localization was 
demonstrated in a prospective multicenter study, where an area under the receiver 
operating characteristic curve was obtained for discriminating normal peripheral zone 
tissue from cancer [Ref. 70]. Classification thresholds for the (Cho+Cr)/Cit ratio are needed 
to apply MR spectroscopy for prostate disease in clinical routine.  
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2.3.1 - Establishing the Ratio of (Cho + (Spm+) Cr)/Cit  
 
The simplest method of calculating the [(Cho+Cr)/Cit] ratio is to use integration 
techniques and calculate a ratio based on these values (integral values; see Table 2, Ref. 52).  
However, as discussed above, strong coupling effects and a long TE can produce a 
spectral shape of citrate that has an integral close to zero, and small differences in citrate 
intensity will induce very variable ratios.  
One way to circumvent this problem is by fitting the metabolites to a model signal. 
Model signals can be measured with phantom solutions [e.g., Ref. 66]. Alternatively, they can 
be simulated, when the chemical shifts and J-coupling constants are known for the 
metabolites of interest [e.g., Ref. 66, 71]. There are several software packages available that 
can be used to make model signals, including NMRSIM (part of Topspin, Bruker BioSpin 
Corporation, Billerica, Massachusetts, USA), GAMMA [Ref. 72], and its successor VeSPA 
(http://scion.duhs.duke. edu/vespa/), and jMRUI (java Magnetic Resonance User Interface, 
http://www.mrui.uab.es/mrui/). The model signals can be used to obtain fits of the 
metabolites in the time [Ref. 73, 74] or frequency domain [Ref. 75]. The output is typically a 
relative metabolite concentration value incorporating the amount of protons of the 
metabolite. These relative concentrations depend on the goodness of the fit and correlation 
between fits; for overlapping metabolites, overestimation of one metabolite at the cost of 
underestimation of another will result in a ratio that is unrepresentative for the tissue if the 
metabolites have a different amount of protons. Therefore, if the metabolites are fitted 
individually with such a quantification algorithm, the concentrations must be reconverted to 
their relative spectral amplitude prior to summation and division in the ratio. This 
procedure removes individual information gained from each metabolite but improves the 
reliability of the ratio. For spectral patterns dominated by absorption components, this 
amplitude ratio will give comparable results as the integral ratio. However, in contrast to 
the integral ratio, the amplitude ratio is less sensitive to the dispersive parts of citrate. The 
amplitude ratio gave good results for discrimination between different prostate tissues in a 
3T study, where the spectral citrate shape had non-negligible dispersive parts [Ref. 70].  
The fit of the individual metabolites has been used to derive the choline over citrate 
plus spermine ratio [Cho/(Cit+Spm)], a ratio that takes the counteracting effects of the 
increase in choline and decrease in citrate and spermine in prostate cancer into account 
[Ref. 66]. However, due to the inherent uncertainty in individual metabolite quantification 
[Ref. 76], it is usually recommended to use a [(Cho+Cr)/Cit] ratio rather than a simpler 
choline/citrate (or [Cho/(Cit+Spm)]) ratio. In most studies, spermine is not fitted 
individually [e.g., Ref. 87, 76-79], and spermine resonances are included in the creatine and 
choline fits [Ref. 63]. The ratio should therefore be seen as the [(Cho+(Spm+)Cr)/ Cit] ratio.  
 
2.3.2 - Classification Thresholds for (Cho + (Spm+) Cr)/Cit Ratio  
 
In the previous sections, the acquisition parameters that influence the prostate 
metabolite signals, and consequently the (Cho+(Spm+)Cr)/Cit ratio, were discussed. In 
principle, it is possible to correct for T1, T2 relaxation, and J-modulations and obtain a 
normalized ratio that is acquisition-independent. However, this requires knowledge of their 
precise values, which are not available (current reports show quite some variation in T1, T2), 
and these values may also vary for different tissue morphology (e.g., cancer, benign disease, 
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and normal prostate). Moreover, fitting of the individual metabolite signals is also 
necessary, which can be challenging due to the overlap between choline, creatine, and 
spermine signals. For that reason, we cannot work with a normalized ratio, and the 
[(Cho+Cr)/Cit] ratio thus has to be established per institution or per protocol.  
The mean [(Cho+Cr)/Cit] plus two or three times the standard deviation of normal 
tissue was used as a cutoff value to classify voxels as cancerous [Ref. 29, 80-82]. The use of a 
five-point classification scale based on the mean and standard deviation of the 
[(Cho+Cr)/Cit] ratio of normal prostate tissue has been proposed [Ref. 68]. Because the 
[(Cho+Cr)/Cit] ratio is higher for normal transition zone tissue than for peripheral zone 
tissue, the cutoff values vary for the two tissues. Tables 2 and 3 in Ref. 52 provide an 
overview of reported mean [(Cho+Cr)/Cit] ratios for normal peripheral zone tissue at 1.5T 
and 3T. For 1.5T, the used TE ̓s in these studies are quite similar (120–130 ms) and often the 
same platform and post-processing methods are used, but there is quite some variation in 
the reported [(Cho+Cr)/Cit] ratios. At 3T, there are considerable differences between 
prostate spectroscopy packages of the vendors, with TE ̓s varying from 85 to 145 ms and TRs 
from 750 to 1300 ms (27). At 7T, optimal acquisition protocols still need to be established 
[Ref. 83]. The studies reporting [(Cho+Cr)/Cit] values for 3T spectra are still limited, but it 
can be expected that the metabolite ratios for normal tissue at 3T will be more variable 
among studies, and quite different [(Cho+Cr)/Cit] values would be obtained for the same 
patient measured on systems of different vendors. The dependency on acquisition and post-
processing protocols asks for assessment of the mean and standard deviation of normal 
tissue per institution or per used protocol.  
The derived classification thresholds are not necessarily institution-dependent. If 
the same acquisition protocol and post-processing method are used at different institutions, 
the [(Cho+(Spm+)Cr)/Cit] ratio can be compared between these institutions. Previously, no 
significant differences in the (Cho+Cr)/Cit amplitude ratio were found of any of the benign 
prostate tissues between patients among different institutions [Ref. 70]. Furthermore, the 
amplitude ratio gave good reproducibility in repeated measurements of the same subjects 
[Ref. 84].  
 
2.4 - Magnetic field homogeneity  
 
Spectral resolution is determined primarily by three factors. First, the transverse 
relaxation time (T2) of the metabolite is inversely proportional to the ideal peak width. 
Second, the separation between peaks (in Hz) increases linearly with magnetic field 
strength. Third, the local magnetic field inhomogeneities widen and distort the spectral lines 
from their ideal Lorentizian forms. Maximum homogeneity is accomplished by adjusting DC 
currents in the gradient coils and room temperature shim coils. The name for this process is 
‘‘shimming,’’ which is a historical term that is derived from a time when magnetic resonance 
researchers were working on resistive pole–gap magnets and adjusted the magnetic field by 
placing thin brass shim stock between the magnet and pole faces to make them parallel.  
 
Shimming 
 
Improving magnetic field homogeneity increases SNR and narrows peak widths. 
Thus shimming improves both sensitivity and spectral resolution. Modern clinical MRI 
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systems use automated shimming routines to improve the homogeneity of the magnetic 
field by monitoring either the time-domain or frequency-domain MRS signal [Ref. 15, 88]. 
Note that the water signal (unsuppressed) is always used for shimming. In vivo a linewidth 
less than 0.05 ppm at 2-4 T is the requirement to perform MRS. 
 
2.4.1 - Test Phantom 
 
The MR system’s manufacturer will supply a test phantom, usually an 18 to 20 cm 
diameter sphere containing metabolites. These concentrations emulate in vivo 
concentrations. Because test phantoms lack many in vivo metabolites, lipids, ma-
cromolecules, and susceptibility problems, they lead to well-resolved spectra with flat 
baselines, facilitating the detection of MRS acquisition or post- processing problems. A good 
MRS phantom is also required for an effective MRS quality control (QC) program.  
Siemens supplies a spherical phantom, filled with a 0.1 M solution of NaH2C3O2 (8.2g 
Sodium Acetate) + C2H5O3Li (9.6g Lithium Lactate) [Ref. 89, Siemens Manual].  
The spectrum has a clean baseline. The acetate peak (about 1.9 ppm) and lactate 
doublet of the phantom fluid are clearly delimited and narrow. 
The lactate molecule has 2 weakly coupled resonances: a doublet (split by coupling 
to the methine [CH] proton) at 1.31 ppm, arising from 3 magnetically equivalent methyl 
(CH3) protons, and a quartet (split by coupling to the protons of the methyl group) at 4.10 
ppm, arising from the methine proton, which is usually not visible in vivo. The scalar 
coupling gives rise to a phase evolution of the methyl doublet, which depends on the echo 
time (TE). For TE = 144 ms, the resonance shows a phase of 180° leading to a negative in-
phase doublet, whereas TE = 288 ms gives rise to a positive in-phase doublet. Since only in-
phase resonances can be quantified, echo times of 144 ms and 288 ms are preferable for 
lactate detection and assignment. The coupling evolution can also be exploited for spectral 
editing techniques, increasing the sensitivity of lactate detection. 
Lactate doblet and quadruplet have a J-coupling of 6.933 Hz. 
With STEAM measurements, the lactate and acetate signals are always in phase 
(using TM = 10 ms). With spin echo measurements, the lactate and acetate signals have an 
inverted pahse if TE = 135 ms and are in phase if TE = 270 ms. 
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Siemens Manual
 
1. San Giovanni di Dio Hospital 
Siemens Aera 1.5 T
 
3. A.O.U. Meyer, Philips Achieva 3T
 
2. Santa Maria Nuova Hospital 
Philips Achieva 1.5 T 
 
  
 
Figure 1: Siemens phantom. Top left: spectrum from Siemens Manual [Ref. 89];  
top right: 1. spectrum acquisition at San Giovanni di Dio Hospital with Siemens Aera MR scanner at 1.5 T;  
middle right: 2. spectrum acquisition at Santa Maria Nuova with Philips Achieva MR scanner at 1.5 T.  
Left middle panel: spectrum acquisition at Meyer Philips Achieva 3 T; 
Bottom left: Metabolites concentration certified from Siemens; Bottom right: ID number. 
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Figure 2: Siemens phantom inserted into the Philips Achieva 1.5 T MR scanner 
at the Santa Maria Nuova hospital. 
   
Chapter 3 
 
SPECTROSCOPIC SEQUENCES 
 
 
This is a short review of the principal sequences used for T1, T2 determination and 
MRS. More details can be found in Laterbour [Ref. 9], Brix G. “Basics of Magnetic Resonance 
Imaging and Magnetic Resonance Spectroscopy” [Ref. 90], “Quantitative MRI of the Brain” 
[Ref. 143], [Ref. 144]. 
3.1 - Standard Pulse Sequences  
 
In an MR experiment, only the RF signal can be determined by measurement, which 
is induced by the rotating transverse magnetization 𝑀𝑥𝑦  in the receiver coil. Nevertheless, a 
large variety of MR experiments can be realized that differ in the way by which the spin 
system is excited and prepared by means of RF pulses before the signal is acquired. A 
defined sequence of RF pulses, which is usually repeated several times, is called a pulse 
sequence. In the following, three “classical” pulse sequences are described that are 
frequently used for MR experiments. 
 
3.1.1 - Saturation Recovery Sequence  
 
The saturation recovery (SR) sequence consists of only a single 90° pulse, which 
rotates the longitudinal magnetization 𝑀𝑧 into the 𝓍y plane. The FID signal is acquired 
immediately after the RF excitation of the spin system. After a delay time, the repetition time 
TR, the sequence is repeated. The SR sequence is described schematically by the pulse 
scheme (90°– AQ – TR) (AQ =signal acquisition period).  
If the repetition time TR is long compared to T1, the magnetization M relaxes back to 
its equilibrium state. In this case, the initial amplitude of the FID, even after repeated 
excitations, does only depend on the equilibrium magnetization M0 and does not show any 
T1 dependency. However, if the repetition time is shortened to a value that is comparable to 
T1, the longitudinal magnetization Mz will not fully relax after excitation, and the following 
90° pulse will rotate the reduced longitudinal magnetization  
 
𝑀𝑧(𝑇𝑅) = 𝑀0[1 − exp⁡(−𝑇𝑅 𝑇1⁄ )] 
 
into the 𝓍y plane. Under the assumption that the transverse magnetization after the 
repetition time TR has been decreased to zero (TR ≫T2*), the following expression is 
obtained for the initial amplitude SSR of the FID signal:  
 
𝑆SR ∝ 𝑁[1 − exp⁡(−𝑇𝑅 𝑇1⁄ )] 
 
which exclusively depends on the relaxation time TR and the number N of the excited spins 
 18                                                                                                                          MAGNETIC RESONANCE SPECTROSCOPY -  DATA ANALYSIS FOR CLINICAL APPLICATIONS 
 
 
in the sample.  
3.1.2 - Inversion Recovery Sequence 
 
In the inversion recovery (IR) method, the longitudinal magnetization is inverted by 
a 180° pulse (inversion pulse), which is followed after an inversion time TI by a 90° pulse 
(readout pulse). Immediately after the 90° pulse, which rotates the partially relaxed 
longitudinal magnetization Mz(TI) into the xy plane, the FID signal is acquired.  
The IR sequence is described by the pulse scheme (180°― TI ― 90° ― AQ). The initial 
amplitude SIR of the FID signal is directly proportional to the longitudinal magnetization 
immediately before irradiation of the read-out pulse, just as is the case in the SR method. In 
contrast to the SR sequence, however, the change in the longitudinal magnetization is twice 
as high and thus the following expression is obtained:  
 
𝑆IRS ∝ 𝑁[1 − 2exp⁡(−𝑇I 𝑇1⁄ )]⁡ 
 
The derivation of this relation is based on the assumption that the spin system is in its 
equilibrium state before it is excited by the inversion pulse. When repeating the IR 
sequence, one has therefore to make sure that the repetition time TR is markedly longer 
than the relaxation time T1.  
If the IR sequence is repeated several times with different inversion times TI, it is possible to 
sample the temporal course of the longitudinal magnetization step by step, since the initial 
amplitude of the FID signal is directly proportional to the longitudinal magnetization at time 
TI. This procedure is applied frequently in order to determine the relaxation time T1 of a 
sample. 
 
3.1.3 - Spin-Echo Sequence  
 
As explained above the temporal decay of the transverse magnetization Mxy is 
caused by two effects: fluctuating local magnetic fields and spatial inhomogeneities of the 
magnetic field B0. The transverse magnetization 𝑀𝑥𝑦 therefore relaxes not with the 
substance-specific relaxation time T2 but rather with the effective time constant T2* (T2*< 
T2). When determining the relaxation time T2, it is therefore important to compensate the 
effect of the field inhomogeneities. This can be done, as E. Hahn has shown in 1950, by using 
the so-called spin- echo (SE) sequence. This sequence utilizes the fact that the dephasing of 
the transverse magnetization caused by B0 inhomogeneities is reversible since they do not 
vary in time, whereas the influence of the fluctuating local magnetic fields is irreversible.  
In order to understand the principle of the SE sequence with the pulse scheme     
(90° ― τ ― 180° ― τ ― AQ), we initially neglect the influence of the fluctuating local magnetic 
fields and solely consider the static magnetic field inhomogeneities. Immediately after the 
90° pulse, all magnetization components composing the transverse magnetization 𝑀𝑥𝑦 point 
along the y′-axis. Shortly afterward, some components precess faster, others more slowly 
around the direction of the B0 field, so that the initial phase coherence is lost. When looking 
at this situation from a rotating frame, one observes a fanning out of the magnetization 
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components around the y ′-axis. If a 180° pulse is applied after a time delay τ along the 𝓍 ′-
axis, the magnetization components will be mirrored with respect to this axis. However, the 
180° pulse does not change the rotational direction of the magnetization components, but 
merely inverts the distribution of the components: the faster components now follow the 
slower ones. After the time t = 2τ, all magnetization components again point to the same 
direction, and the signal comes to a maximum. The 180° pulse thus induces a rephasing of 
the dephased transverse magnetization, which causes the MR signal to increase and to 
generate a spin echo. After the spin-echo time TE = 2τ, the echo decays again— as the 
original FID does—with the time constant T2*.  
Due to the rephasing effect of the 180° pulse, the spin-echo signal SSE(TE) is 
independent from the inhomogeneities of the static magnetic field: the loss of signal at the 
time t = TE as compared to the initial signal SSE(0) is determined exclusively via the 
substance-specific relaxation time T2. If one irradiates a sequence of K 180° pulses at the 
times τ, 3τ, 5τ,..., (2K―1)τ, one can detect a spin echo in between the subsequent 180° 
pulses. The envelope of the echo signals SSE(2τk) (k = 1, 2, 3, ..., K) decays exponentially with 
the relaxation time T2: 
𝑆SE ∝ 𝑁exp[−2𝜏𝑘 𝑇2⁄ ] 
The major advantage of this multi echo sequence consists in the fact that the T2 decay can 
very effectively be detected by a single measurement.  
 
3.2 - PRESS and STEAM  
 
The most common in vivo 1H spectroscopy acquisition techniques are STimulated Echo 
Acquisition Mode (STEAM, Ref. 136)
 
and Point-RESolved Spectroscopy (PRESS Ref. 91). 
The STEAM technique generates a cubic or rectangular voxel by the acquisition of three 
orthogonal slice selective 90-degree pulses. By using 90-degree pulses, a well-delineated voxel is 
created within the sample. This technique minimizes signal contamination from outside the region of 
interest. The second technique, PRESS, also generates a cubic or rectangular voxel by the acquisition 
of three orthogonal slice selective pulses, differing by using a 90-degree pulse followed by two 180-
degree pulses. The voxel generated by PRESS is not as precisely defined as that of STEAM, however, 
the signal to noise gained by using PRESS is twice as large over STEAM. 
Both STEAM and PRESS need a technique to suppress the water signal found in their voxels. 
A commonly used technique, CHEmically Selective Saturation (CHESS), is applied prior to the selected 
localization technique. Three frequency selective pulses are applied along with a dephasing gradient 
to suppress the water. 
Both of these sequences use three slice-selective radiofrequency pulses with orthogonal 
magnetic field gradients where the intersection of the slices defines the volume of interest (VOI). The 
three RF pulses produce FIDs, multiple spin echoes (SE), and a stimulated echo (STE)[Ref. 16, 138]. 
Four time intervals (τ1, τ2, τ3, τ4) associated with the RF pulses are defined as follows: τ1 is the time 
between the first and second RF pulses, τ2 + τ3 is the time between the second and third RF pulses, 
and τ4 is some time period after the third RF pulse. The FID of the first RF pulse refocused by the 
second RF pulse [SE(1,2)] occurs at 2τ1 . If 2(τ2 + τ3) > 2 τ1, the echo SE(1,2) is refocused by the third 
RF pulse to produce the spin echo, SE(2,1), at 2(τ2 + τ3). The FID from the second RF pulse refocused 
by the third RF pulse [SE(2,3)] occurs at τ1 + 2(τ2 + τ3). The FID from the first RF pulse refocused by 
the third RF pulse [SE(1,3)] occurs at 2 (τ1 + τ2 + τ3). The stimulated echo occurs at 2 τ1 + τ2 + τ3 . 
Note that all times are from the center of the first selective RF pulse. 
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In practice, both PRESS and STEAM use several crusher gradients after each RF pulse to 
dephase unwanted signals from echoes and FIDs. Although more crusher gradients can be added, this 
increases the probability of eddy current artifacts in the spectrum. Typical clinical in vivo 1H-MRS 
acquisitions have TE ̓s of 20 ms with STEAM and 30 ms or 135 ms with PRESS; TR ̓s greater than or 
equal to 1.5 s; and data acquisition times of 1 s. Research MRS groups have reduced TE from 1 to 6 ms 
with STEAM and to 13 ms with PRESS [Ref. 110, 139, 140].  
Examples of PRESS and STEAM spectra are shown in [Ref. 13, 141]. Because STEAM 
uses only 90° RF pulses with a TM period, the TE can be shorter than with a PRESS sequence, 
which reduces signal decay and distortion due to J coupling. Large and lengthy crusher 
gradients can be applied during the TM interval to dephase unwanted signals, which will 
reduce out of volume contamination [Ref. 110]. The specific absorption ratio (SAR) with 
PRESS is about twice that with STEAM. Finally, the effects of J coupling can change whether 
STEAM or PRESS is used, although the effects depend more on the TM, TE, and actual flip 
angles  chosen [Ref. 17, 18, 88, 101]. There is an additional complication in that the 
chemical shift that occurs with RF selective slices means that a particular metabolite such as 
lactate has coupled nuclei which are excited by one RF pulse, but not necessarily both the 
remaining two selective RF pulses. This can lead to signal cancellation within the voxel, 
which depends on both the type of sequence and the bandwidth of the RF pulses [Ref. 142]. 
PRESS: Point RESolved Spectroscopy 
 
PRESS is a multi echo single shot technique to obtain spectral data. A PRESS 
sequence has three slice-selective RF pulses with the form of:  
90° ―τ1 ― 180° ― (τ2 + τ3) ― 180°― τ4 ― SE(2,1)  
Usually in a PRESS sequence, τ1 = τ2 and τ3 = τ4. The TE of the SE(2,1) in this PRESS 
sequence is equal τ1 + τ2 + τ3 + τ4.  
The 90° RF rotates the spins in the xy-plane, followed by the first 180° pulse (spin 
rotation in the 𝓍z-plane) and the second 180° pulse (spin rotation in the 𝓍y-plane), which 
gives the signal.  
With the long echo times used in PRESS, there is a better visualization of metabolites 
with longer relaxation times. Many of the metabolites depicted by stimulated echo 
technique are not seen on point resolved spectroscopy, but PRESS is less susceptible to 
motion, diffusion, and quantum effects and has a better SNR than STEAM. 
 
STEAM: STimulated Echo Acquisition Mode 
 
A STEAM sequence has three slice-selective RF pulses with the form of: 
90° ― τ1 ― 90° ― (τ2 + τ3) ― 90°― τ4 ― STE. 
For the STEAM sequence, τ1 is equal to τ4 , τ1 + τ4 is the echo time, and τ2 + τ3 is called the 
mixing time (TM). An important feature of STEAM is that only half of the transverse 
magnetization prepared by the first 90° pulse is transformed into longitudinal 
magnetization by the second 90° pulse, decreasing SNR by a factor of 2. During the TM 
period, longitudinal magnetization decays with T1 rather than T2. The third RF pulse 
transforms the longitudinal magnetization stored by the second RF pulse back into the 
transverse plane to form the stimulated echo.  
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Figure 1: PRESS – Point RESolved Spectroscopy sequence scheme. Images reprinted from “Basic of MR 
Spectroscopy I, Imaging Science Educational Workshop 2008, Ulrike Dydak” 
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3.3 - Chemical shift imaging  
MR Spectroscopic Imaging (MRSI, Ref. 1) is a widely available routine clinical 
imaging tool and clinical research tool for spatially mapping and characterizes multiple 
tissue metabolites signals in vivo. This technology, which is available on many clinical MR 
scanners, has reached a remarkable degree of maturity in recent years and has stimulated 
considerable interest in clinical applications. As most MRSI development and applications 
have been focused on the brain, MRSI (as well as MRS in general) is sometimes viewed as 
having importance only within the neuroradiological community, while many others 
promising clinical applications are reaching maturity.  
To a large extent, MRSI technology is built upon earlier work developing localized 
single voxel MRS (SV-MRS). First described by Brown et al. in 1982 [Ref. 2] and further 
developed by Maudsley et al. in 1983 [Ref. 3], MRSI increasingly is supplanting SV-MRS for 
clinical applications and research due to its ability to rapidly and simultaneously assess 
tissue spatial heterogeneity of chemical concentrations. However, several technical 
challenges currently limit more widespread clinical acceptance of MRSI. Furthermore, MRSI 
historically has required a high degree of user training and integration into clinical routine 
is nontrivial.  
In general terms, MRSI uses the same phase encoding procedures that are used in 
MRI to map the spatial distribution of MR signals. In the case of 1H-MRSI, proton MR signals 
produced by metabolites within the tissue produce the signals that are imaged. The 
molecular concentrations of these metabolites are at least 10.000 times lower than water 
and metabolites produce correspondingly much lower signal strengths than does water, 
which is used to form conventional MR images. To detect enough signal above noise for 
quantification 1H-MRSI must use much larger voxel sizes in comparison to MRI. Voxel 
volumes on the order of 0.3 cc can be readily measured at 3T [Ref. 4, 5] and the use of 
surface coils and array coils allows much smaller voxel volumes on the order of 0.1 cc [Ref. 
6], or smaller. The lower spatial resolution of MRSI compared with anatomical imaging 
makes consideration of the spatial point spread function (PSF), correspondingly more 
important. The PSF expresses the fact that the combination of the phase-encoded imaging 
process and the image reconstruction process cause metabolite signals that are produced by 
one tissue voxel to bleed into the surrounding voxels, producing a blurring effect. This is 
conceptually not different from conventional MRI, but is expressed on a larger spatial scale. 
The PSF can be responsible for spectral artifacts and significant partial volume effects. 
Spatial filtering is used in the reconstruction process to reduce between-voxel signal 
bleeding and to increase the signal-to-noise ratio (SNR), but increases the effective voxel 
size. MRSI can be time consuming to acquire, making it sensitive to motion artifacts, which 
in contrast to MRI are distributed across all acquired spatial dimensions.  
MRSI is also highly sensitive to macroscopic magnetic field inhomogeneity within a 
voxel and across the volume of interest, which introduces regionally varying spectral line 
broadening. Typically, a spectral line width of less than 0.1 part per million (ppm) is 
required for quantifiable MRSI data. Accordingly, MRSI studies may require sacrificing 
coverage of some anatomical regions having strong magnetic field inhomogeneity. 
Unacceptable field homogeneity is usually present at tissue-bone or tissue-air interfaces and 
such regions are difficult to study with MRSI. In these regions SV-MRS may be the only 
choice.  
In 1H-MRSI there are often artifacts related to water and lipid signals that are related 
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to field inhomogeneity and the PSF. Water produces a much larger signal than the target 
metabolites, requiring the use of frequency selective RF pulses to presaturate the water 
signal. However magnetic field inhomogeneity associated with interfaces can produce water 
signal that is frequency shifted and the water suppression process will not suppress water 
signal being produced by interface regions. Furthermore, water signal produced by such 
regions is broadened as well, which makes signal contamination due to the blurring effect 
difficult to identify. In tissue with a large fraction of adipocytes, a lipid signal that are as 
much as 1000 times stronger than metabolite signals can be produced, producing 
problematic in terms of bleeding into nearby voxels. Because the problem of lipid and water 
signal bleeding can be so significant in 1H-MRSI, very precise spatial localization methods 
are required. Most 1H-MRSI pulse sequences use volume excitation procedures analogous to 
those used in SV-MRI to select a box shaped tissue region over which the field homogeneity 
is excellent and that does not contain adipose tissue. Alternatives are to presaturate regions 
that would produce large lipid signal, or to use lipid nulling using the Short T1 Inversion 
Recovery (STIR) [Ref. 7]. While improving overall results quality, prelocalization of a box-
shaped region inside the organ of interest can result in considerable loss of volume coverage 
in peripheral regions of the organ. Furthermore, the majority of 1H-MRSI studies to date are 
still performed using intermediate to long echo time (TE) to attenuate lipid signals due to 
short lipid signal T2 values. This is in part due to the difficulties of quantifying strongly 
overlapping multiplet resonances at short TE. However, the use of long TE results in 
substantially decreased sensitivity to the metabolite signals due to T2 loss and J-modulation 
of multiplet resonances. Improved localization performance now allows MRSI mapping at 
much shorter TE, to measure J-coupled metabolites that have traditionally been measurable 
only with SV-MRS [Ref. 8].  MRSI studies involving nuclei other than protons, usually do not 
have problems corresponding to the lipid and water problems present in 1H-MRSI, but 
signal strength in these studies is usually lower than in 1H-MRSI and the volume resolution 
must be even more coarse and this engenders more concern regarding voxel signal bleeding.  
STEAM or PRESS can either be used to acquire data from a single voxel or from 
multiple voxels using chemical shift imaging (CSI) [Ref. 2, 16, 91 - 98]. Phase encoding 
gradients are used in CSI spectroscopy to encode spatial information analogous to imaging. 
The selected CSI volume to be phase- encoded will be larger than a single volume 
acquisition. 
 
3.3.1 - Single voxel versus chemical shift imaging 
 
Proton MRS with CSI acquisition has several advantages over single voxel 
acquisitions (SVA).  
1. CSI provides better SNR as compared to two or more sequential SVA since 
the signal from each voxel is averaged for the total data collection time with 
CSI.   
2. The CSI grid can be shifted after data acquisition (similar to image scrolling), 
allowing precise positioning of a voxel after data acquisition.   
3. Many more voxels of data are collected in a practical acquisition time.   
There are also disadvantages of CSI compared to SVA.   
 24                                                                                                                          MAGNETIC RESONANCE SPECTROSCOPY -  DATA ANALYSIS FOR CLINICAL APPLICATIONS 
 
 
1. Since with CSI only the whole CSI volume is shimmed rather than each 
individual voxel as in SVA, the shim for each CSI voxel is not as good as on a 
SVA voxel in the same location.   
2. The poorer shim causes more problems with lipid contamination although 
additional techniques, such as outer volume suppression (OVS), can be used 
to reduce this problem [Ref. 92, 94, 99]. Water suppression will also vary 
across the CSI volume because of both changes in B1 and magnetic field 
inhomogeneities.  
3. Because three ‘‘slice’’ selective RF pulses are used to select the CSI PRESS or 
STEAM volume, there are imperfect slice profiles which cause problems for 
spectra from voxels near the outside of the CSI volume. The resulting 
alterations in tip angle and phase for different voxel locations will alter J 
coupling effects as a function of location that in turn will make consistent 
metabolite quantification more difficult. Non-optimal tip angles at the outer 
edges of the CSI volume also reduce SNR in the outer voxels.   
4. The minimum CSI data collection time is determined by the required number 
of phase encode steps and can become long, especially if an unsuppressed 
water reference set is required. Time cannot be reduced by decreasing the 
size of k space since this increases lipid contamination from the CSI point 
spread function [Ref. 93]. The acquisition time can be reduced by 25% with a 
circularly bounded k-space acquisition [Ref. 97], a reduced FOV and number 
of phase encoded steps across the narrow direction of the head [Ref. 100] 
(similar to a rectangular field of view in imaging), or with the echo planar 
imaging (EPI) spectroscopy approach [Ref. 95, 96]. 
5. The metabolite concentrations measured from a spectrum associated with 
one voxel actually correspond to the integrated metabolite concentrations 
over the CSI point spread function. This means the measured metabolite 
concentrations will depend on such factors as voxel location and how quickly 
metabolite concentrations change spatially throughout the brain. Since the 
point spread function usually has negative lobes (sinc function) and spectra 
quantification is done in the absorption mode, metabolite peaks from 
adjacent voxels will be added in negative phase. This will cause peak shape 
distortions because adjacent voxels usually have different center frequencies 
than the voxel of interest.  
In summary, consistent, high quality, short TE spectra in vivo are best acquired with 
the SVA technique, but time restraints limit acquiring data from only a few VOIs. CSI is best 
when more VOIs are required. A long echo time (TE >130 ms) can be used to simplify the 
spectra and reduce the lipid and macromolecule signal, which will make metabolite 
quantification reasonably consistent. However, the long TE time reduces the number of 
quantified metabolites to NAA, Cho, Cr, and lactate.  
 
3.3.2 - Signal to noise ratio 
 
Since the MRS time domain signal is complex, two frequency domain signals result 
from the Fourier transform that are typically labeled ‘‘real’’ and ‘‘imaginary.’’ These signals 
are linear combinations of the absorptive and dispersive components of the Lorentzian line 
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shape. In principle proper phase adjustments can make the ‘‘real’’ signal purely absorptive 
and the ‘‘imaginary’’ signal purely dispersive.  
The signal from a metabolite is the area under its peak. The full-width at half-
maximum value (FWHM) of the Lorentzian absorption spectral peak in Hz is defined as, 
FWHM = 1/T2*, where 1/T2* = 1/T2 + γΔB0. For an absorptive Lorentzian peak the area 
under the peak is equal to 𝜋/2 × FWHM × (peak height). For the Lorentzian dispersion 
component, the peak width is much broader and the area under the peak integrates to zero, 
so the dispersion peak is not typically used in clinical MRS analysis.  
In a well-shimmed spectrum, the peak’s height is an easily measured indicator of the 
signal. Noise in a spectrum can be evaluated by measuring the standard deviation in a 
region that contains no signal, therefore, SNR can be defined as the ratio of peak height 
divided by the rms noise [Ref. 101]. Different definition can be found in literature, but 
careful reading may be required to learn which definition a particular paper uses.  
The area of a Lorentzian peak is independent of the shim quality measured by 
FWHM, therefore a definition involving the area under the peak is a more absolute measure 
of SNR and a better parameter for testing hardware performance on a MRS phantom, 
especially for quality control (QC) and for comparing different hardware. However, in vivo, 
metabolite peaks typically overlap and the precision in determining metabolite peak areas 
depends as much on the FWHM as on the peak area SNR. Therefore, our definition of SNR is 
more pertinent for comparing in vivo data and optimizing MRS methodology. Note, however, 
that metabolite concentrations are calculated from peak areas. In addition, when comparing 
SNR between two spectra, the comparison will be valid only if identical data acquisition and 
post-processing were used. These conditions are rarely met when spectra are collected on 
MR systems from two different vendors. As an example, peak area which is proportional to 
the amplitude of the first time domain point is usually not affected by post-processing time 
domain filters, but these filters reduce noise and peak heights. Therefore post-processing 
filters change peak area SNR differently than peak height SNR.  
The magnitude of the noise is independent of the VOI size, but depends on the tissue 
volume detected by the RF coil, and increases with the square root of the number of signals 
that were added coherently (n). The magnitude of the signal is directly proportional to the 
volume of the VOI, proton density, and the number of averages (n). With averaging, SNR is 
proportional to √𝑛 .  
Averaging is a specific example illustrating the principle that SNR is proportional to 
the square root of the total signal data acquisition time [Ref. 102]. Therefore, SNR (peak 
height) will also depend on the duration of the STEAM or PRESS echo which decays with T2*, 
assuming that the data acquisition time is ≥ 5T2* in duration. The specific value of T2* will 
depend on the shim, metabolite T2*, and tissue susceptibility. A good single voxel shim in the 
brain’s parietal–occipital lobe will give a linewidth approaching 4 Hz corresponding to a T2* 
= 80 ms. In vitro on a spherical phantom, voxel shims below 1 Hz are typical corresponding 
to a T2* > 318 ms. Therefore, in vivo, an echo data acquisition time of 400 ms (5T2*) is 
sufficient, but in vitro, data acquisition times >1500 ms are required to maximize SNR. 
When comparing two different MR systems on SNR, one must ensure that both systems are 
using the same data acquisition time. Also, since in a typical in vivo 1H-MRS acquisition TR is 
≥1.5 s allowing a data acquisition time ≥1 s, SNR will increase from the longer signal 
duration obtained with better shimming.  
Depending on the system software, two of the following three parameters must be 
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set prior to a spectroscopy acquisition: the data acquisition time, the number of complex 
data points, or the sampling frequency (bandwidth) of the analog-to-digital converter (ADC). 
Setting two of these automatically calculates the other. Besides having a sufficiently long 
enough data acquisition time one must also have a high enough sampling frequency to cover 
the bandwidth of the desired spectrum. Note that this required bandwidth scales linearly 
with B0.  
SNR can be influenced by many factors, as shown in brief below.  
Eddy currents  
 
Eddy currents are induced in the magnet structure by field gradient pulses. These 
eddy currents create additional magnetic fields that add to the static field. Eddy currents can 
be classified into two categories [Ref. 103]:  
1. zero order eddy current or time-varying B0 offset which could be 
compensated with a B0 coil 
2. time-varying first or higher order gradient. 
 Zero-order eddy currents will cause a frequency-dependent phase shift during 
signal readout but no decrease in SNR from spin dephasing within the VOI. First-order eddy 
currents will dephase the spins within the VOI, decreasing SNR. Both types of eddy currents 
plus magnetic field inhomogeneities will distort peak shapes, making spectral quantification 
more difficult, especially when peak fitting to modeled line shapes. The distortion from eddy 
currents can be corrected by either dividing the 1H spectra time domain signal by the 
unsuppressed water time domain signal, dubbed QUAntification by converting to the 
LorentzIan TYpe (QUALITY) deconvolution [Ref. 104], or by doing a point by point phase 
correction of the time domain signal, again using the unsuppressed water signal as a 
reference often referred to as an Eddy Current Correction (ECC) [Ref. 105-106]. Note that 
QUALITY will correct peak distortion caused by zero- and first- order eddy currents and B0 
inhomogeneities, while ECC only corrects peak distortion for zero-order eddy currents.  
Phase cycling 
  
Physical differences between the two channels of an analog quadrature receiver can 
introduce artifacts into a magnetic resonance image or magnetic resonance spectrum.  
There will be ghosting of the peaks mirrored about zero frequency if the phase 
difference between the two channels is not 90° or the amplifier gains of the two channels 
are not equal. This is often called a quadrature ghost. If the DC offsets of the two channels 
are not equal to zero, there will be a spike at zero frequency. CYCLically Ordered Phase 
Sequences (CYCLOPS) can be used to correct for these artifacts [Ref. 107]. CYCLOPS involves 
rotating the transmitter phase by 0°, 90°, 180°, and 270°, then adding and subtracting the 
two receiver channels. CYCLOPS is usually implemented on NMR spectrometers, but not on 
whole body MR scanners because image acquisitions almost never use four acquisitions. MR 
scanners implement a reduced version of CYCLOPS, called phase cycling that toggles the 
transmitter phase between 0° and 180°. The signal obtained with the transmitter phase at 
180° is subtracted from the signal obtained with the transmitter phase at 0°. This adds the 
signal and subtracts the DC offsets. Phase cycling corrects for the DC artifact but does not 
correct for the quadrature ghost. Another purpose for phase cycling is the compensation for 
imperfect 180° flip angles in multiecho MRI acquisitions.  
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Modern digital receivers use only one amplifier plus ADC and are no longer plagued 
with unequal DC offsets, unequal gains, or non 90° quadrature, but phase cycling can still be 
useful. References 108 - 110 demonstrate that phase cycling can inhibit unwanted 
transverse magnetization and unwanted echo signals (despite gradient spoiling) from 
corrupting the spectra. Therefore phase cycling should be used with in vivo 1H spectroscopy, 
when possible. Single voxel acquisitions, which normally use 16 or more data averaging, 
allow 8 cycle phase cycling. However, CSI acquisitions rarely have enough data averaging 
per phase encode step to allow full phase cycling, but even if only two data acquisitions are 
used at each k space point, it is important to phase cycle the third selective RF pulse 0 and 
180 degrees to reduce the echo contamination from the third RF pulse FID. RF pulse FIDs 
arise from non-ideal slice profiles and imperfect RF pulse flip angles.  
The problem with water 
The concentration of pure water is 55.6 M or 111 M for 1H. The water concentration 
in the brain, calculated from an average MR visible brain water content of 70%, is 36 M [Ref. 
111]. In vivo 1H spectroscopy requires water suppression because the 36 M water signal 
overpowers the 1–10 mM signal of the metabolites. Water suppression is normally 
accomplished with one or more narrow band (60 Hz) radio frequency CHemical-Shift 
Selected (CHESS) pulses [Ref. 112] followed by spoiling gradients at the beginning of the 
STEAM or PRESS acquisition. This is similar to frequency selective fat RF saturation in 
imaging. The quality or degree of water suppression depends on the in vivo shim, the 
stability and linearity of the RF amplifier at low power output, the severity of eddy currents, 
and the number and implementation of the CHESS pulses. For maximal water suppression, 
the transmitter voltage (flip angle) of the CHESS pulses (s) must be adjusted for each exam. 
Even though water suppression is optimized for the voxel or volume (CSI) of interest, the 
water is suppressed globally and will reduce out of volume water contamination. Normally, 
an unsuppressed water spectrum is acquired by turning off the water suppression RF pulse 
(s). This signal can then be used for an ECC or QUALITY correction as well as a reference for 
absolute metabolite quantification [a mode detailed bibliography can be found in Ref. 13]. 
 
The problem with lipids 
 
Another problem associated with in vivo proton MR spectra is the ubiquitous 
presence of lipid peaks. These lipid peaks may obscure other peaks of less abundant 
metabolites. Lipid contamination usually arises from outside the skull due to non-ideal 
selective slice profiles [Ref. 114]. Often increasing TE can reduce the spectral contribution of 
lipids, but this strategy also reduces the SNR ratio of all peaks in the spectrum. Other 
strategies include moving the STEAM or PRESS VOI away from the skull, outer volume 
saturation bands [Ref. 92, 94, 114, 115] an inversion pulse [Ref. 113] similar to Short TI 
Recovery (STIR) MR imaging, and/or spatial k-space data processing before the CSI 
reconstruction. Note that STIR will also add T1 weighting to the proton metabolites reducing 
metabolite SNR. Along with lipids, there are broad macromolecule [Ref. 113, 114, 115] peaks 
under the spectrum. As with lipids, these peaks are reduced with long TE times and/or the 
lipid STIR technique. However unlike lipids, macromolecule peaks are a natural component 
of brain tissue present within the selected voxel. Therefore improved slice profiles, outer 
volume suppression, and improved gradient spoiling, all techniques that reduce lipid 
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contamination, will not reduce macromolecule peaks.  
 
3.3.3 - Prescan adjustments 
 
Before the spectral data are acquired, the MR system will initiate a prescan routine 
that is often automatic. The prescan will shim the VOI, set the RF transmitter center 
frequency, set the RF transmitter gain, set the receiver gain, and set the flip angle for the 
water suppression pulses. On some systems, the VOI will have to be shimmed manually or 
semi-automatically. If second order or higher resistive shims are available, optimum shim 
results are obtained by using the higher order shims plus linear shims in a global shim 
before collecting the localizer images, followed by a localized voxel shim using the linear 
shims only. The data acquisition without water suppression is acquired by setting the 
water-suppression pulses to zero flip angle, and should be obtained just before or just after 
the water-suppressed acquisition. The water data is used for ECC or QUALITY eddy current 
correction and sometimes it is used as a reference value for absolute metabolite 
quantification.  
 
3.3.4 - Post-processing 
 
There are many post-processing techniques used in proton MRS [Ref. 75, 112, 116 - 
123]. The vendors of clinical MR systems usually provide post-processing software that 
provides a good starting. The individual steps embedded in these software packages are 
described below. In general, these packages fit model peaks to the observed spectrum in the 
frequency domain with the vendor supplying suggested starting peak templates. However, 
all post-processing packages will require user tweaking for each different acquisition 
technique. Some packages also require that the user first acquire in vitro data on a set of 
metabolites, to be used for a priori knowledge. The a priori knowledge can either be 
measured experimentally or simulated. This will also have to be repeated for each 
acquisition technique. Typically as much or more time is required to analyze spectra as is 
expended in developing a MRS protocol and acquiring the MRS data.  
Although raw and fitted spectra are displayed in the frequency domain, fitting can be 
done in either the time or frequency domain. The time domain fit is inherently simpler and 
slightly more flexible, but the frequency domain fit will give exactly the same final result, 
provided that all the limitations of the discrete FT are taken into account [Ref. 126, 127, 128, 
130]. We will discuss some typical techniques and provide illustrations for each step. 
Several references provide a general introduction to post-processing [Ref. 101, 125, 129]. 
The signal received in proton MRS, whether it is a free induction decay (FID) or the last half 
of an echo (i.e., STEAM, PRESS), can be described mathematically as either a damped 
complex exponential (one component) or a sum of damped complex exponentials (multiple 
components). The conventional display of an FID signal received in quadrature is as plots of 
‘‘real’’ signal versus time and ‘‘imaginary’’ signal versus time. The conventional display of 
the FID in the frequency domain is as a correctly phased absorption (real) spectrum 
although sometimes the dispersive (imaginary) and absolute spectra are displayed as well. 
However, metabolite concentrations are represented by the absorption spectrum.  
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Zero filling  
 
Zero filling in the time domain is equivalent to a sinc convolution (interpolation) in 
the frequency domain. This interpolation improves the visual display of the data in the 
frequency domain, although no additional information is added. This is identical to image 
interpolation in MRI. For example, an N point FID has N real and N imaginary, or 2N points 
sampled at Δt intervals. After Fourier transformation, there are N real and N imaginary 
points with frequency spacing equal to 1/(NΔt). The spectral width (SW) of the spectrum is 
1/Δt with the abscissa going from SW/2 to -SW/2. Zeros can be added to the end of the FID 
to decrease the frequency spacing over the same bandwidth.  
 
Apodization filter  
 
The signal in a free induction decay contains the signal from the metabolites being 
studied and the noise in the detector channels. A line broadening filter decreases the 
received signal at the end of the sampling window, which increases the signal-to-noise ratio 
in a spectrum (peak area definition of SNR) but increases the linewidth of the peak in the 
frequency domain. This filter multiplies the time domain FID by the filter before 
transforming to the frequency domain. This weighing of the time domain data is known as 
apodization. A line broadening filter can also ensure that the FID is not truncated to 
eliminate sinc ringing (leakage). Examples can be found in [Ref. 13, 123].  
 
Water suppression filter  
 
Often the water suppression used with proton spectroscopy does not completely 
eliminate the water signal. Post-processing with a convolution difference filter can be used 
to eliminate any residual water signal [Ref. 101, 125, 131]. This filter applies a low-pass 
filter to the FID, then subtracts the filtered signal from the original data in the time domain. 
The low frequency component is obtained by convolution with a window function (e.g. 
Gaussian). Another technique to eliminate or reduce water fits a set of peaks using a linear 
least squares algorithm to the water peak and  subtracts this from the FID [Ref. 124].  
 
Phasing  
 
Whenever the initial phase of an FID is not zero, the real and imaginary channels 
after Fourier transform will contain mixtures of absorption mode and dispersion mode 
spectra. Phasing a spectrum sorts the real and imaginary channels into absorption mode 
and dispersion mode spectra [Ref. 13]. 
Phase is the sum of the zero-order phase (constant for all frequencies) and the first-
order phase (linear with frequency). The zero-order phase term corrects for the initial 
phase of the FID. Delay in the time domain corresponds to a frequency dependent phase 
shift in the frequency domain. The first-order phase term is necessary whenever the start of 
the ADC sampling window does not start at the peak of the damped exponential.  
The zero-order phase is equal to the phase of the first point in the FID (time 
domain). The zero-order phase is also equal to the four-quadrant arctangent of the sum of 
the real points and the sum of the imaginary points in the frequency domain, providing that 
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there were no alterations to the FID before Fourier transformation such as applying 
saturation pulses when acquiring a FID or shifting the time domain points after a FID is 
acquired (for first-order phase correction).  
When correcting water-suppressed spectra for eddy currents with post-processing 
such as ECC, the phase of a water FID is subtracted from the phase of a water-suppressed 
FID. Besides linearizing the phase, this subtraction also applies a zero-order phase to the 
spectra because the phase offset of the water FID is equal to the phase offset of the water-
suppressed FID. If the ADC sample window is placed correctly in a STEAM or PRESS 
sequence, first-order phasing is not required, and the eddy current corrected spectrum is 
properly phased.  
Software post-processing usually has a left shift tool that allows one or more data 
points to be deleted from the beginning of the complex FID. This is equivalent to changing 
the delay time by 1 ADC sample point and may correct the ADC sample window position if it 
was positioned early. Sometimes, the first points in a FID may be corrupted and these points 
can be removed with the left shift tool, but first-order phasing will be required to correct for 
the additional delay time.  
Baseline correction  
 
The quantification of MR spectra requires evaluating the area under the peaks in the 
absorption mode spectrum. Distortions of the baseline around these peaks may greatly 
affect the accuracy of these areas. Methods for defining the baseline of a spectrum include 
DC offset correction, correction with linear tilts, and cubic or higher order splines. This 
baseline is subtracted from the spectrum before calculating the areas. Therefore, a better 
approach to dealing with baseline peaks is to include them in the overall metabolite fitting 
algorithm, either as a baseline fit [Ref. 75, 133] or to model them as peaks [Ref. 132]. 
Discrepancies in metabolite values between investigators [Ref. 133] often arise from 
differences in baseline processing.  
 
 
 
 
 
 
 
 
 
 
   
Chapter 4 
 
SOFTWARE FOR POST-PROCESSING 
 
The challenge is to quantify spectra which exhibit many metabolites, and to estimate 
their relaxing time and concentrations. To that effect, the software package jMRUI with a 
Java-based graphical user interface (GUI) [Ref. 73, 135, 145 – 148, 151] is being developed 
for user-friendly time-domain analysis of MRS, MRSI and HRMAS-NMR signals.  
Graphical user interface (GUI) in jMRUI is managed by java development kit (JDK), 
while native code is written in FORTRAN and ANSI C is used for the interface between the 
GUI and the native code. In comparison to LCModel software, jMRUI requires user 
interaction. jMRUI allows time-domain MRS single voxel as well as in multiple voxel data 
and can handle large data sets such as time resolved MRS, and MRSI data. Theoretically, 
signals from metabolites can be computed by quantum mechanics using NMR scope based 
on the product-operator formalism.  
MRS data processing using jMRUI is subdivided into two stages: preprocessing and. 
quantitation. There are number of preprocessing steps in the time domain. HLSVD filter and 
HLSVDPro-filter are used for the suppression of water molecules. The time-domain 
QUALITY deconvolution method helps to remove magnetic field inhomogeneity, contribu-
tion to the line-shape yielding Lorenzian line shapes. The Cadzow function is used to filter 
the signal. jMRUI also uses gabor as a tool for peak extraction and dynamic phase correction. 
Mathematical operators, like addition, subtraction, multiplication of the signal with a scalar 
quantity, are available for the normalization of a signal or over a series of signals. It also 
provides the preprocessing operator to convert an echo signal into an FID signal. All the 
above operations are performed in time domain except the ER filter and the baseline 
correction, which are done in frequency domain.  
jMRUI software provides for a number of quantitation methods broadly classified as 
black box methods like Hankel Singular Value Decomposition (HSVD)/Hankel Lanczos 
Singular Value Decomposition (HLSVD), Hankel Total Least Squeres (HTLS)/Hankel Lanczos 
Total Least Squares (HLTLS), Linear Predictive Singular Value Decomposition (LPSVD) or 
interactive methods like VARPRO, AMARES, QUEST and AQSES.  
The black box methods are based on either LP (linear prediction) principle or state 
space formalism. LPSVD method is based on LP principle and uses SVD decomposition to 
estimate the prediction coefficients in the forward linear prediction procedure expressed as 
a matrix in a least squares sense. The HSVD/HLSVD and HTLS/HLTLS methods are state 
space based, where the data is arranged in a Hankel matrix. HSVD computes the Eigen 
values of the Hankel matrix which are estimates of the signal poles. The HLSVD algorithm is 
a computationally efficient version of HSVD, which computes only part of the SVD using the 
Lanczos bidiagonalization algorithm. A variant to the HSVD algorithm is the HTLS algorithm 
that computes the Total Least Squares (TLS) solution leading to more accurate parameter 
estimates. HLTLS, like the HLSVD, is a computationally efficient version of HTLS using 
Lanczos algorithm.  
In the interactive quantitation methods the line-widths and concentrations are part 
of a nonlinear model and are optimized by fitting the in vivo signal with a combination of 
metabolite signals by nonlinear least squares techniques.  
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Summarizing, the jMRUI software package offers:  
 Black box quantitation algorithms based on singular-value decomposition (SVD): the 
state space methods HSVD, HLSVD, and HTLS and the linear prediction method 
LPSVD. These non-interactive black box techniques are efficient for quantitating 
signals with good signal-to-noise ratios. They are also helpful in parametrizing 
signals of unknown composition and shape, but they cannot make use of all available 
prior knowledge. 
 Nonlinear least-squares (NLLS) quantitation algorithm: AMARES and QUEST [Ref. 
149, 150]. AMARES is an improved version of VARPRO enabling us to impose prior 
knowledge on the model-function parameters. QUEST is based on the availability of 
a metabolite signal basis set.  
 Preprocessing algorithms such as rapid removal of dominant signals using HLSVD 
and HLSVD-Pro, or time–frequency analysis, the Cadzow enhancement procedure 
for noise reduction, the ER-filter for frequency selection, and Gabor tools for peak 
extraction and dynamic phase correction. 
 Estimation of spectral parameters with their confidence intervals (Cramér–Rao 
lower bounds). 
 Conversion routines for data files from most manufacturers (Bruker, General 
Electric, Philips, Siemens, Varian, etc). Moreover, the software package jMRUI 
handles the new advanced DICOM format for MRS, MRSI and MRI.  
 Signal simulations from a model function.  
 Quantum-mechanical signal simulator based on NMR-SCOPE [Ref. 15] that can 
handle various measurement protocols and enables the simulation of metabolite 
signal basis sets.  
 The jMRUI software package works with Windows, Linux and Unix platforms.  
Some details on the interactive quantification methods in jMRUI are described below.  
 
AMARES 
 
AMARES method performs fitting of Lorentzian, Gaussian or Voigt peaks to the 
signal, with the possibility of including prior knowledge about relations between peaks, 
such as equal line-widths, or fixed frequency shifts. It minimizes a general functional 
consisting of the sum of squared differences between the data and the model function. The 
available biochemical prior knowledge can be expressed as a set of linear relations between 
parameters resulting in a minimization problem with linear equality constraints. AMARES 
uses a singlet approach for imposition of prior knowledge. Each of the parameters can be  
left unconstrained or kept fixed. In AMARES, a fixed shift or ratio, or a variable shift or ratio, 
with respect to any unconstrained or fixed parameter of the same type can be imposed. 
These variable shifts or ratios can then be linked between different groups of peaks. These 
constraints are substituted in the original functional in order to obtain an unconstrained 
NLLS optimization problem. AMARES uses a modified version of NL2SOL, a sophisticated 
NLLS algorithm to minimize the general functional. This algorithm allows the user to specify 
the upper and lower bounds on the variables. This can be used to impose positive dampings, 
amplitudes, and upper and lower bounds on frequencies and phases based on the spectral 
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width. AMARES also offers the ability to fit echo signals, an echo being modeled as two FIDs 
back to back. The left and right parts of the echo are considered to have the same 
amplitudes, frequencies and phases, but different damping. The damping of the right and 
left parts can be linked to each other.  
MRS data processed using AMARES are displayed in a table giving information about 
the estimated components: their frequencies, dampings, amplitudes and phases, respec-
tively. CR lower bounds can be used as a measure of the accuracy of the calculation of the 
amplitude of a certain component.  
 
QUEST: Quantitation based on Quantum ESTimation 
 
QUEST, the most recent method, uses a basis set of metabolite signals that are 
combined to fit the in vivo signal. In this linear combination model, the 
amplitude/concentration, line-width, phase and frequency shift of each metabolite are 
considered as free parameters and a nonlinear least square function is min- imized with the 
Levenberg–Marquardt method for nonlinear optimization. All these computations are 
performed on both the real and imaginary parts of the FID, in the time domain, and not on 
the frequency domain, as opposed to the LCModel. QUEST can also accommodate a baseline 
(or background) coming from macromolecules, by truncating a number of points at the FID, 
fitting the truncated signal with the metabolite basis set, back-extrapolating the estimated 
model, subtracting it from the in vivo signal, and smoothening the result to yield an 
approximation for the baseline. The metabolite basis set .ml and the peaks file .peak can be 
generated using NMR scope and used as prior knowledge input for QUEST quantitation 
method.  
 
NMRScope 
 
NMRScope-B is a plugin for program jMRUI. The plugin provides the functionality 
useful for the simulation of coupled spin systems during the NMR experiment. In the 
simulation, such properties as chemical shifts, spin-spin coupling, relaxation, spatial and/or 
spectral excitation selectivity, and customized pulse sequences are accounted for. The 
primary target is to support the simulation of metabolite FIDs in biomedical MR 
spectroscopy, as needed for spectroscopic quantitation, but many functions are meant to 
support the development of methods for MR spectroscopic imaging.  
Some advantages: 
 Implemented model of relaxation (Redfield matrix model - including Solomon 
equations, T1 and T2 relaxation)   
 Pulse sequence programming by table filling, tabular definition of phase cycles   
 Protocols for more complex pulse sequences, programmable by scripts   
 Pulse sequence graphs   
 Full support for simultaneous activities (rf pulses incl.  heteronuclear excitation, 
gradient pulses, observation)   
 Trick operations (e.g. for modeling a perfect crusher or  full relaxation)   
 Faster Bloch model for isolated spin-1/2   
 Spin system and pulse sequence parameter cycles  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 Arbitrary observables defined by formulas   
 Arbitrary observation timepoints (even during excitation)   
4.1 - Absolute quantitation using jMRUI  
 
The measured area under a spectral peak (from a known volume) is directly 
proportional to the concentration of the metabolite, after normalizing to the number of 
protons in the metabolite peak. Since spectroscopy sequences do not have TR = ∞ and TE = 
0, the measured area must be corrected for saturation and relaxation effects [Ref. 13, 117, 
134, 135]. 
Most clinical MRS papers do not correct for T1 or T2 effects since typically spectral 
changes are studied over time, or spectra from a group of normal subjects are compared to 
spectra from a group of subjects with pathology. Therefore, a constant correction term for 
T1 or T2 relaxation will not change the results. However, if metabolite levels are altered in a 
diseased state or over time, one can never rule out that these changes are due to changes in 
metabolite T1 or T2 relaxation times rather than actual changes in metabolite levels. 
Although a few authors have measured metabolite T1 and T2, this is a very time-consuming 
procedure since spectra have to be acquired at several TR/TE time points [Ref. 117, 119, 
120]. Since the effects on peak distortions due to J coupling change with TE ,T2 measure-
ments become difficult for metabolites with J coupled spins [Ref. 88].  
The absolute concentration of metabolites from signal intensity as derived by jMRUI 
can be obtaind by a simplified equation: 
 
𝐶M =
𝑆M
𝑆W
× 𝐶W ×
𝑛W
𝑛M
×
𝑓W(𝑇1)
𝑓M(𝑇1)
×
𝑓W(𝑇2)
𝑓M(𝑇2)
 
 
where indexes M for metabolite and W for water, C stands for concentration, S for signal 
intensity, n for the number of chemically equivalent protons. Cw stands for concentration of 
water about 55.5 mol/L in pure water. 
f(T1) and f(T2) are correction factors for spin-lattice and spin-spin relaxation 
functions respectively [Ref.13, 152]:  
 
{
 
 
 
 
 
 
 
 
 
 
𝑓(𝑇1;  𝑃𝑅𝐸𝑆𝑆, 𝑅𝑒𝑓. 135) = 1 − 2 exp [
−(𝑇𝑅 −
𝑇𝐸
2 )
𝑇1
] + exp (−
𝑇𝑅
𝑇1
)   
𝑓(𝑇1;  𝑆𝑇𝐸𝐴𝑀, 𝑅𝑒𝑓. 13) = [1 − exp−(
𝑇𝑅 − 𝑇𝑀 −
𝑇𝐸
2
𝑇1
)] ∙ exp (−
𝑇𝑀
𝑇1
)
𝑓(𝑇1;  𝑃𝑅𝐸𝑆𝑆, 𝑅𝑒𝑓. 152) = 1 − exp [−
𝑇𝑅
𝑇1
] − 2 exp [
−(𝑇𝑅 −
3𝑇𝐸
4 )
𝑇1
] + 2 exp [
−(𝑇𝑅 −
𝑇𝐸
4 )
𝑇1
] ≅ (𝑖𝑓 𝑇𝐸 ≪ 𝑇𝑅) 1 − exp [−
𝑇𝑅
𝑇1
]
𝑓(𝑇2) = exp(−𝑇𝐸 𝑇2⁄ ) ;
 
So, in order to perform an absolute quantitation of metabolites concentration we have to  
1. Evaluate T1, T2 of metabolites 
2. Evaluate the signal of metabolites 
3. Correct the signal for saturation and relaxation effects 
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4. Correct for the number of active protons 
The receiver attenuation must be keep fixed in all measurements in order to perform an 
aboslute quantitation. 
Error estimation in absolute quantitation 
 
Error estimation in the metabolites absolute quantitation can be found using the 
error propagation formula, where contributions from signals intensity (SM and SW) can be 
usually trascurated respect to the other. CW is usually assumed 55.5 M for distilled water 
without error. ΔT1 and ΔT2 can be estimated by the fitting procedure as shown in Chapter 7. 
 
{
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
∆𝐶M
𝐶M
=
∆𝐶W
𝐶W
+
∆𝑆M
𝑆M
+
∆𝑆W
𝑆W
+
∆𝑓(𝑇1)M
𝑓(𝑇1)M
+
∆𝑓(𝑇2)M
𝑓(𝑇2)M
+
∆𝑓(𝑇1)W
𝑓(𝑇1)W
+
∆𝑓(𝑇2)W
𝑓(𝑇2)W
≅ 
∆𝑓(𝑇1)M
𝑓(𝑇1)M
+
∆𝑓(𝑇2)M
𝑓(𝑇2)M
+
∆𝑓(𝑇1)W
𝑓(𝑇1)W
+
∆𝑓(𝑇2)W
𝑓(𝑇2)W
∆𝑓(𝑇1)
𝑓(𝑇1)
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𝑇𝐸
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𝑇1
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𝑇𝐸
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−
𝑇𝑅
𝑇1
⁄
1 − 2exp [
−(𝑇𝑅 −
𝑇𝐸
2 )
𝑇1
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𝑇𝑅
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∙
∆𝑇1
𝑇1
2
∆𝑓(𝑇2)
𝑓(𝑇2)
=
𝑇𝐸
𝑇2
2 ∆𝑇2
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Chapter 5 
 
QUALITY CONTROL MEASURES: PARTICIPATION IN NATIONAL PROJECT 
FOR SPECTROSCOPY INTERCOMPARISON 
 
 
Several fundamental requirements must be met so that MRI and the related 
techniques can be formally adopted into clinical practice. Here we report an 
intercomparison exercise, which has evaluated the effectiveness of 1H MRS to generate 
comparable data sets from different machine vendors, using the available MR scanner in the 
different hospital of Florence:  
 Philips Achieva 3 T (Azienda Ospedaliero Universitaria Meyer) 
 Philips Achieva 1.5 T (P.O. Santa Maria Nuova Azienda Sanitaria di Firenze) 
 Siemens Aera 1.5 T (P.O. San Giovanni di Dio, Azienda Sanitaria di Firenze)  
This intercomparison is part of a national project of AIFM for validation of MRS data. 
The research will be performed analyzing the spectroscopic signal coming from a 
specific test phantom, as described above.  
This spectroscopic data will be analized with the jMRUI software package, looking 
for: 
 Linearity of Amplitude of water signal with VOI volume 
 Independence of Linewidth of water signal with VOI volume 
 T2 of water 
 Spatial homogeneity of the signals 
Overall, the comparability of data sets from the participating laboratories was good.  
These results demonstrate that MRS-based study can generate data that are 
sufficiently comparable between hospitals to support its continued evaluation for clinical 
studies. 
5.1 - Original intercomparison protocol 
 
Here we report in italian language the original protocol. 
 
Istruzioni per la partecipazione all’interconfronto di Spettroscopia  
 
Strumenti necessari: bobina head, fantoccio proprietario di almeno 10 cm di 
diametro (se a disposizione maggiore di 15 cm di diametro), preferibilmente sferico (non 
necessariamente deve essere il fantoccio dedicato alla spettroscopia).  
Preparazione:  
1. Lasciare il fantoccio all’interno della sala magnete almeno dal giorno prima 
dell’acquisizione per permettere il raggiungimento di un buon equilibrio termico  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2. Posizionare il fantoccio possibilmente al centro della bobina ed effettuare il 
centraggio in modo che il centro del fantoccio si venga a trovare all’isocentro dello 
scanner.   
3. Attendere 5 minuti per permettere una buona stabilizzazione del liquido   
4. Registrare la temperatura all’interno della sala magnete all’inizio e alla fine 
dell’acquisizione.   
Acquisizione:  
1. Eseguire una scout   
2. Eseguire, se necessario,una scansione di calibrazione della bobina(se multicanale).  
3. Effettuare le seguenti acquisizioni con tecnica PRESS e con i seguenti parametri:  
 
a. 1. PRESS senza soppressione dell’acqua (PRESS n.1)  
i. impostare la bobina di ricezione in quadratura se possibile   
ii. dimensioni del VOI: 20x20x20 mm3 
iii. posizionare il VOI al centro del fantoccio   
iv. TE = 30 ms (o minimo raggiungibile se TE-min > 30ms)   
v. TR = 4000ms   
vi. Numero di medie = 16   
vii. Phase cycle = 16   
viii. Fissare se possibile il guadagno   
ix. Samples = 1024   
x. Bandwidth = 1000 Hz negli scanner a 1.5T e 2000 Hz negli scanner a 
3T   
b. Ripetere la misura di cui al punto 1 spostando il centro del VOI di 4 cm in 
direzione alto-basso e destra-sinistra (PRESS n. 2a, PRESS n. 2b)   
c. Ripetere 5 volte la misura di cui al punto 1 nella stessa posizione, cambiando 
ogni volta la dimensione del VOI e impostando 10, 15, 20, 25, 30 mm di lato 
(per la misura 20 mm può essere utilizzata l’acquisizione al punto 1) (PRESS 
n. 3-10, PRESS n. 3-15, PRESS n. 3-25, PRESS n. 3-30)   
d. Ripetere 5 volte la misura di cui al punto 1 modificando ogni volta il TE e 
impostando TE=30, 100, 150, 300, 400 ms (PRESS n. 4-30, PRESS n. 4-100, 
PRESS n. 4-150, PRESS n. 4-300, PRESS n. 4-400). Per la misura con TE= 30 
ms può essere utilizzata la misura di cui al punto 1.   
La durata delle singole acquisizioni è di circa 1 minuto (a cui aggiungere eventuali 
preacquisizioni di preparazione e le operazioni di shimming).  
Per valutare la riproducibilità dei dati a lungo termine è auspicabile che questo 
protocollo sia ripetuto più volte con cadenza più possibile regolare nel tempo. In particolare 
è ottimale che si acquisiscano le misure cinque volte in due mesi. A seconda delle 
disponibilità delle apparecchiature e delle possibilità di ciascuno dei partecipanti questo 
numero può essere ridotto. I dati verranno analizzati di conseguenza.  
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Istruzioni per l’elaborazione degli spettri 
 
1. Esportare gli spettri secondo la modalità e il formato disponibile presso il proprio 
centro 
2. Salvare i dati in cartelle nominate con la data delle acquisizioni.  
3. Rinominare i file corrispondenti alle singole acquisizioni secondo quanto riportato 
tra parentesi nel paragrafo “acquisizioni” e come anche indicato nel file Excel 
allegato (PRESS n.1, PRESS n. 2a, PRESS n. 2b, etc...).  
4. Utilizzare il programma jMRUI per le elaborazioni  
 
a) Lanciare Jmrui  
b) scegliere l’opzione 1D Time Series.  
c) caricare il file relativo all’acquisizione.  
d) rifasare lo spettro per verificare eventuali distorsioni da disomogeneità (eddy 
currents etc.) o artefatti. 
e) Selezionare quindi dalla barra del menu in alto la voce “Quantitation-SVD-Hlsvd”.  
a. Inserire in “Number of components” il numero 1 e lanciare la 
quantificazione, premendo il tasto Hlsvd.  
b. Apparirà una finestra “Results 1d mode” nella quale si potranno leggere: 
i. la frequenza 
ii. la larghezza a metà altezza (Linewidth in Hz) 
iii. l’ampiezza (Amplitude) 
iv. la fase (Phase in deg).  
c. Da questa finestra selezionare Options “Noise from original FID” 
scegliere 100 punti di misura e dare l’ok.  
d. Impostare inoltre le unità di misura in Hz e scegliere Linewidth in Hz per 
la misura della larghezza del picco (da “Options” e poi “Units”).  
e. Infine selezionare “File, Save This, Save as a Text” e salvare i risultati 
ottenuti in un file di testo.  
f) Nel file di testo saranno riportate delle informazioni di questo tipo:  
jMRUI Results Textfile: 
Filename: CQ_SPETTRO_PRESS-H2O_3_2_raw_act.SDAT  
Name of Patient: / Date of Experiment: / Spectrometer:  
Additional Information: 
Points  Samp.Int.  ZeroOrder  BeginTime  Tra.Freq.  Magn.F. 
 Nucleus  
1024   1E0   0E0   0E0   6.39E7  1.5009E0 
 0E0  
Name of Algorithm: HLSVD  
PEAK #0  
Frequencies (ppm): -2.6754E-2  
40                                                                                                                         MAGNETIC RESONANCE SPECTROSCOPY -  DATA ANALYSIS FOR CLINICAL APPLICATIONS
 
 
Standard deviation of Frequencies (ppm): 1.7517E-5  
Amplitudes (-): 3.7397E0  
Standard deviation of Amplitudes (-): 2.5012E-2  
Linewidths (Hz): -1.1016E0  
Standard deviation of Linewidths (Hz): -1.0581E-2  
Phases (degrees) -1.2344E2  
Standard deviation of Phases (degrees) 3.832E-1  
Noise: 2.1158E-1 
pH  Standard deviation of pH   [Mg2+]   Standard 
deviation of [Mg2+] 
Not known  Not known    Not known   Not known  
g) Riportare quindi questi risultati nel file Excel allegato e corrispondentemente ad 
ogni singola acquisizione, per la quale dovrà essere effettuato l’intero processo 
di elaborazione.  
h) A questo punto per le acquisizioni di cui al punto 3 inserire un grafico 
dell’ampiezza in funzione del volume: 
a.  elevare al cubo la dimensione del lato del VOI 
b.  fare un fit lineare.  
i) Sempre in funzione del volume riportare anche l’andamento della linewidth.  
j) Per le acquisizione del punto 4 inserire un grafico dell’ampiezza in funzione del 
TE e fare un fit monoesponenziale. 
k) Vedi file Excel già riempito come esempio.  
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5.2  - Intercomparison results 
 
Azienda Ospedaliero Universitaria Meyer 
 
 
Figure 1: Meyer, Amplitude as a function of VOI volume. 
 
Figure 2: Meyer, Linewidth as a function of VOI volume. 
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Figure 3: Meyer, Amplitude as a function of TE. 
P.O. San Giovanni di Dio, Azienda Sanitaria di Firenze 
 
 
Figure 4: P.O. S.G.D., Amplitude as a function of VOI volume. 
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Figure 5: P.O. S.G.D, Linewidth as a function of VOI volume. 
 
 
 
Figure 6: P.O. S.G.D., Amplitude as a function of TE. 
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P.O. Santa Maria Nuova Azienda Sanitaria di Firenze  
 
 
Figure 7: P.O. S.M.N., Amplitude as a function of VOI volume. 
 
 
Figure 8: P.O. S.M.N., Linewidth as a function of VOI volume. 
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Figure 9: P.O. S.M.N., Amplitude as a function of TE. 
 
The same analysis was performed with a difference setting of sequence parameters:  
- Numberofkspacetrajectories: Press_SV_1 = 16;  XX_0001 = 128 
- Patientweight: Press_SV_1 = 10;  XX_0001 = 20 
- Transmitterfrequency: Press_SV_1 = 63.86;  XX_0001 = 63.87 
- suppression: Press_SV_1 = FAT;  XX_0001 = NONE 
- 0x2005,0x142b: Press_SV_1 = COMPLETED;  XX_0001 = PARTIAL 
- 0x2005,0x142c: Press_SV_1 = INITIAL;  XX_0001 = PARTIAL 
A different setting of sequence parameters reflects on signal amplitude and 
linewidth:  
- Amplitude: Press_SV_1 = 2.025;  XX_0001 = 5.4307 
- Linewidth (Hz): Press_SV_1 = 0.9568;  XX_0001 = 1.8581 
Some results are shown below. 
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Figure 10: P.O. S.M.N., Amplitude as a function of VOI volume. 
 
 
 
Figure 11: P.O. S.M.N., Linewidth as a function of VOI volume. 
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5.3  - Discussion of the results 
Amplitude vs VOI volume 
 
All hospital show a very good linearity of the amplitude of water signal as a function 
of VOI volume. 
Linewidth vs VOI volume 
 
Linewidth as a function of VOI volume is better for P.O. S.G.D. (0.44 Hz) than S.M.N. 
(1.3 Hz). Meyer has a mean linewidth of 0.94 Hz but with a static magnetic field of 3.0 T, 
then in relative very similar to S.G.D. 
T2 of water 
Meyer  = 639 ms  
S.G.D. = 1252 ms 
S.M.N. = 316 ms 
Spatial homogeneity of the signal 
 
Meyer has a low amplitude spatial homogeniety due to the problems in shimming at 
3T respect to 1.5T. Note that data are normalized to “Central position” (Figure 12).  
Linewidth shows some variations with positions in particular for Meyer MR scanner 
at 3.0 T, still due to the problems discussed above. Please note that data from Meyer come 
from a 3T MR scanner, this must be taken into account when confront data coming from MR 
scanner at different B0. 
 
Figure 12: Amplitude spatial homogeneity. “C” means central position, “+4U”  
means a displacement of 4 cm upper, while “+4L” means  lateral. Data are normalized to “Central position”. 
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Figure 13: Linewidth spatial homogeneity. “C” means central position, “+4U”  
means a displacement of 4 cm upper, while “+4L” means  lateral.  
For Meyer data it must be taken in account that data come from a 3T MR scanner. 
 
Some disomogeneity effects at 3t may be interpreted by the dielectric effect [Ref. 
153, 154, 155].  
In MRI we often focus on magnetic fields like B0 and B1, so it is easy to forget that a 
coexisting electric field (E) is always present. As described by the Maxwell equations, B and 
E fields oscillate perpendicular to each other and to the direction of wave 
propagation. When electromagnetic waves encounter the human body, several phenomena 
occur: 1) the wavelength decreases; 2) electrical currents are generated; and 3) wave 
reflection/refraction may develop at tissue interfaces. The term dielectric effect refers to the 
interaction of matter with the E component of an electromagnetic field.  
Abnormal bright and dark areas due to B1 field inhomogeneity are frequently noted 
at very high fields (3T and above). Although the nature of these artifacts is not entirely clear, 
these are commonly referred to as dielectric artifacts. 
The argument that these artifacts are due to dielectric effects is based on considering 
RF-wavelengths in tissues as a function of field strength. At fields of 1.5T and lower, RF 
wavelengths are long compared to the size of the body, but as the magnetic field is 
increased, these wavelengths become the same or smaller than the anatomic regions 
imaged. In theory standing wave currents might arise flowing in opposite directions from 
two sides of the patient creating a pattern with destructive interference (dark areas) and 
constructive interference (bright areas) separated by quarter wavelengths. 
The degree to which significant dielectric resonances cause these bright and dark 
areas remain controversial. The relatively high electrical conductivity of tissues introduces a 
"skin-depth" term that serves to damp standing wave phenomena. Central brightening has 
been demonstrated in high-conductivity phantoms where dielectric resonances should be 
minimal.  
   
Chapter 6 
 
SIEMENS PHANTOM T1 AT 3 T 
 
 
In this part some results about the MRS measurements pe rformed using the Philips 
Achieva 3 T scanner at the Azienda Ospedaliero Universitaria Meyer are shown. 
In this part we focus on the estimation of water and metabolites (Acetate, Lactate) T1 
relaxation time at 3 T.  
Spectra have been acquired with the Siemens phantom using different sequences 
parameters, looking for the difference in the estimation. E.g. data have been acquired with 
different inversion bandwidth in the case of multi-inversion sequence, or using a different 
TE in order to highlight the behavior of Lactate. All of this will be discussed here. At the 
same time post-processing has been performed using different algorithms (HLSVD, AMARES 
and in one case QUEST), with and without apodization (lorentzian apodization with 5 Hz) of 
spectra and using different fit functions, looking for the difference in the estimations. A good 
reference to understand problems in spectra fitting can be found in Ref. 214. 
 
6.1 - T1 relaxation time 
 
Measurements were performed using a inversion recovery sequences at different TI.  
Peaks area were estimated with HLSVD and AMARES (in some case with QUEST too). 
It is very important to highlight the importance of removing the residual water peak in the 
metabolites spectrum, allowing a good estimation of meatabolites peaks as small as the 
lactate quadrouplet. 
 
 
 
Figure 1: Example Water spectrum with multi-inversion time displayed in jMRUI. TI(ms): 30, 250, 700, 2500, 
5400. TE = 35 ms. TR = 6000 ms. NSA = 16, Phase cycles = 16. Inv. Bandwidth = 1500 Hz. 
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Figure 2: Example of metabolities spectrum with multi-inversion time displayed in jMRUI. The residual water 
peak is visible at about 4.7 ppm. Metabolites peaks: acetate at about 1.9 ppm, lactate doublet at about 1.3 ppm 
and lactate quadruplet at about 4.1 ppm. TI (ms): 30, 250, 700, 2500, 5400. TE = 35 ms. TR = 6000 ms. NSA = 16, 
Phase cycles = 16. Inv. Bandwidth = 1500 Hz. 
 
In this case the fitting were performed with three different function: 
{
 
 
 
 𝑓1(𝑇1) = 𝑎(1 − 2 ∗ 𝑒
−
𝑇𝐼
𝑇1)
𝑓2(𝑇1) = 𝑎(1 − 2 ∗ 𝑒
−
𝑇𝐼
𝑇1 + 𝑒
−
𝑇𝑅−𝑇𝐸
𝑇1 )
𝑓3(𝑇1) = 𝑎(1 − (1 − 𝑘) ∗ 𝑒
−
𝑇𝐼
𝑇1 + 𝑘𝑒
−
𝑇𝑅−𝑇𝐸
𝑇1 )
 
where “a” is the signal at equilibrium magnetization, K the cosine of the effective flip angle of the 
inversion pulse. A perfect inversion pulse has k =―1. 
f1 is an approximation of f2 when TR ≫ T1, usually TR = 5𝑇1, while f3 account for an 
incomplete inversion pulse.  
Usually f3 is used when the inversion band is large (e.g. 1500 Hz for Acetate and 
Lactate). 
A multi-inversion time inversion recovery sequences with inversion time up to 15 
seconds were used to estimate 𝑇1, allowing to evaluate the difference in fitting between f1, 
f2 and f3. Long inversion time allows to saturate the signal of metabolites, reaching a better 
fit estimation of the relaxation time. 
A different number of NSA and phase-cycles were used in the different cases to 
highlight differences in the estimation, looking for criticity. A low number of NSA and/or 
phase cycles might reflect in some distortion in the peaks shape due to a low SNR and to 
eddy currents. 
Using cftool toolbox in MATLAB we can find the best fit of data versus 𝑇𝐼 , which give 
an estimation for the amplitude of the signal and the 𝑇1 of water and metabolites. 
Cftool uses the method of least squares when fitting data. Fitting requires a 
parametric model that relates the response data to the predictor data with one or more 
coefficients. The result of the fitting process is an estimate of the model coefficients. The 
supported types of least-squares fitting include Linear least squares, Weighted linear least 
squares, Robust least squares, Nonlinear least squares. 
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While water data fitting is not influenced by errors in the estimated amplitude by 
jmrui, metabolites fitting have many problems. Lactate quadrouplet fitting is very difficult 
and sometimes won’t be considered. 
It is usually assumed that the response errors follow a normal distribution, and that 
extreme values are rare. Still, extreme values called outliers do occur. The main 
disadvantage of least-squares fitting is its sensitivity to outliers. Outliers have a large 
influence on the fit because squaring the residuals magnifies the effects of these extreme 
data points. To minimize the influence of outliers, fit data can be performed using robust 
least-squares regression. The toolbox provides these two robust regression methods: 
  Least absolute residuals (LAR) — The LAR method finds a curve that 
minimizes the absolute difference of the residuals, rather than the squared 
differences. Therefore, extreme values have a lesser influence on the fit. 
  Bisquare weights — This method minimizes a weighted sum of squares, 
where the weight given to each data point depends on how far the point is from the 
fitted line. Points near the line get full weight. Points farther from the line get reduced 
weight. Points that are farther from the line than would be expected by random 
chance get zero weight. 
For most cases, the bisquare weight method is preferred over LAR because it 
simultaneously seeks to find a curve that fits the bulk of the data using the usual least-
squares approach, and it minimizes the effect of outliers. 
Robust fitting with bisquare weights uses an iteratively reweighted least-squares 
algorithm. Water and metabolites fitting have been fitted with one of the previous methods 
always looking for the best fit in terms of Chi-square. 
Errors in the estimates have been evaluated automatically by the fitting procedure. 
Data on the sequences parameters can be found in Appendix 2. 
 
6.1.1 - Water T1 relaxation time 
 
In Table 1 are shown results about 𝑇1 for water. Estimation of amplitude signal and 
parameter K for fit function f3 are shown too. 
 
Table 1: Water results for T1. 
Algorithm T1 
[ms] 
ΔT1 
[ms] 
A ΔA K ΔK Date 
HLSVDf1 2335 532 0.1004 0.0142   70315 
HLSVDf2 3167 633 0.1123 0.0098   70315 
HLSVDf3 3197 1751 0.1432 0.0684 -0.575 0.3922 70315 
HLSVDAPOf1 2343 374 0.09674 0.00956  0 70315 
HLSVDAPOf2 3152 282 0.1078 0.0043  0 70315 
HLSVDAPOf3 2981 323 0.129 0.0122 -0.6327 0.0849 70315 
AMARESf1 2333 352 0.101 0.0095  0 70315 
52                                                                                                                          MAGNETIC RESONANCE SPECTROSCOPY -  DATA ANALYSIS FOR CLINICAL APPLICATIONS
 
 
AMARESf2 3106 418 0.1121 0.0066  0 70315 
AMARESf3 2892 647 0.1315 0.0256 -0.6556 0.1808 70315 
AMARESAPOf1 2344 583 0.1011 0.0156  0 70315 
AMARESAPOf2 3230 668 0.1137 0.0104  0 70315 
AMARESAPOf3 3389 1876 0.1514 0.0734 -0.5351 0.3706 70315 
QUESTf1 2371 516 0.08714 0.01181  0 70315 
QUESTf2 3232 983 0.09785 0.01305  0 70315 
QUESTf3 3060 2357 0.1182 0.08 -0.6175 0.5925 70315 
QUESTAPOf1 2355 333 0.09209 0.00811  0 70315 
QUESTAPOf2 3169 424 0.1027 0.006  0 70315 
QUESTAPOf3 2909 393 0.1197 0.0142 -0.6566 0.1098 70315 
HLSVDf1 3077 142 0.1152 0.0033  0 10615 
HLSVDf2 3127 169 0.1155 0.0036  0 10615 
HLSVDf3 3024 335 0.1148 0.0083 -1.003 0.1 10615 
HLSVDAPOf1 3105 47 0.1119 0.0011  0 10615 
HLSVDAPOf2 3159 68 0.1123 0.0013  0 10615 
HLSVDAPOf3 3100 118 0.1127 0.0029 -0.9858 0.0342 10615 
AMARESf1 3085 149 0.1155 0.0034  0 10615 
AMARESf2 3136 177 0.1158 0.0037  0 10615 
AMARESf3 3031 354 0.1151 0.0087 -1.003 2.112 10615 
AMARESAPOf1 3140 293 0.1131 0.0065  0 10615 
AMARESAPOf2 3193 345 0.1134 0.007  0 10615 
AMARESAPOf3 2946 612 0.1093 0.0149 -1.051 0.196 10615 
HLSVDf1 3194 40 0.1199 9.00000E-04  0 20615 
HLSVDf2 3260 60 0.1203 0.0013  0 20615 
HLSVDf3 3201 102 0.1212 0.0026 -0.9797 0.0293 20615 
HLSVDAPOf1 3203 22 0.1145 0.0005  0 20615 
HLSVDAPOf2 3270 32 0.1149 7.00000E-04  0 20615 
HLSVDAPOf3 3230 39 0.1163 9.00000E-04 -0.973 0.0112 20615 
AMARESf1 3205 41 0.1186 9.00000E-04  0 20615 
AMARESf2 3273 40 0.119 8.00000E-04  0 20615 
AMARESf3 3248 83 0.1208 0.0021 -0.9681 0.0233 20615 
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AMARESAPOf1 3136 299 0.109 0.0064  0 20615 
AMARESAPOf2 3192 341 0.1093 0.0067  0 20615 
AMARESAPOf3 3068 725 0.1083 0.017 -1.007 0.217 20615 
HLSVDf1 3294 173 0.1241 0.0041  0 30615 
HLSVDf2 3370 213 0.1247 0.0045  0 30615 
HLSVDf3 3243 443 0.1241 0.0117 -0.9953 0.1277 30615 
HLSVDAPOf1 3262 67 0.1173 0.0016  0 30615 
HLSVDAPOf2 3336 91 0.1178 0.0019  0 30615 
HLSVDAPOf3 3262 175 0.1185 0.0044 -0.9801 0.0499 30615 
AMARESf1 3369 225 0.1253 0.0053  0 30615 
AMARESf2 3452 297 0.1259 0.0062  0 30615 
AMARESf3 3152 448 0.1209 0.0119 -1.048 0.14 30615 
AMARESAPOf1 3091 295 0.1137 0.0066  0 30615 
AMARESAPOf2 3146 322 0.114 0.0067  0 30615 
AMARESAPOf3 3149 750 0.1161 0.0183 -0.9655 0.2105 30615 
HLSVDf1 3134 220 0.1179 0.0051  0 40615 
HLSVDf2 3199 219 0.1183 0.0047  0 40615 
HLSVDf3 3381 463 0.1253 0.0117 -0.9075 0.1175 40615 
HLSVDAPOf1 3157 117 0.1129 0.0026  0 40615 
HLSVDAPOf2 3222 97 0.1133 0.002  0 40615 
HLSVDAPOf3 3321 174 0.118 0.004 -0.9316 0.0459 40615 
AMARESf1 3132 217 0.1172 0.005  0 40615 
AMARESf2 3195 221 0.1176 0.0044  0 40615 
AMARESf3 3333 497 0.1234 0.0125 -0.9206 0.1284 40615 
AMARESAPOf1 3184 270 0.112 0.0059  0 40615 
AMARESAPOf2 3240 331 0.1123 0.0066  0 40615 
AMARESAPOf3 2933 492 0.1069 0.0119 -1.07 2.301 40615 
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Figure 3: example of water data fitting with MATLAB-cftool using f1 function for fitting.  
Data obtained by HLSVD algorithm. 
 
 
Figure 4: Water T1 estimation at different time with different sequence parameters, algorithms (HLSVD, 
AMARES and QUEST). Apodization has been tested for all the algorithms. Error bars have been estimated 
automatically by the fitting procedure with MATLAB-cftool. 
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Function fitting f1 is too aproximated for short TR, while f3 is too complex, however 
giving estimates very similar to f2. 
The best estimates are choosen as average and standard deviation for f2 function 
fitting in dependence of different sequence parameters. 
 
Table 2: Water T1 average and std for the different sequences.  
The estimate have been evaluated with f2 fit function. 
 T1 [ms] ΔT1 [ms] 
7/03/15 3176 44 
1/06-2/06-2/06 2th 3243 99 
2/06 3th 3214 18 
 
 
6.1.2 - Acetate T1 relaxation time 
 
Table 3: Acetate T1 results. 
Algorithm T1 [s] ΔT1 [s] A ΔA K ΔK Date 
HLSVDf1 2.60E-00 5.14E-01 3.65E-04 4.80E-05 0.00E+01 0.00E+01 70315 
HLSVDf2 4.14E-00 4.23E-01 4.42E-04 2.14E-05 0.00E+01 0.00E+01 70315 
HLSVDf3 3.86E-00 5.00E-01 5.72E-04 6.61E-05 -4.91E-01 8.18E-02 70315 
HLSVDAPOf1 2.62E-00 5.51E-01 3.42E-04 4.78E-05 0.00E+01 0.00E+01 70315 
HLSVDAPOf2 4.28E-00 3.24E-01 4.19E-04 1.54E-05 0.00E+01 0.00E+01 70315 
HLSVDAPOf3 4.06E-00 4.25E-01 5.55E-04 5.22E-05 -4.67E-01 6.30E-02 70315 
AMARESf1 2.61E-00 5.05E-01 3.66E-04 4.71E-05 0.00E+01 0.00E+01 70315 
AMARESf2 4.15E-00 6.19E-01 4.44E-04 3.16E-05 0.00E+01 0.00E+01 70315 
AMARESf3 3.81E-00 9.86E-01 5.67E-04 1.31E-04 -5.01E-01 1.66E-01 70315 
AMARESAPOf1 2.63E-00 5.51E-01 3.43E-04 4.79E-05 0.00E+01 0.00E+01 70315 
AMARESAPOf2 4.28E-00 3.20E-01 4.22E-04 1.52E-05 0.00E+01 0.00E+01 70315 
AMARESAPOf3 4.05E-00 1.65E-01 5.60E-04 2.04E-05 -4.66E-01 2.44E-02 70315 
HLSVDf1 3.47E-00 3.41E-01 4.15E-04 3.37E-05 0.00E+01 0.00E+01 200515 
HLSVDf2 3.95E-00 3.53E-01 4.23E-04 2.24E-05 0.00E+01 0.00E+01 200515 
HLSVDf3 4.12E-00 8.14E-01 4.94E-04 7.43E-05 -7.25E-01 1.79E-01 200515 
HLSVDAPOf1 3.54E-00 2.52E-01 3.90E-04 2.32E-05 0.00E+01 0.00E+01 200515 
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HLSVDAPOf2 4.06E-00 1.78E-01 3.98E-04 1.03E-05 0.00E+01 0.00E+01 200515 
HLSVDAPOf3 4.09E-00 4.08E-01 4.55E-04 3.50E-05 -7.50E-01 9.40E-02 200515 
AMARESf1 3.55E-00 2.67E-01 4.19E-04 2.62E-05 0.00E+01 0.00E+01 200515 
AMARESf2 4.07E-00 2.14E-01 4.27E-04 1.32E-05 0.00E+01 0.00E+01 200515 
AMARESf3 4.10E-00 4.93E-01 4.90E-04 4.55E-05 -7.47E-01 1.13E-01 200515 
AMARESAPOf1 3.56E-00 2.62E-01 3.93E-04 2.40E-05 0.00E+01 0.00E+01 200515 
AMARESAPOf2 4.10E-00 1.38E-01 4.01E-04 8.00E-06 0.00E+01 0.00E+01 200515 
AMARESAPOf3 4.17E-00 3.09E-01 4.64E-04 2.66E-05 -7.36E-01 6.88E-02 200515 
HLSVDf1 3.80E-00 1.38E-01 4.30E-04 1.34E-05 0.00E+01 0.00E+01 10615 
HLSVDf2 3.97E-00 1.12E-01 4.34E-04 9.00E-06 0.00E+01 0.00E+01 10615 
HLSVDf3 4.08E-00 3.06E-01 4.62E-04 2.70E-05 -8.84E-01 7.69E-02 10615 
HLSVDAPOf1 3.77E-00 1.95E-01 4.32E-04 1.90E-05 0.00E+01 0.00E+01 10615 
HLSVDAPOf2 3.93E-00 1.71E-01 4.35E-04 1.40E-05 0.00E+01 0.00E+01 10615 
HLSVDAPOf3 4.20E-00 3.71E-01 4.77E-04 3.28E-05 -8.44E-01 8.70E-02 10615 
AMARESf1 3.80E-00 2.60E-01 4.50E-04 2.64E-05 0.00E+01 0.00E+01 10615 
AMARESf2 3.95E-00 2.75E-01 4.53E-04 2.33E-05 0.00E+01 0.00E+01 10615 
AMARESf3 4.18E-00 8.18E-01 4.93E-04 7.52E-05 -8.53E-01 1.95E-01 10615 
AMARESAPOf1 3.85E-00 1.21E-01 4.17E-04 1.13E-05 0.00E+01 0.00E+01 10615 
AMARESAPOf2 4.02E-00 1.39E-01 4.20E-04 1.08E-05 0.00E+01 0.00E+01 10615 
AMARESAPOf3 3.97E-00 3.99E-01 4.35E-04 3.40E-05 -9.25E-01 1.07E-01 10615 
HLSVDf1 3.95E-00 1.82E-01 4.14E-04 1.66E-05 0.00E+01 0.00E+01 2.06E+04 
HLSVDf2 4.16E-00 1.52E-01 4.18E-04 1.13E-05 0.00E+01 0.00E+01 2.06E+04 
HLSVDf3 4.36E-00 3.91E-01 4.57E-04 3.30E-05 -8.47E-01 9.01E-02 2.06E+04 
HLSVDAPOf1 3.98E-00 8.60E-02 4.00E-04 7.60E-06 0.00E+01 0.00E+01 2.06E+04 
HLSVDAPOf2 4.20E-00 6.60E-02 4.04E-04 4.70E-06 0.00E+01 0.00E+01 2.06E+04 
HLSVDAPOf3 4.17E-00 1.90E-01 4.23E-04 1.55E-05 -9.06E-01 4.87E-02 2.06E+04 
AMARESf1 3.96E-00 2.06E-01 4.20E-04 1.90E-05 0.00E+01 0.00E+01 2.06E+04 
AMARESf2 4.18E-00 1.85E-01 4.24E-04 1.39E-05 0.00E+01 0.00E+01 2.06E+04 
AMARESf3 4.42E-00 4.95E-01 4.67E-04 4.22E-05 -8.37E-01 1.12E-01 2.06E+04 
AMARESAPOf1 3.97E-00 1.25E-01 3.99E-04 1.10E-05 0.00E+01 0.00E+01 2.06E+04 
AMARESAPOf2 4.19E-00 8.20E-02 4.03E-04 5.80E-06 0.00E+01 0.00E+01 2.06E+04 
AMARESAPOf3 4.26E-00 2.33E-01 4.30E-04 1.88E-05 -8.77E-01 5.67E-02 2.06E+04 
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HLSVDf2 4.09E-00 3.82E-01 4.54E-04 3.14E-05 0.00E+01 0.00E+01 3.06E+04 
HLSVDf3 4.25E-00 1.20E-00 4.92E-04 1.10E-04 -8.60E-01 2.85E-01 3.06E+04 
HLSVDAPOf2 4.05E-00 3.82E-01 4.23E-04 2.95E-05 0.00E+01 0.00E+01 3.06E+04 
HLSVDAPOf3 3.90E-00 1.05E-00 4.30E-04 9.02E-05 -9.53E-01 2.95E-01 3.06E+04 
AMARESf2 4.04E-00 4.98E-01 4.63E-04 4.23E-05 0.00E+01 0.00E+01 3.06E+04 
AMARESf3 4.28E-00 1.60E-00 5.08E-04 1.50E-04 -8.45E-01 3.71E-01 3.06E+04 
AMARESAPOf2 3.77E-00 8.49E-01 3.88E-04 6.49E-05 0.00E+01 0.00E+01 3.06E+04 
AMARESAPOf3 4.18E-00 2.85E-00 4.35E-04 2.25E-04 -8.17E-01 6.44E-01 3.06E+04 
HLSVDf2 4.85E-00 5.91E-01 4.44E-04 3.90E-05 0.00E+01 0.00E+01 4.06E+04 
HLSVDf3 4.38E-00 1.49E-00 4.42E-04 1.30E-04 -9.60E-01 3.99E-01 4.06E+04 
AMARESf2 4.89E-00 5.75E-01 4.55E-04 3.85E-05 0.00E+01 0.00E+01 4.06E+04 
AMARESf3 4.38E-00 1.41E-00 4.51E-04 1.25E-04 -9.65E-01 3.79E-01 4.06E+04 
HLSVDf2 4.35E-00 4.07E-01 4.13E-04 2.81E-05 0.00E+01 0.00E+01 5.06E+04 
HLSVDf3 3.71E-00 4.59E-01 3.88E-04 3.84E-05 -1.07E-00 1.54E-01 5.06E+04 
AMARESf2 4.42E-00 4.75E-01 4.19E-04 3.27E-05 0.00E+01 0.00E+01 5.06E+04 
AMARESf3 3.69E-00 5.43E-01 3.88E-04 4.60E-05 -1.10E-00 1.88E-01 5.06E+04 
HLSVDf2 4.20E-00 1.11E-01 4.25E-04 8.30E-06 0.00E+01 0.00E+01 6.06E+04 
HLSVDf3 4.18E-00 3.32E-01 4.48E-04 2.86E-05 -8.96E-01 8.41E-02 6.06E+04 
AMARESf2 4.21E-00 1.29E-01 4.30E-04 9.60E-06 0.00E+01 0.00E+01 6.06E+04 
AMARESf3 4.23E-00 3.92E-01 4.57E-04 3.40E-05 -8.84E-01 9.71E-02 6.06E+04 
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Figure 5: Example of Acetate T1 estimation with cftool using f1 function for fitting. Area under the peaks have 
been estimated by AMARES. As shown the signal don’t saturates. 
 
 
Figure 6: Acetate T1 estimation at different time with different sequence parameters, algorithms (HLSVD, 
AMARES). Apodization has been tested for all the algorithms. Error bars have been estimated automatically  
by the fitting procedure with MATLAB-cftool. 
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Table 4: Acetate T1 average and std results for the different sequences parameters.  
The estimate have been evaluated with f2 fit function. 
Acetate T1 [ms] ΔT1 [ms] 
7/03/15 4212 77 
20/05/15 4046 64 
1/06 - 2/06 - 2/06 2th - 2/06 
4th – 5th 
4108 163 
2/06 3th 4867 18 
 
 
6.1.3 - Lactate T1 relaxation time 
 
Lactate estimation is complicate due to a lower SNR respect to Acetate and to a 
different evolution of peaks with TE. Acquisition were performed with TE shortest (28, 30 
ms) when possible, at 288 and 272 ms looking for the best SNR [Ref. 215, 216, 217].  
Lactate estimation were performed with and without the quadrouplet peaks area 
estimation. Quadrouplet peaks area has a low SNR respect to the doublet, and many times 
estimation is impossible. However when possible we performed this estimation, allowing to 
estimate the T1 of doublet alone and doublet and quadrouplet all together. 
 
Table 5: Lactate doublet T1 estimation. 
Lactate doublet T1 [s] ΔT1 [s] A ΔA K ΔK Date 
HLSVDf1 1.60E-00 1.15E-01 2.84E-04 1.25E-05 0.00E+01 0.00E+01 70315 
HLSVDf2 1.71E-00 5.20E-02 2.86E-04 4.30E-06 0.00E+01 0.00E+01 70315 
HLSVDf3 1.74E-00 1.47E-01 3.06E-04 1.67E-05 -8.74E-01 7.54E-02 70315 
HLSVDAPOf1 1.67E-00 1.56E-01 2.59E-04 1.49E-05 0.00E+01 0.00E+01 70315 
HLSVDAPOf2 1.80E-00 8.40E-02 2.62E-04 5.80E-06 0.00E+01 0.00E+01 70315 
HLSVDAPOf3 1.87E-00 1.73E-01 2.86E-04 1.79E-05 -8.37E-01 8.19E-02 70315 
AMARESf1 1.60E-00 1.22E-01 2.60E-04 1.21E-05 0.00E+01 0.00E+01 70315 
AMARESf2 1.67E-00 8.60E-02 2.62E-04 6.60E-06 0.00E+01 0.00E+01 70315 
AMARESf3 1.69E-00 2.67E-01 2.78E-04 2.77E-05 -8.88E-01 1.41E-01 70315 
AMARESAPOf1 1.64E-00 1.35E-01 2.39E-04 1.21E-05 0.00E+01 0.00E+01 70315 
AMARESAPOf2 1.75E-00 5.90E-02 2.41E-04 3.90E-06 0.00E+01 0.00E+01 70315 
AMARESAPOf3 1.80E-00 1.48E-01 2.61E-04 1.42E-05 -8.58E-01 7.36E-02 70315 
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HLSVDf1 1.65E-00 7.70E-02 3.01E-04 8.30E-06 0.00E+01 0.00E+01 2.01E+05 
HLSVDf2 1.65E-00 7.50E-02 3.01E-04 8.00E-06 0.00E+01 0.00E+01 2.01E+05 
HLSVDf3 1.72E-00 9.00E-02 3.07E-04 7.50E-06 -9.39E-01 5.27E-02 2.01E+05 
HLSVDAPOf1 1.68E-00 1.23E-01 2.84E-04 1.24E-05 0.00E+01 0.00E+01 2.01E+05 
HLSVDAPOf2 1.69E-00 1.24E-01 2.83E-04 1.22E-05 0.00E+01 0.00E+01 2.01E+05 
HLSVDAPOf3 1.73E-00 2.34E-01 2.88E-04 1.84E-05 -9.55E-01 1.37E-01 2.01E+05 
AMARESf1 1.58E-00 1.44E-01 2.78E-04 1.48E-05 0.00E+01 0.00E+01 2.01E+05 
AMARESf2 1.59E-00 1.47E-01 2.78E-04 1.47E-05 0.00E+01 0.00E+01 2.01E+05 
AMARESf3 1.58E-00 2.78E-01 2.78E-04 2.26E-05 -1.01E-00 1.85E-01 2.01E+05 
AMARESAPOf1 1.67E-00 6.80E-02 2.66E-04 6.40E-06 0.00E+01 0.00E+01 2.01E+05 
AMARESAPOf2 1.68E-00 6.60E-02 2.66E-04 6.10E-06 0.00E+01 0.00E+01 2.01E+05 
AMARESAPOf3 1.75E-00 6.70E-02 2.71E-04 5.00E-06 -9.44E-01 3.88E-02 2.01E+05 
HLSVDf1 1.82E-00 1.93E-01 3.52E-04 2.34E-05 0.00E+01 0.00E+01 10615 
HLSVDf2 1.82E-00 1.93E-01 3.52E-04 2.33E-05 0.00E+01 0.00E+01 10615 
HLSVDf3 1.97E-00 3.29E-01 3.64E-04 2.94E-05 -8.97E-01 1.58E-01 10615 
HLSVDAPOf1 2.05E-00 3.63E-01 3.78E-04 4.41E-05 0.00E+01 0.00E+01 10615 
HLSVDAPOf2 2.05E-00 3.66E-01 3.78E-04 4.39E-05 0.00E+01 0.00E+01 10615 
HLSVDAPOf3 1.75E-00 1.21E-01 2.90E-04 9.90E-06 -1.04E-00 7.40E-02 10615 
AMARESf1 1.77E-00 2.13E-01 3.25E-04 2.41E-05 0.00E+01 0.00E+01 10615 
AMARESf2 1.77E-00 2.13E-01 3.25E-04 2.40E-05 0.00E+01 0.00E+01 10615 
AMARESf3 1.98E-00 2.76E-01 3.40E-04 2.25E-05 -8.58E-01 1.27E-01 10615 
AMARESAPOf1 1.80E-00 7.70E-02 2.93E-04 7.80E-06 0.00E+01 0.00E+01 10615 
AMARESAPOf2 1.80E-00 7.70E-02 2.93E-04 7.80E-06 0.00E+01 0.00E+01 10615 
AMARESAPOf3 1.75E-00 1.21E-01 2.90E-04 9.90E-06 -1.04E-00 7.40E-02 10615 
HLSVDf1 1.74E-00 1.37E-01 3.11E-04 1.50E-05 0.00E+01 0.00E+01 2.06E+04 
HLSVDf2 1.74E-00 1.38E-01 3.11E-04 1.50E-05 0.00E+01 0.00E+01 2.06E+04 
HLSVDf3 1.79E-00 2.71E-01 3.15E-04 2.27E-05 -9.61E-01 1.51E-01 2.06E+04 
HLSVDAPOf1 1.86E-00 2.39E-01 3.07E-04 2.48E-05 0.00E+01 0.00E+01 2.06E+04 
HLSVDAPOf2 1.86E-00 2.40E-01 3.07E-04 2.48E-05 0.00E+01 0.00E+01 2.06E+04 
HLSVDAPOf3 1.82E-00 4.70E-01 3.04E-04 3.91E-05 -1.03E-00 2.74E-01 2.06E+04 
AMARESf1 1.74E-00 1.28E-01 2.95E-04 1.32E-05 0.00E+01 0.00E+01 2.06E+04 
AMARESf2 1.74E-00 1.28E-01 2.95E-04 1.32E-05 0.00E+01 0.00E+01 2.06E+04 
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AMARESf3 1.80E-00 2.45E-01 2.99E-04 1.95E-05 -9.60E-01 1.36E-01 2.06E+04 
AMARESAPOf1 1.75E-00 8.60E-02 2.75E-04 8.30E-06 0.00E+01 0.00E+01 2.06E+04 
AMARESAPOf2 1.75E-00 8.60E-02 2.75E-04 8.20E-06 0.00E+01 0.00E+01 2.06E+04 
AMARESAPOf3 1.80E-00 1.55E-01 2.78E-04 1.14E-05 -9.63E-01 8.63E-02 2.06E+04 
HLSVDf2 1.88E-00 2.74E-01 3.53E-04 3.24E-05 0.00E+01 0.00E+01 3.06E+04 
HLSVDf3 2.06E-00 5.40E-01 3.67E-04 4.73E-05 -8.86E-01 2.45E-01 3.06E+04 
HLSVDAPOf2 2.23E-00 5.48E-01 3.87E-04 6.40E-05 0.00E+01 0.00E+01 3.06E+04 
HLSVDAPOf3 2.37E-00 1.28E-00 4.00E-04 1.17E-04 -9.20E-01 5.19E-01 3.06E+04 
AMARESf2 1.86E-00 2.51E-01 3.32E-04 2.80E-05 0.00E+01 0.00E+01 3.06E+04 
AMARESf3 2.04E-00 4.85E-01 3.44E-04 4.01E-05 -8.90E-01 2.23E-01 3.06E+04 
AMARESAPOf2 1.84E-00 3.27E-01 3.02E-04 3.35E-05 0.00E+01 0.00E+01 3.06E+04 
AMARESAPOf3 1.52E-00 1.94E-01 2.80E-04 1.83E-05 -1.27E-00 1.62E-01 3.06E+04 
HLSVDf2 1.87E-00 7.20E-02 3.18E-04 7.60E-06 0.00E+01 0.00E+01 4.06E+04 
HLSVDf3 1.93E-00 1.22E-01 3.21E-04 1.01E-05 -9.64E-01 6.37E-02 4.06E+04 
AMARESf2 1.88E-00 6.20E-02 2.98E-04 6.20E-06 0.00E+01 0.00E+01 4.06E+04 
AMARESf3 1.94E-00 9.40E-02 3.02E-04 7.30E-06 -9.60E-01 4.86E-02 4.06E+04 
HLSVDf2 1.80E-00 2.36E-01 2.66E-04 2.15E-05 0.00E+01 0.00E+01 5.06E+04 
HLSVDf3 1.58E-00 1.43E-01 2.52E-04 1.15E-05 -1.19E-00 1.09E-01 5.06E+04 
AMARESf2 1.82E-00 2.66E-01 2.79E-04 2.53E-05 0.00E+01 0.00E+01 5.06E+04 
AMARESf3 1.56E-00 1.54E-01 2.63E-04 1.30E-05 -1.22E-00 1.20E-01 5.06E+04 
HLSVDf2 1.83E-00 7.80E-02 2.91E-04 7.70E-06 0.00E+01 0.00E+01 6.06E+04 
HLSVDf3 1.91E-00 8.60E-02 2.97E-04 6.50E-06 -9.44E-01 4.39E-02 6.06E+04 
AMARESf2 1.78E-00 1.15E-01 3.06E-04 1.22E-05 0.00E+01 0.00E+01 6.06E+04 
AMARESf3 1.88E-00 1.69E-01 3.12E-04 1.36E-05 -9.31E-01 8.79E-02 6.06E+04 
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Figure 7: Example of Lactate T1 estimation with cftool using f1 function for fitting. Area under the peaks have 
been estimated by AMARES. As shown the signal saturates at about 8 s. 
 
 
Figure 8: Lactate T1 doublet estimation at different time with different sequence parameters, algorithms 
(HLSVD, AMARES). Apodization has been tested for all the algorithms. Error bars have been estimated 
automatically by the fitting procedure with MATLAB-cftool. 
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Table 6: Lactate doublet T1 average and std results for the different sequences parameters.  
The estimate have been evaluated with f2 fit function. 
Lactate doublet T1 [ms] ΔT1 [ms] 
7/03/15 1732,5 57 
20/05/15 1651 44 
1/06 - 2/06 - 2/06 2th - 2/06 
4th – 5th 
1848 127 
2/06 3th 1875 7 
 
Table 7: Lactate doublet and quadrouplet T1 estimation. 
Lactate doublet 
and quadrouplet 
T1 [s] ΔT1 [s] A ΔA K ΔK Date 
HLSVDf1 1.83E-00 9.60E-02 3.53E-04 1.16E-05 0.00E+01 0.00E+01 200515 
HLSVDf2 1.84E-00 9.50E-02 3.53E-04 1.09E-05 0.00E+01 0.00E+01 200515 
HLSVDf3 1.90E-00 1.66E-01 3.60E-04 1.56E-05 -9.50E-01 8.84E-02 200515 
HLSVDAPOf1 1.90E-00 2.16E-01 3.35E-04 2.41E-05 0.00E+01 0.00E+01 200515 
HLSVDAPOf2 1.91E-00 2.25E-01 3.34E-04 2.40E-05 0.00E+01 0.00E+01 200515 
HLSVDAPOf3 1.91E-00 4.47E-01 3.37E-04 4.03E-05 -9.87E-01 2.46E-01 200515 
AMARESf1 1.79E-00 1.36E-01 3.31E-04 1.56E-05 0.00E+01 0.00E+01 200515 
AMARESf2 1.80E-00 1.41E-01 3.30E-04 1.54E-05 0.00E+01 0.00E+01 200515 
AMARESf3 1.80E-00 2.77E-01 3.32E-04 2.53E-05 -9.90E-01 1.61E-01 200515 
AMARESAPOf1 1.89E-00 9.70E-02 3.13E-04 1.01E-05 0.00E+01 0.00E+01 200515 
AMARESAPOf2 1.90E-00 1.02E-01 3.12E-04 1.03E-05 0.00E+01 0.00E+01 200515 
AMARESAPOf3 1.88E-00 1.95E-01 3.13E-04 1.66E-05 -1.00E-00 1.10E-01 200515 
HLSVDf1 2.03E-00 3.03E-01 4.36E-04 4.26E-05 0.00E+01 0.00E+01 10615 
HLSVDf2 2.04E-00 3.05E-01 4.36E-04 4.25E-05 0.00E+01 0.00E+01 10615 
HLSVDf3 2.26E-00 6.26E-01 4.57E-04 6.50E-05 -8.75E-01 2.55E-01 10615 
HLSVDAPOf1 2.45E-00 6.27E-01 5.93E-04 1.08E-04 0.00E+01 0.00E+01 10615 
HLSVDAPOf2 2.46E-00 6.40E-01 5.93E-04 1.07E-04 0.00E+01 0.00E+01 10615 
HLSVDAPOf3 3.20E-00 1.64E-00 6.86E-04 2.05E-04 -7.17E-01 3.97E-01 10615 
AMARESf1 1.97E-00 2.60E-01 3.93E-04 3.36E-05 0.00E+01 0.00E+01 10615 
AMARESf2 1.98E-00 2.61E-01 3.93E-04 3.34E-05 0.00E+01 0.00E+01 10615 
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AMARESf3 2.25E-00 3.95E-01 4.17E-04 3.66E-05 -8.40E-01 1.56E-01 10615 
AMARESAPOf1 1.89E-00 1.99E-01 3.32E-04 2.21E-05 0.00E+01 0.00E+01 10615 
AMARESAPOf2 1.89E-00 1.99E-01 3.32E-04 2.21E-05 0.00E+01 0.00E+01 10615 
AMARESAPOf3 2.09E-00 2.75E-01 3.46E-04 2.25E-05 -8.76E-01 1.22E-01 10615 
HLSVDf1 1.90E-00 1.98E-01 3.49E-04 2.32E-05 0.00E+01 0.00E+01 2.06E+04 
HLSVDf2 1.91E-00 2.00E-01 3.49E-04 2.31E-05 0.00E+01 0.00E+01 2.06E+04 
HLSVDf3 1.96E-00 4.17E-01 3.53E-04 3.76E-05 -9.65E-01 2.13E-01 2.06E+04 
HLSVDAPOf1 2.17E-00 5.15E-01 3.57E-04 5.72E-05 0.00E+01 0.00E+01 2.06E+04 
HLSVDAPOf2 2.17E-00 5.22E-01 3.57E-04 5.72E-05 0.00E+01 0.00E+01 2.06E+04 
HLSVDAPOf3 2.02E-00 9.85E-01 3.46E-04 9.12E-05 -1.09E-00 5.44E-01 2.06E+04 
AMARESf1 1.90E-00 1.81E-01 3.30E-04 1.99E-05 0.00E+01 0.00E+01 2.06E+04 
AMARESf2 1.90E-00 1.81E-01 3.30E-04 1.99E-05 0.00E+01 0.00E+01 2.06E+04 
AMARESf3 1.96E-00 3.73E-01 3.35E-04 3.16E-05 -9.57E-01 1.89E-01 2.06E+04 
AMARESAPOf1 1.94E-00 1.60E-01 3.13E-04 1.66E-05 0.00E+01 0.00E+01 2.06E+04 
AMARESAPOf2 1.94E-00 1.62E-01 3.13E-04 1.66E-05 0.00E+01 0.00E+01 2.06E+04 
AMARESAPOf3 1.88E-00 3.07E-01 3.09E-04 2.56E-05 -1.04E-00 1.74E-01 2.06E+04 
HLSVDf2 2.00E-00 2.42E-01 4.29E-04 3.36E-05 0.00E+01 0.00E+01 3.06E+04 
HLSVDf3 2.14E-00 5.08E-01 4.42E-04 5.36E-05 -9.21E-01 2.28E-01 3.06E+04 
HLSVDAPOf2 2.55E-00 8.36E-01 5.77E-04 1.33E-04 0.00E+01 0.00E+01 3.06E+04 
HLSVDAPOf3 2.37E-00 1.72E-00 5.58E-04 2.37E-04 -1.08E-00 8.06E-01 3.06E+04 
AMARESf2 2.09E-00 3.09E-01 4.09E-04 3.98E-05 0.00E+01 0.00E+01 3.06E+04 
AMARESf3 2.35E-00 6.28E-01 4.33E-04 6.02E-05 -8.64E-01 2.42E-01 3.06E+04 
AMARESAPOf2 2.04E-00 4.04E-01 3.80E-04 4.89E-05 0.00E+01 0.00E+01 3.06E+04 
AMARESAPOf3 2.03E-00 8.45E-01 3.80E-04 8.21E-05 -1.00E-00 4.31E-01 3.06E+04 
HLSVDf2 2.07E-00 3.99E-01 3.13E-04 3.94E-05 0.00E+01 0.00E+01 5.06E+04 
HLSVDf3 1.66E-00 1.49E-01 2.84E-04 1.39E-05 -1.32E-00 1.19E-01 5.06E+04 
AMARESf2 2.08E-00 3.58E-01 3.25E-04 3.66E-05 0.00E+01 0.00E+01 5.06E+04 
AMARESf3 1.72E-00 2.40E-01 2.99E-04 2.25E-05 -1.26E-00 1.77E-01 5.06E+04 
HLSVDf2 2.01E-00 1.80E-01 3.60E-04 2.08E-05 0.00E+01 0.00E+01 6.06E+04 
HLSVDf3 2.09E-00 3.73E-01 3.67E-04 3.36E-05 -9.48E-01 1.76E-01 6.06E+04 
AMARESf2 2.04E-00 1.59E-01 3.76E-04 1.90E-05 0.00E+01 0.00E+01 6.06E+04 
AMARESf3 2.17E-00 2.94E-01 3.87E-04 2.70E-05 -9.20E-01 1.30E-01 6.06E+04 
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Figure 9: Lactate T1 doublet and quadrouplet estimation at different time with different sequence parameters, 
algorithms (HLSVD, AMARES). Apodization has been tested for all the algorithms. Error bars have been 
estimated automatically by the fitting procedure with MATLAB-cftool. 
 
Lactate estimation is complicate due to a lower SNR respect to Acetate and to a 
different evolution of peaks with TE. Acquisition were performed with TE shortest (28, 30 
ms) when possible, at 288 and 272 ms looking for the best SNR [Ref. 215, 216, 217]. At 288 
ms al peaks are in phase, so in this case we should have the best SNR. 
 
Table 8: Lactate T1 average and std results for the different sequences parameters.  
The estimate have been evaluated with f2 fit function. 
Lactate doublet + quadrouplet T1 [ms] ΔT1 [ms] 
20/05/15 1861 54 
1/06 - 2/06 - 2/06 2th  2080 216 
2/06 4th – 5th 2049 31 
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6.1.4 - Understanding Acetate and Lactate T1 estimation with AMARES 
 
Looking at the above results on T1 Acetate and Lactate estimation what can be 
surprising are the differences between estimation using different sequences parameters. In 
particular there is no apparent explanation at the difference between the measurements 
performed on 2/06/15 3th and the other. The only explanation come from the inversion 
bandwidth used in the sequence. 
To understand this difference we decided to reanalyze these data, using AMARES, 
looking at the best estimation. What we found is very useful and must be taken into account 
for all future measurements. All estimation performed in MRS must be done with best 
accuracy, looking at the best fitting function. E.g. using AMARES the “Staring values” and 
“Prior Knowledge” must be set with the best accuracy, an error of just 0.5 Hz in the position 
of a spectral line, or a linewidth set too large or too narrow can change the result of the 
algorithm fitting, allowing or not the estimation of peaks area.  
The results in table below shown the importance to use a narrow inversion 
bandwidth centered near the metabolites of interest. It is very important to observe how the 
peak area for Acetate at T = 3000 ms is positive for all sequences less than the sequence of 
2/06/15 3th, this means that the spins inversion depends on on the inversion bandwidth, 
with an apparent delay in the “zero” transition of the spins between these cases. 
About Lactate doublet T1 estimation it is very important set the right “Staring values” 
and “Prior Knowledge” in order to have the best estimation of peaks area. The frequency 
difference between spectral lines must be investigated near the theoretical value, looking 
for the best fit. 
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Figure 10: Example os AMARES parameters setting for Acetate and Lactate T1 estimation. Sequence 2/06/15 
3th. Inv. Bw = 300 Hz, center at 400 Hz. Lactate doublet: peaks 1, 2; Lactate quadrouplet: peaks 4, 5, the other 
two have a too low SNR to be estimated; Acetate: peak 3. 
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Table 9: AMARES results about sequence 2/06/15 3th. Inv. Bw = 300 Hz, center at 400 Hz 
Acetate 
AMARES peaks 
setting 
Manual: 
all parameters set manually 
Autopeak, automatic linewidth 
estimation Autopeak, linewidth: 2 Hz 
TI (ms) =  
170 
1000 
2000 
3000 
5000 
8000 
10000 
Peak area =  
-4,14E-04 
-2,70E-04 
-1,41E-04 
-2,77E-05 
1,35E-04 
2,91E-04 
3,53E-04 
Peak area =  
-4,15E-04 
-2,70E-04 
-1,41E-04 
-2,77E-05 
1,35E-04 
2,91E-04 
3,53E-04 
Peak area =  
-4,14E-04 
-2,70E-04 
-1,41E-04 
-2,77E-05 
1,35E-04 
2,91E-04 
3,53E-04 
F2 fit function 
TR = 15 s 
TE = 28 ms 
T1 = 5.164  (5.045, 5.283)  
a = 0.0004633 (0.0004557, 0.0004709) 
R-square: 0.9998 
T1 =  5.17  (5.045, 5.294) 
a = 0.0004635  (0.0004557, 0.0004714) 
R-square: 0.9998 
T1 = 5.169  (5.05, 5.288) 
a = 0.0004633  (0.0004557, 
0.0004709) 
R-square: 0.9998 
f3 fit function 
TR = 15 s 
TE = 28 ms 
 T1 = 5.007  (4.682, 5.332) 
a = 0.0004974  (0.0004685, 0.0005264) 
k =  -0.8462  (-0.9158, -0.7765) 
R-square: 0.9999 
T1 = 5.017  (4.682, 5.353) 
a = 0.0004986  (0.0004687, 0.0005284) 
k =  -0.8432  (-0.9147, -0.7718) 
R-square: 0.9999 
T1 = 5.025  (4.699, 5.351) 
a = 0.0004991  (0.0004701, 
0.0005282) 
k =  -0.8412  (-0.9103, -0.772) 
R-square: 0.9999 
Lactate doublet 
TI (ms) No prior knowledge Line Shift 6.9 Hz Line Shift 7 Hz Line Shift 7.1 Hz 
170 
1000 
2000 
3000 
5000 
8000 
10000 
-2,44E-04 
-5,55E-05 
8,92E-05 
1,83E-04 
2,53E-04 
2,97E-04 
3,03E-04 
-2,42E-04 
-5,54E-05 
8,82E-05 
1,80E-04 
2,52E-04 
2,95E-04 
3,02E-04 
-2,42E-04 
-5,54E-05 
8,84E-05 
1,81E-04 
2,52E-04 
2,95E-04 
3,02E-04 
-2,43E-04 
-5,55E-05 
8,86E-05 
1,81E-04 
2,52E-04 
2,95E-04 
3,02E-04 
f2 fit 
function 
TR = 15 s 
TE = 28 ms 
T1 = 1.896  (1.826, 1.966) 
a = 0.0003017  (0.0002946, 
0.0003088) 
R-square: 0.9995 
T1 = 1.9  (1.832, 1.968) 
a = 0.0003  (0.0002932, 
0.0003068) 
R-square: 0.9995 
T1 = 1.9  (1.831, 1.969) 
a = 0.0003002  
(0.0002934, 0.0003071) 
R-square: 0.9995 
T1 = 1.899  (1.83, 1.968) 
a = 0.0003006  (0.0002937, 
0.0003075) 
R-square: 0.9995 
f3 fit 
function 
TR= 15 s 
TE= 28 ms 
T1 = 1.94  (1.817, 2.063) 
a = 0.0003051  (0.0002955, 
0.0003148) 
k = -0.966 (-1.03, -0.9024) 
R-square: 0.9997 
T1 = 1.96  (1.857, 2.063) 
a = 0.0003043  
(0.0002964, 0.0003123) 
k = -0.96 (-1.012, -
0.9076) 
R-square: 0.9998 
T1 = 1.956  (1.847, 2.065)  
a = 0.0003041  
(0.0002957, 0.0003126) 
k = -0.9618  (-1.017, -
0.9062) 
R-square: 0.9997 
T1 = 1.952  (1.838, 2.067) 
 a = 0.0003043  (0.0002954, 
0.0003132) 
 k = -0.9637  (-1.022, -0.905) 
R-square: 0.9997 
 
T1 and k estimations are very accurated, with k near the “―1” value referring to 
perfect inversion. The MATLAB fitting of the T1 and k must be performed with the best 
accuracy too, looking at the best “initial value” for the fitting algorithm, looking for the best 
fit by iterative trials anytime closer to the “real” values. 
6.2 - Conclusions about T1 estimation 
 
From the results shown above we can conclude that: 
1. Apparently there are no differences between HLSVD and AMARES results, so we can 
average all results together clustering only by sequences parameters in order to have a 
rough estimate; 
2. AMARES must be used with accuracy in order to have the best estimation; 
3. Fit function f1 should be used only when TR ≫ T1, otherwise the estimation of T1 is not 
correct; 
4. Fit function f2 is the best fitting function in all cases; 
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5. Fit function f3 take in account for the effect of not perfect inversion, but estimation of 
T1 is very similar to f2 but with bigger errors; 
6. NSA, phase cycling don’t affect results if SNR is good as in the case of phantom; 
7. TE must be chosen bearing in mind the evolution of metabolites under study, as in the 
case of Lactate; 
8. TI times should be chosen at the best to sample the Inversion recovery curve in order 
to have a good fitting; 
9. The best estimation has been obtained using a sequence with an inversion bandwidth 
centered near the metabolites of interest; 
10. With an inversion bandwidth of 1500 Hz, the estimation of T1 is 4059 ms with an error 
of 172 ms. 
 
 
   
Chapter 7 
 
SIEMENS PHANTOM T2 AT 3 T 
 
 
In this part some results about the MRS measurements performed using the Philips 
Achieva 3 T scanner at the Azienda Ospedaliero Universitaria Meyer are shown. 
In this part we focus on the estimation of water and metabolites (Acetate, Lactate) T2 
relaxation time at 3 T. Spectra have been acquired with the Siemens phantom using 
different multi-echo sequences parameters, looking for the difference in the estimation. 
Details are repoted in Appendix 3. E.g. data have been acquired using a different TE in order 
to highlight the behavior of Lactate. All of this will be discussed here. At the same time post-
processing has been performed using different algorithms (HLSVD, AMARES), with and 
without apodization (lorentzian apodization with 5 Hz) of spectra, looking for the difference 
in the estimations. A good reference to understand problems in spectra fitting can be found 
in Ref. 214. 
 
7.1 - T2 relaxation time 
 
Measurements were performed using a spin-echo sequences at different TE. Peaks 
area were estimated with HLSVD and AMARES. It is very important to highlight the 
importance of removing the residual water peak in the metabolites spectrum, allowing a 
good estimation of meatabolites peaks as small as the lactate quadrouplet. 
In this case the fitting were performed with the function 𝑓(𝑇2) = 𝑆2 exp(−𝑇𝐸 /𝑇2), 
where “S2” is the signal at equilibrium magnetization. 
For all acquisitions, less than when we used TE multiples of 288 ms for Lactate 
estimation, we just estimated acetate peaks ares due to the problems with Lactate 
evolutions of peaks. 
 
 
 
 
 
 
 
 
 
72                                                                                                                          MAGNETIC RESONANCE SPECTROSCOPY -  DATA ANALYSIS FOR CLINICAL APPLICATIONS
 
 
7.1.1 - Water T2 relaxation time 
 
 
Figure 1: Example of Water multi-echo spectrum with Lorentzian apodization of 5 Hz. TE (ms):  
30, 100, 200, 400, 800, 1200, 1600, 2000, 3000. TR = 6000 ms. NSA = phase cycles = 2. 
 
 
Table 1: Water T2 results. 
Algorithm T2 (s) ΔT2 (s) S ΔS Date 
HLSVD 0.6391 0.0320 0.0785 0.0014 70315 
AMARES 0.6280 0.0660 0.0790 0.0030 70315 
HLSVD_APO5L 0.6363 0.0230 0.0748 0.0010 70315 
AMARES_APO5L 0.6341 0.2634 0.0768 0.0114 70315 
HLSVD 0.6058 0.0168 0.0657 0.0008 200515 
AMARES 0.6058 0.0146 0.0654 0.0007 200515 
HLSVD 0.7446 0.0392 0.0967 0.0021 10615 
AMARES 0.7382 0.0495 0.0966 0.0027 10615 
HLSVD 0.7788 0.0429 0.0995 0.0023 20615 
AMARES 0.7666 0.0827 0.1003 0.0046 20615 
HLSVD_APO5L 0.7760 0.0179 0.0971 0.0009 20615 
AMARES_APO5L 0.8023 0.0738 0.0924 0.0036 20615 
HLSVD 0.78280 0.03070 0.10170 0.00170 30615 
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AMARES 0.79080 0.07480 0.09917 0.00393 30615 
HLSVD_APO5L 0.78600 0.01960 0.09779 0.00103 30615 
AMARES_APO5L 0.79890 0.07060 0.10160 0.00380 30615 
 
 
 
Figure 2: Water T2 
 
Table 2: Water T2 average and std results for the different sequences parameters. 
Water T2 [ms] ΔT2 [ms] 
7/03/15 634 47 
20/05/15 606 0 [no sense, only two 
estimations!] 
1/06 - 2/06 - 2/06 2th 776,5 21 
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7.1.2 - Acetate T2 relaxation time 
 
 
Figure 3: Example of Acetate and Lactate spectrum with multi-echo sequence. These TE echo times are not 
correct for estimation of Lactate peaks area as clearly shown. TE(ms):  
30, 100, 200, 400, 800, 1200, 1600, 2000, 3000. TR = 6000 ms. NSA = phase cycles = 16. 
 
Table 3: Acetate T2 results. 
Algoritmo T2(s) ΔT2 (s) S ΔS Date 
HLSVD 2.8000000 0.3010000 0.0002424 0.0000031 70315 
AMARES 2.8140000 0.5250000 0.0002448 0.0000053 70315 
HLSVD 2.0360000 0.1770000 0.0001981 0.0000056 200515 
AMARES 2.1500000 0.6040000 0.0001847 0.0000164 200515 
HLSVD 3.1080000 0.3490000 0.0003157 0.0000105 10615 
AMARES 3.0850000 0.3530000 0.0003178 0.0000108 10615 
HLSVD_APO 3.1140000 0.3210000 0.0002986 0.0000091 10615 
AMARES_APO 3.0630000 0.3050000 0.0003047 0.0000090 10615 
HLSVD 3.1130000 0.4540000 0.0003317 0.0000142 20615 
AMARES 3.0840000 0.5850000 0.0003359 0.0000188 20615 
HLSVD_APO 3.1290000 0.3460000 0.0003124 0.0000102 20615 
AMARES_APO 2.8950000 0.5020000 0.0003168 0.0000169 20615 
HLSVD 3.0600000 0.2900000 0.0003357 0.0000095 30615 
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AMARES 3.0920000 0.3150000 0.0003383 0.0000102 30615 
HLSVD_APO 3.1120000 0.2880000 0.0003135 0.0000085 30615 
AMARES_APO 3.1310000 0.2850000 0.0003152 0.0000084 30615 
HLSVD 2.8200000 0.4080000 0.0003304 0.0000180 50615 
AMARES 2.8080000 0.4130000 0.0003352 0.0000186 50615 
HLSVD_APO 2.8800000 0.4120000 0.0003082 0.0000164 50615 
AMARES_APO 2.8700000 0.4040000 0.0003099 0.0000163 50615 
HLSVD 2.8200000 0.3760000 0.0003344 0.0000168 60615 
AMARES 2.8110000 0.3740000 0.0003399 0.0000172 60615 
HLSVD_APO 2.8650000 0.3710000 0.0003118 0.0000151 60615 
AMARES_APO 2.8610000 0.3630000 0.0003135 0.0000149 60615 
 
 
 
Figure 4: Acetate T2. Error bars have been estimated automatically  
by the fitting procedure with MATLAB-cftool. 
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Table 4: Acetate T2  average and std results for the different sequences parameters. For the last 2 sequences 
parameters are the same less than the sampling time TE, so we decide in this case to average all these results. 
Acetate T2 [ms] Δ T2[ms] 
7/03/15 2807 10 
20/05/15 2093 8 
1/06 - 2/06 - 2/06 2th 3082 63 
2/06 4th - 2/06 5th 2842 30 
1/06 - 2/06 - 2/06 2th - 2/06 
4th - 2/06 5th 
2986 131 
 
7.1.3 - Lactate T2 relaxation time 
 
Lactate estimation is complicate due to a lower SNR respect to Acetate and to a 
different evolution of peaks with TE. Lactate acquisitions were performed when possible 
with TE multiples of 288 ms (or 272 ms) looking for the best SNR [Ref. 215, 216, 217]. At 
288 ms al peaks are in phase, so in this case we should have the best SNR, but we lost SNR 
due to T2 relaxation time. We tried to use multiples of 272 ms for TE but the results is the 
same as with 288 ms. 
 
 
Figure 5: Lactate and Acetate peaks. Distorsions in Lactate peaks are clearly visible in the backward spectrum 
(TE = 700 ms), while in the front spectrum (TE = 35 ms) there are no distorsions. 
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Figure 6: Acetate and Lactate spectrum with multi-echo sequence acquired with TE multiples of 288 ms. TE (ms) 
= 29, 288, 576, 864, 1152, 1440, 1728, 2304, 2880. TR = 6000 ms. NSA = phase cycles = 16. 
 
 
Figure 7: Acetate and Lactate spectrum with multi-echo sequence acquired with TE multiples of 288 ms. 
Spectrum have been apodized with a Lorentzian of 5 Hz. TE multiples of 288 ms. 
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Table 5: Lactate T2 results. 
Algorithm 
Lactate 
doublet 
T2 (s) T2(s) S ΔS Date 
HLSVD 1.4240000 0.1270000 0.0003209 0.0000149 50615 
AMARES 1.3500000 0.1490000 0.0003558 0.0000210 50615 
HLSVD_APO 1.3490000 0.1060000 0.0003190 0.0000133 50615 
AMARES_APO 1.3520000 0.1640000 0.0003404 0.0000220 50615 
HLSVD 1.3270000 0.0920000 0.0003443 0.0000128 60615 
AMARES 1.3260000 0.1440000 0.0003684 0.0000215 60615 
HLSVD_APO 1.3310000 0.0890000 0.0003258 0.0000117 60615 
AMARES_APO 1.3310000 0.1560000 0.0003475 0.0000218 60615 
Lactate doublet + quadrouplet 
HLSVD 1.3680000 0.1130000 0.0003946 0.0000172 50615 
AMARES 1.3670000 0.1590000 0.0004179 0.0000257 50615 
HLSVD_APO 1.3570000 0.1170000 0.0003807 0.0000175 50615 
AMARES_APO 1.3640000 0.1810000 0.0004024 0.0000284 50615 
HLSVD 1.328000 0.094000 0.000415 0.000016 60615 
AMARES 1.339000 0.146000 0.000436 0.000026 60615 
HLSVD_APO 1.323000 0.081000 0.000397 0.000013 60615 
AMARES_APO 1.337000 0.160000 0.000417 0.000027 60615 
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Figure 8: Lactate doublet and doublet plus quadrouplet T2. Error bars have been estimated automatically by the 
fitting procedure with MATLAB-cftool. 
 
Table 6: Lactate T2 average and std results. 
Lactate doublet T2[ms] ΔT2[ms] 
2/06 4th - 2/06 5th 1349 32 
Lactate doublet + quadrouplet 
2/06 4th - 2/06 5th 1348 18 
 
7.2 - Conclusions about T2 estimation 
 
From the results shown above we can conclude that: 
1. There are no differences between HLSVD and AMARES results, so we can average all 
results together clustering only by sequences parameters 
2. Fit function f1 should be used only when TR ≫T2, otherwise the estimation of T2 is 
not correct 
3. NSA, phase cycling don’t affect results if SNR is good as in the case of phantom 
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4. TE must be chosen bearing in mind the evolution of metabolites under study, as in 
the case of Lactate 
5. TE times should be chosen at the best to sample the multi-echo curve in order to ave 
a good fitting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Chapter 8 
 
SIEMENS PHANTOM: QUANTITATION OF METABOLITES CONCENTRATION 
 
 
Quantitation of metabolites inside the Siemens phantom can be performed 
measuring the area under the peaks of metabolites and water reference. Measurements 
have been performed on three different hospitals. 
For San Giovanni di Dio and Santa Maria Nuova we have a quantitation of 
metabolites concentration in Siemens phantom without f(T1) and f(T2) corrections, while for 
Meyer a complete characterization of the phantom has been performed so corrections for T1 
and T2 have been evaluated. 
The errors in the metabolites concentration have different components: peaks area 
estimations, T1 and T2 estimations and corrections. 
 
8.1 - P.O. San Giovanni di Dio 
 
8.1.1 - Quantitation with PRESS 
 
The sequence is a PRESS with and without water suppression, with the following 
parameters: 
 B0 = 1.5 T 
 VOI at the center of phantom, dimension 20x20x20 mm3 
 TE  = 30 ms  
 TR = 4000ms   
 Number of means =16   
 Phase cycle = 16   
 Samples = 1024   
 Bandwidth = 1000 Hz   
Acetate and Lactate results are reported in Table 1. Because all area were estimated 
for a different number of protons, corrections are necessary.  
E.g. for Lactate doublet (d) and quadruplet (q) the total number of protons is 4. 
Using only Lactate doublet area we have to correct for 3 protons (Area(Lacd)/3), while if we 
use all areas (doublet + quadrouplet) we have to correct for 4 protons (Area(Lacd+q)/4). In 
this case we don’t correct for T1 and T2 relaxing time. 
Errors in peaks area evaluation with AMARES and HLSVD have been estimated by 
the “Std. Amplitude” result given by jMRUI. In this case we found an error of about 2% for 
Acetate area and 4% for Lactate area. 
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Table 1: Results of Acetate and Lactate quantitation using HLSVD and AMARES. For  Lactate the Amplitude is the 
sum of area under all peaks corrected for the right number of protons. 
 Amplitude [a.u.] Metabolites concentration [M] 
Metabolite Water Acetate  Lactate D  Lactate Q [Acetate] [Lac D] 
[Lac D+Q] N° of 
protons 
nW = 2 nA = 3 nLD = 3 nLQ = 1 
HLSVD 1.747e6 5370 5301 654 0.114 0.112 
0.095 
AMARES 1.8e6 5000 4652  0.103 0.096 
 
 
Figure 1: Metabolites spectrum from Siemens phantom acquired at SGD. Data: 
Spettro_04feb2015_fantoccio_Siemens” 
 
8.1.2 - PRESS and STEAM at different echo time 
 
Spectrum form Siemens phantom were acquired with PRESS and STEAM sequence 
with water suppression at multiple echo time, evaluating T2 of metabolites. Lactate 
quadruplet was not considered in this case due to the associated errors in area estimation. 
Spectra were acquired with water suppression with the following parameters: 
  Date 5 september 2014 
  File name: SVS_QA_fantoccio_siemens_5set14 
  Voxel 20⨯20⨯20 mm 
  Number of Average: 16 
 TE PRESS: 30/135/270 ms 
 TE STEAM: 20/135/270 ms 
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 TR: 1500/1500/1610 ms 
T2 estimation however is not possible due to an oscillation of the signal at time TE = 
135 ms. This can be due to a change in the gain of the antennae. 
Table 2: PRESS and STEAM results for the measurements performed on Siemens phantom  
in date 5 september 2014. Data from “SVS_QA_fantoccio_siemens_5set14” 
 TE[ms] Acetate Lactate d 
HLSVD AMARES HLSVD AMARES 
PRESS 30 2.409e3 2.418e3 3.204e3 2.824e3 
135 2.466e3 2.474e3 -1921e3 n.a. 
270 2.198e3 2.194e3 2.74e3 2.722e3 
STEAM 20 1.249e3 1.245e3 1.749e3 1.688e3 
135 1.284e3 1.296e3 n.a. 129 
270 1.177e3 1.176e3 1.458e3 1.472e3 
 
 
Figure 2: PRESS and STEAM spectra performed on Siemens phantom in date 5 september 2014.  
Data from “SVS_QA_fantoccio_siemens_5set14” 
 
8.2 - P.O. Santa Maria Nuova 
 
The sequence is a PRESS with and without water suppression, with the following 
parameters: 
 B0 = 1.5 T  
 VOI at the center of phantom, dimension 20⨯20⨯20 mm3 
 TE  = 30 ms  
 TR = 4000ms   
 Number of means = 16   
 Phase cycle = 16  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 Samples = 1024   
 Bandwidth = 1000 Hz   
The estimated concentration evaluated using HLSVD and AMARES are reported in 
Table 3. In this case we don’t correct for T1 and T2 relaxing time of water and acetate.  
Errors in peaks area evaluation with AMARES and HLSVD have been estimated by 
the “Std. Amplitude” result given by jMRUI. In this case we found an error of about 1% for 
Acetate area and 10% for Lactate area. 
 
Table 3: Results of Acetate and Lactate quantitation using HLSVD and AMARES.  
For Lactate the Amplitude is the sum of area under all peaks. 
Algorithm Amplitude 
Water [a.u.] 
Amplitude 
Acetate [a.u.] 
Amplitude 
Lactate-d 
[a.u.] 
Amplitude 
Lactate-d+q 
[a.u.] 
[Acetate] 
estimated 
 
[Lac-d] 
known 
 
[Lac-d+q] 
known 
HLSVD 3.78 0.0122 0.0122 0.013993 0.119  
 
0.119 
 
0.103 
 
AMARES 3.89 0.0122 0.01065 0.01218 0.115 0.101 0.087 
 
 
 
Figure 3: Siemens phantom spectrum with water suppression, acquired at SMN with PRESS sequence.  
TE 30 ms. Data: “Phantom_siemens_19marzo15” 
8.3 - Azienda Ospedaliera Universitaria Meyer 
 
A PRESS sequence with and without water suppression (see Appendix 2, 3, 4) can be used to 
perform quantitation of Acetate and Lactate in Siemens phantom. The estimated concentration eva-
luated using HLSVD and AMARES are reported in In this case we correct for T1 and T2 of water. 
 Acetate and Lactate estimated by multi-inversion time and multi-echo sequences as shown 
in Chapter 6 and 7. Errors in peaks area evaluation with AMARES and HLSVD have been estimated by 
the “Std. Amplitude” result given by jMRUI. In this case we found an error of about 0.3% for Acetate 
area and 0.5% for Lactate area. 
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{
 
 
 
 
𝑓(𝑇1) = 1 − 2 ∗ exp(−
𝑇𝑅 −
𝑇𝐸
2
𝑇1
)+ exp⁡(−𝑇𝑅/𝑇1)
𝑓(𝑇2) = exp⁡(−𝑇𝐸/𝑇2)
 
 
Table 4: Summary of results for T1 and T2 at 3T. 
 T1(ms) ΔT1 (ms) T2 (ms) ΔT2 (ms) 
Water 3214 18 776.5 21 
Acetate 5169 119 2986 131 
Lactate doublet 1900 68 1349 32 
Lactate doublet + 
quadrouplet 
2080 216 1348 18 
 
Table 5: Correction factors for water and metabolites at various TR and TE.  
Errors have been evaluated with the errors propagation formula. 
 Parameters Water ΔW(%) Acetate ΔA(%) Lactate 
D 
ΔLD(%) Lactate ΔL(%) 
f(T1) TR: 4000 ms 
TE: 35 ms 
0.71 0.2 0.54 0.82 0.88 0.93 0.85 2.94 
f(T2) 0.96 0.12 0.99 0.05 0.97 0.06 0.97 0.035 
f(T1) TR: 15000 
ms 
TE: 288 ms 
0.99 0.026 0.94 0.38 1 0.012 1 0.062 
f(T2) 0.69 1 0.91 0.42 0.81 0.51 0.81 0.29 
 
Table 6: Errors on estimations due to f(T1), f(T2).  
For metabolite the total error is the sum of water and  metabolite. 
Sequence 
parameters 
 ΔWater (%) ΔAcetate (%) ΔLactate D (%) ΔLactate (%) 
TR: 4000 ms 
TE: 35 ms 
Δ 0.32 0.87 0.99 2.975 
Metab total 
Error 
Δ (Water + 
Metab) 
 1.19 1.31 3.295 
TR: 15000 ms 
TE: 288 ms 
Δ 1.026 0.8 0.522 0.352 
Metab total 
Error 
Δ (Water + 
Metab) 
 1.826 1.548 1.378 
 
Example 1  
Date: 7 march 2015 
TR = 4000 ms, TE = 35 ms, NSA = 16, Phase cycles = 16;  
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Figure 4: Spectrum of Siemens phantom. Metabolites peaks are visible. TR = 4000 ms, TE = 35 ms. 
 
Table 7: Absolute quantitation results for example 1 using the same sequence  
with and without water suppression. 
Algorithm Amp. 
Water 
[a.u.] 
Amp. 
Acetate 
[a.u.] 
Amp. 
Lactate-
d [a.u.] 
Amp. 
Lactate-
d+q [a.u.] 
[Ac]  
 
[Ac] 
corr 
[Lac-d]  
 
[Lac-d]  
corr 
[Lac-
d+q]  
 
[Lac-
d+q]  
corr 
HLSVD 0.0694 2.321e-4 2.406e-4 2.7401e-4 0.124 0.159 0.128 0.1016 0.109
6 
0.0895 
AMARES 0.0681 2.352e-4 2.263e-4 2.5838e-4 0.1277 0.163 0.143 0.1135 0.105 0.086 
HLSVD_A
PO5L 
0.0664 2.175e-4 2.253e-4 2.5459e-4 0.121 0.155 0.1255 0.0996 0.106 0.0866 
AMARES_
APO5L 
0.0667 2.189e-4 2.087e-4 2.3601e-4 0.121 0.155 0.116 0.0921 0.098
2 
0.080 
 
 
Table 8: Absolute quantitation results for example 1 using water reference. 
Algorithm Amp. 
Water 
[a.u.] 
Amp. 
Acetate 
[a.u.] 
Amp. 
Lactate-
d [a.u.] 
Amp. 
Lactate-
d+q [a.u.] 
[Ac]  
 
[Ac] 
corr 
[Lac-d]  
 
[Lac-d]  
corr 
[Lac-
d+q]  
 
[Lac-
d+q]  
corr 
HLSVD 0.0735 2.321e-4 2.406e-4 2.7401e-4 0.117 0.149
5 
0.121 0.096 0.103
5 
0.085 
AMARES 0.0762 2.352e-4 2.263e-4 2.5838e-4 0.114 0.146 0.110 0.087 0.094 0.077 
HLSVD_A
PO5L 
0.0703 2.175e-4 2.253e-4 2.5459e-4 0.1145 0.146
5 
0.119 0.094 0.100
5 
0.082 
AMARES_
APO5L 
0.0752 2.189e-4 2.087e-4 2.3601e-4 0.108 0.138 0.103 0.0815 0.087
1 
0.071 
In the corrections the right number of protons must be taken into account, 2 for 
water, 3 for Acetate and Lactate doublet, 4 for Lactate in general.  
The concentration of metabolites in the Siemens phantom is provided as 0.1 M, then 
we found an error  ranging around 40% for Acetate, ranging from 4% to 20% for Lactate 
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doublet and from 15% to 29% for Lactate. For Lactate there is a clear indication that 
absolute quantitation of doublet is better than quadrouplet due to the errors in estimation 
of area.  
For Acetate the big error could be due to a TR < T1. In this case a different formula 
must be used to correct. Apodization can be used to give a better estimation too.  
Quantification by a sequence with and without water suppression must takes into 
account the “RF drive scale”, which is a parameter connected to the transmitted power. 
In this case 0.5362 for water and 0.5327 for water suppressed (metabolites 
spectrum), so just a correction of 0.6% is possible. This correction can be important when 
different phantoms are used for quantitation. 
 
Example 2  
Date: 2 june 2015 
TR = 15000 ms, TE = 288 ms, NSA = 4, Phase cycles = 4; 
Table 9: Metabolites quantitation results for example 2. 
Algorithm Amp. 
Water 
[a.u.] 
Amp. 
Acetate  
[a.u.] 
Amp. 
Lactate-
d  
[a.u.] 
Amp. 
Lactate-d+q  
[a.u.] 
[Ac]  
 
[Ac] 
corr 
[Lac-d]  
 
[Lac-d]  
corr 
[Lac-
d+q]  
 
[Lac-
d+q]  
corr 
HLSVD 0.0875 3.94e-4 2.69e-4 3.1413e-4 0.167 0.133 0.114 0.096 0.1 
 
0.08
4 
AMARES 0.0913 4.013e-4 2.859e-4 3.346e-4 0.163 0.130 0.116 0.098 0.102 0.08
6 
HLSVD_A
PO5L 
0.0829 3.696e-4 2.563e-4 3.0338e-4 0.165 0.132 0.114 0.097 0.102 0.08
6 
AMARES_
APO5L 
0.0872 3.721e-4 2.733e-4 3.2135e-4 0.158 0.126 0.116 0.098 0.102 0.08
7 
 
In this case we use water reference as a measure of water instead than repeat the 
same measurement without water suppression. 
The concentration of metabolites in the Siemens phantom is provided as 0.1 M, then 
we found an error  ranging around 30% for Acetate, ranging around 3% for Lactate doublet 
and 15% for Lactate doublet and quadrouplet. For Lactate there is a clear indication that 
absolute quantitation of doublet is better than quadrouplet due to the errors in estimation 
of area. Apodization can be used to give a better estimation too.  
 
8.3.1  - Understanding quantitation of Acetate  
 
In the case of Acetate different results can be found using a different T1, e.g. 4059 ms 
with an error of 172 ms. In this case we found correction factors f(T1) of 0.62 and 0.97 for  
TR  = 4 s and 15 s respectively.  
In this case estimations are always nearest the “known” concentration of 0,1 M 
declared by Siemens. The error due to f(T1) and f(T2) is about 1-2%. 
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Table 10: Quantitation of Acetate with a T1 of 4059 ms. 
 Water “ext”,  
TR = 4 s 
Water “REF”,  
TR = 4 s 
Water “REF”,  
TR = 15 s 
HLSVD 0.136 0.128 0.129 
AMARES 0.140 0.125 0.126 
HLSVD_APO5L 0.133 0.126 0.127 
AMARES_APO5L 0.133 0.118 0.122 
8.3.2 - Conclusions about quantitation at Meyer 3T 
 
Results above shown that: 
1. Acetate estimation is always bigger than theoretical value given by manifacturer 
2. Lactate estimation is always lesser than theoretical value given by manifacturer 
3. Lactate doublet is very near to the theoretical value given by manifacturer 
4. Errors coming from correction factor f(T1), f(T2) are very small and can’t take into 
account of the wrong estimation in concentration of metabolites 
5. For the case T1 > TR a new theoretical formula must be taken into account  
6. Water acquired in the same sequence (“Water REF”) gives the best estimation of 
water content for quantitation 
7. The best estimation of metabolites concentration can be obtained taking into 
account all corrector factors, RF drive scale too  
8. For Acetate estimation depends on the T1, with the best estimation given by a T1 of 
about 4 s. In this case we are unable to give the best result due to the different T1 
estimations with the inversion bandwidth, so we prefer give to the reader all the 
solutions aiming to highlight the difficulties of MRS. We are already planning new 
measurements in order to completely characterize the phantom.  
9. A phantom with a perfectly known concentration is mandatory to understand 
sequence parameters influences on measurements results. 
 
 
 
 
 
 
   
Chapter 9 
 
IN VIVO MAGNETIC RESONANCE SPECTROSCOPY 
 
 
In this part of the thesis we will explore the potential of magnetic resonance 
spectroscopy for the detection of prostate cancer using in vivo data coming from Santa Maria 
Nuova hospital patients. Data will be analyzed using Philips software and jMRUI-v5.0 
looking for discrepancies in the metabolites ratio. 
Some examples of CSI are reported too, using only the Philips software. 
In vivo acquisitions are very complex due to different problems: 
 Location of the target: a target in the center of the organ is simpler to analize than a 
peripherical one due to distortions from the interface between organs 
 Dimension of the target: a small target inside a voxel can give a very small signal 
due to the contemporary presence of healthy and disead tissue  
 Acquisition time: it should be shortest to prevent movement artifacts and to the 
confort of the patient 
 Dimension of the patient: the physical dimension of the patient is a critical point 
due to the presence of fat and the distance from the antennae 
 Water and fat suppression: great care should be taken in using suppression 
tecniques bacause some artifacts can be introduced in the acquired spectrum. 
 
Before to show the results of analysis we summarize some “good practice” in accord 
with our and Philips experience, hoping to help people to perform in vivo acquistion better 
day by day. 
Good practice for patient: 
 well positioned in the center of the gantry 
 fast (“digiuno”) 
 Cleaning of the rectum 
 Empty bladder 
 Buscopan for relaxation 
 Biopsy at least 1-2 months before MRS to prevent contamination problems 
 Breath with thorax and not with abdomen (japanese method) 
 Maximum immobilization, legs too 
Good practice for scanner: 
 Coil: FLEX M 
 Right position of the shimming volume 
 No saturation bands 
 Basing PULSE: FAT and WATER saturation 
 VOI: only in the prostate area, avoiding air in the rectum 
 Spectrum acquisition just after the survey sequence 
 The area under investigation must be positioned at the center of the voxel. In this 
way we are very confident that signal is coming from the suspected lesion 
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 Sequence: SV PRESS 120, 3D PRESS 120 
 Short and long TE spectroscopic sequences in order to see all metabolites 
  The multivoxel sequence must be named as “AX”, allowing to merge anatomical and 
spectroscopic images with the same axial reference system 
Sequences: SV_PRESS_120 and 3D_PRESS_120 
 
Table 1: Parameters setting for SVS and CSI sequences  
for in vivo acquisitions at 1.5 T Philips of P.O. S.M.N.. 
SVS CSI 
Coil selection =  "SENSE-Flex-M"; 
     element selection = "12"; 
     connection =  "d"; 
Dual coil =   "no"; 
VOI orientation =  "transverse"; 
VOI size AP (mm) =  17.2081547; 
         RL (mm) =  18.3262787; 
         FH (mm) =  16.7638588; 
Samples =   512; 
Spectral BW (Hz) =  1000; 
      Ang.  AP (deg) =  0; 
            RL (deg) =  0; 
            FH (deg) =  0; 
VOI offc. AP (P=+mm) =  12.5349264; 
          RL (L=+mm) =  16.5764351; 
          FH (H=+mm) =  23.2685833; 
VOI ang. AP (deg) =  0.717895746; 
         RL (deg) =  2.6025157; 
         FH (deg) =  -0.0295728277; 
Chem. shift Dir AP =  "A"; 
Chem. shift Dir LR =  "L"; 
Chem. shift Dir FH =  "F"; 
Large table movement =  "no"; 
REST slabs =   2; 
    shared =   "no"; 
    type =   "free", "circular", 
    (10) "parallel"; 
    circular slabs =  (12) 10; 
    orientation =  (12) "transverse"; 
    thickness (mm) =  (12) 60; 
    position =   (2) "feet", (10) 
"left"; 
    gap =   (12) "default"; 
        (mm) =   (2) 6, (10) 20; 
    distance (mm) =  (12) 50; 
Rest  Offc. AP (P=+mm) = 11.4959831, 
    12.5349264, (10) 0; 
            RL (L=+mm) = 8.17602348, 
    16.5764351, (10) 0; 
            FH (H=+mm) = -21.2756672, 
    23.2685833, (10) 0; 
      Ang.  AP (deg) =  -8.44129562, 
    0.717895746, (10) 
0; 
            RL (deg) =  -5.59742785, 
    2.6025157, (10) 0; 
            FH (deg) =  -3.36176729, 
    -0.0295728277, 
(10) 0; 
    angulation (deg) =  (12) 0; 
    FM shape =   (12) "no"; 
    composite elements = (12) 1; 
    correction factor = (12) 1; 
    power =  (12) "1"; 
    target =   (12) "fat"; 
    timed =   "no"; 
      start (phase) =  1; 
      stop (phase) =  2; 
Patient position =  "head first"; 
        orientation =  "supine"; 
Coil selection =  "SENSE-Flex-M"; 
     element selection = "12"; 
     connection =  "d"; 
Dual coil =   "no"; 
CLEAR =    "yes"; 
    body tuned =  "no"; 
FOV          RL (mm) =  170; 
             AP (mm) =  340; 
             FH (mm) =  53.5499992; 
Voxel size   RL (mm) =  2.5; 
             AP (mm) =  2.5999999; 
Slice thickness (mm) =  3.5; 
Recon voxel size (mm) =  2.20000005; 
Fold-over suppression =  "no"; 
Reconstruction matrix =  160; 
SENSE =    "no"; 
Stacks =   1; 
    type =   "parallel"; 
    slices =   14; 
    slice gap =   "default"; 
    slice orientation =  "transverse"; 
    fold-over direction = "AP"; 
    fat shift direction = "P"; 
Stack Offc. AP (P=+mm) = 15.685936; 
            RL (L=+mm) = 9.36958981; 
            FH (H=+mm) = 23.5021114; 
      Ang.  AP (deg) =  0.717895746; 
            RL (deg) =  2.6025157; 
            FH (deg) =  -0.0295728277; 
Minimum number of packages = 1; 
Slice scan order =  "default"; 
Large table movement =  "no"; 
PlanAlign =   "no"; 
REST slabs =   0; 
Shim  Size  AP (mm) =  83.9444275; 
            RL (mm) =  103.144699; 
            FH (mm) =  59.3506508; 
      Offc. AP (P=+mm) = 15.6880255; 
            RL (L=+mm) = 9.17329025; 
            FH (H=+mm) = 23.1999207; 
      Ang.  AP (deg) =  0.523141384; 
            RL (deg) =  2.34501886; 
            FH (deg) =  -0.00299369078; 
Patient position =  "head first"; 
        orientation =  "supine"; 
Scan type =   "Imaging"; 
Scan mode =   "MS"; 
    technique =   "SE"; 
Modified SE =   "no"; 
Acquisition mode =  "cartesian"; 
Fast Imaging mode =  "EPI"; 
    shot mode =   "single-shot"; 
Echoes =   1; 
    partial echo =  "no"; 
TE =    "shortest"; 
Flip angle (deg) =  90; 
TR =    "shortest"; 
Halfscan =   "yes"; 
    factor =   0.616822422; 
Water-fat shift =  "minimum"; 
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Scan type =   "Spectroscopy"; 
Scan mode =   "SV"; 
    technique =   "ECHO"; 
VOI selection =   "volume"; 
    method =   "PRESS"; 
Gradient Spoiling =  "no"; 
Fast Imaging mode =  "none"; 
Echo acquisition =  "half"; 
TE =    "user defined"; 
    (ms) =   120; 
Flip angle (deg) =  90; 
RF pulse set =   "normal"; 
TR =    "user defined"; 
    (ms) =   1500; 
Shim =    "iterative VOI"; 
    Shim TR =   "same"; 
    Shim TE =   "same"; 
Water suppression =  "excitation"; 
    window (Hz) =  80; 
    second pulse angle = 300; 
WS prescan =   "auto"; 
BASING pulse =   "water sup."; 
    window (Hz) =  80; 
    flip angle (deg) =  180; 
    frequency offset =  "default"; 
    inv. delay (ms) =  5; 
Fat suppression =  "SPAIR"; 
   inversion delay (ms) = 165; 
   frequency offset =  "user defined"; 
       offset (Hz) =  40; 
Pre-saturation =  "no"; 
SAR mode =   "high"; 
B1 mode =   "default"; 
PNS mode =   "low"; 
Gradient mode =   "default"; 
SofTone mode =   "no"; 
Cardiac synchronization = "no"; 
Respiratory compensation = "no"; 
Startup acquisitions =  2; 
NSA =    256; 
Phase cycles =   16; 
Frequency stabilization = "no"; 
Parameter series =  "no"; 
Manual start =   "no"; 
Dynamic study =   "no"; 
Preparation phases =  "auto"; 
Manual Offset Freq. =  "no"; 
Receiver optimization =  "ON"; 
Spectral correction =  "no"; 
Reference tissue =  "White matter"; 
PlanScan metabolite =  "Citrate"; 
Shifted metabolite displayed = "Lactate/Lipid"; 
Preset window contrast = "soft"; 
Save raw data =   "no"; 
Hardcopy protocol =  "no"; 
Elliptical k-space shutter = "default"; 
IF_info_seperator =  1634755923; 
Total scan duration =  "06:27.0"; 
Rel. signal level (%) =  100; 
Act. TR/TE (ms) =  "1500 / 120"; 
Min. TR/TE (ms) =  "1133 / 117"; 
SPAIR TR (ms) =   1500; 
SPAIR offset act./default (Hz) = "40 [8]"; 
Spectral resolution (Hz/point) = 1.953125; 
Readout duration (ms) =  512; 
SAR / whole body =  "< 13 % / 0.5 W/kg"; 
Whole body / level = "< 0.5 W/kg / normal"; 
B1 rms [uT] =   1.60499966; 
PNS / level =   "33 % / normal"; 
Sound Pressure Level (dB) = 0; 
Shim =    "volume"; 
ShimAlign =   "no"; 
Fat suppression =  "SPIR"; 
   strength =   "strong"; 
   frequency offset =  "default"; 
Water suppression =  "no"; 
BB pulse =   "no"; 
MTC =    "no"; 
Diffusion mode =  "DWI"; 
    gradient overplus =  "yes"; 
    nr of b-factors =  4; 
    b-factor order =  "user defined"; 
    b-factors =   0, 500, 1000, 
    1500, (12) 0; 
    average high b =  "no"; 
SAR mode =   "high"; 
B1 mode =   "default"; 
PNS mode =   "low"; 
Gradient mode =   "default"; 
SofTone mode =   "no"; 
Cardiac synchronization = "no"; 
Respiratory compensation = "no"; 
Navigator respiratory comp = "no"; 
Flow compensation =  "no"; 
NSA =    11; 
SMART =    "no"; 
Manual start =   "no"; 
Dynamic study =   "no"; 
Preparation phases =  "full"; 
Manual Offset Freq. =  "no"; 
MIP/MPR =   "no"; 
Images =   " M", (3) " no"; 
Autoview image =  " M"; 
Calculated images =  (4) " no"; 
Reference tissue =  "Liver"; 
Preset window contrast = "soft"; 
Reconstruction mode =  "real time"; 
Save raw data =   "no"; 
Hardcopy protocol =  "no"; 
Ringing filtering =  "rectangular"; 
Geometry correction =  "default"; 
IF_info_seperator =  1634755923; 
Total scan duration =  "04:53.7"; 
Rel. signal level (%) =  100; 
Act. TR (ms) =   "2623"; 
Act. TE (ms) =   "84"; 
ACQ matrix M x P =  "68 x 131"; 
ACQ voxel MPS (mm) =  "2.50 / 2.60 / 3.50"; 
REC voxel MPS (mm) =  "2.13 / 2.13 / 3.50"; 
Scan percentage (%) =  96.3235321; 
Packages =   1; 
Min. slice gap (mm) =  0; 
Act. slice gap (mm) =  0.349999994; 
EPI factor =   131; 
WFS (pix) / BW (Hz) =  "19.975 / 10.9"; 
BW in EPI freq. dir. (Hz) = "2001.5"; 
SAR / whole body =  "< 5 % / 0.2 W/kg"; 
Whole body / level = "< 0.2 W/kg / normal"; 
B1 rms [uT] =   1.00594115; 
PNS / level =   "60 % / normal"; 
Sound Pressure Level (dB) = 14.8767385; 
 
92                                                                                                                          MAGNETIC RESONANCE SPECTROSCOPY -  DATA ANALYSIS FOR CLINICAL APPLICATIONS
 
 
 
Metabolites spectrum peaks info 
 
In the prostate spectrum are usually visible these peaks: 
1. Water residual from suppression at about 4.7 ppm 
2. Choline, 3.19 ppm 
3. Creatine, 3.03 ppm 
4. CH2 NAA, Citrate doublet, 2.67 ppm 
5. CH2 NAA, Citrate doublet, 2.49 ppm 
 
9.1 - Patients info 
 
More than 40 cases of suspected prostate cancer have been acquired at the Santa 
Maria Nuova Hospital. Some significative examples are reported here. All SVS spectra have 
been acquired using the SV_PRESS_120 sequence described above. Usually a “positive case” 
is when the ratio (Ch + Cr)/Citr > 0.5. 
Gleason grading system 
 
The Gleason grading system is used to help evaluate the prognosis of men with 
prostate cancer using samples from a biopsy. Together with other parameters, it is 
incorporated into a strategy of prostate cancer staging which predicts prognosis and helps 
guide therapy. A Gleason score is given to prostate cancer based upon its microscopic 
appearance. Cancers with a higher Gleason score are more aggressive and have a worse 
prognosis. 
 
jMRUI and Philips software  
 
Some examples of jMRUI-v5.0 and Philips software metabolites quantitation ratio 
are reported below in order to understand the differences between data elaboration. Philips 
software is a “black box” because user can only modify some fitting parameters, while jMRUI 
gives to the user more flexibility. Different estimations in the metabolites ratio have been 
found using the two software with discrepancies of 50% too. In these cases the clinical use 
of MRS is very difficult.  
Some errors can be due to Philips software fitting procedure, which e.g. for Citrate 
use just one component for the doublet, introducing an error in the area estimation.  
 
9.1.1 - Patient 1: Positive case 
 
ID Bobina & Seq Gleason 
score 
Diffusion Morfological 
MV Phased array 
external; T1, T2, 
DWI, SV e 3D 
PRESS 
3+3 Nella porzione periferica della ghiandola 
nella metà sinistra in sede medioghiandolare 
si evidenziano segni di restrizione dell’ADC 
per stipamento cellulare patologico. 
Zona sospetta 
nella parte 
sinistra 
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Figure 1: Patient 1 CSI. Philips software. 
 
 
Figure 2: Patient 1 CSI. Philips software. 
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Figure 3: Patient 1 CSI. Philips software. 
 
 
Figure 4: Patient 1. Philips software. Single-Voxel-Spectroscopy (SVS). Results with “h” are evaluated with 
height ratio, but won’t be considered because only peak area is proportional to metabolite concentration. 
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Figure 5: Patient 1, SVS. Spectrum without residual water peak removing. jMRUI software. 
 
 
Figure 6: SVS, spectrum from Patient 1 with jMRUI software.  
Choline, Creatine and Citrate doublet are clearly visible. 
Table 2: AMARES results for Patient 1. (Ch+Cr)/Citrate > 0.5. 
 Choline Creatine Ch/Cr Citrate Ch/Citrate (Ch+Cr)/Citrate Noise 
std 
Philips 0.031 0.038 0.82 0.092 0.33 0.74  
jMRUI 7.333e-5 5.890e-5 1.24 1.428e-4 0.51 0.926 1.67e-5 
Apodization 
Lorentzian 5 
Hz 
7.623e-5 5.530e-5 1.38 1.429e-4 0.53 0.92 1.47e-6 
 
96                                                                                                                          MAGNETIC RESONANCE SPECTROSCOPY -  DATA ANALYSIS FOR CLINICAL APPLICATIONS
 
 
Fitting errors from AMARES have been estimated as Ch 1.3%, Cr 2.1%, Citrate 0.7%, 
so in the estimated ratio we have an error of about 4%. 
Results from AMARES and Philips software show differences around 20% in the 
estimated ratio. (Ch+Cr)/Citrate>0.5 in all estimations, so this can be considered a “positive” 
case. 
 
9.1.2 - Patient 2 
 
ID 
Bobina & 
Seq 
Gleason 
score 
Diffusion Morfological 
DeSA 
Phased 
array 
external 
T1, T2, 
DWI, SV 
4+4 
Si evidenziano 
segni di 
restrizione ADC 
Estesa alterazione morfo strutturale della 
ghiandola prostatica con estensione 
dell’apice fino alla base ed interessamento 
della porzione periferica e centrale e del 
fascio vescicolo-deferenziale 
 
 
 
Figure 7: Patient 2, SVS from Philips software. Spectrum fit 1. 
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Figure 8: Patient 2, SVS. Philips software. Spectrum fit 2. 
 
 
 
Figure 9: Patient 2, original spectrum withot removing water residual peak. jMRUI softare. 
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Figure 10: Patient 2, spectrum after removing water residual peak. 
Choline and Citrate peaks are visible. jMRUI softare. 
 
 
 
Figure 11: AMARES results for Choline and Citrate. jMRUI softare. 
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Table 3: AMARES results. Simbol “?” in the data means that software estimation probably is not correct. 
 Choline Creatine Ch/Cr Citrate Ch/Citrate (Ch+Cr)/Citrate Noise 
std 
Philips 
software 
Fit 1 
0.032 0.002? 19.87? 0.654 0.05 0.05  
Philips 
software 
Fit 2 
0.1 0.0? 2.56? -1102? Not 
Available 
Not Available  
jMRUI 6.388e-5 Not 
Available 
Not 
Available 
4.594e-
6? 
13.9? Not Available 1.59e-5 
Apodization 
Lorentzian 5 
Hz 
5.459e-5 Not 
Available 
Not 
Available 
Not 
Available 
Not 
Available 
Not Available 1.39e-6 
 
In this patient only Choline is estimable, apodization with a Lorentzian 5 Hz doesn’t 
give a better estimation. Estimations from Philips software are completely wrong. 
 
9.1.3 - Patient 3: an example of “strongly positive” case. 
 
In this case only Choline is present. 
 
Figure 12: Patient 3, spectrum with jMRUI software. Only Choline peak is present. 
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9.1.4 - Patient 4: Prostata SV 27/11 
 
 
Figure 13: Patient 4, SVS. Philips software. 
 
 
Figure 14: Patient 4. SVS, jMRUI software. 
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Figure 15: AMARES results. jMRUI software. 
 
Table 4: AMARES results for Patient 4. 
 Choline Creatine Ch/Cr Citrate Ch/Citrate (Ch+Cr)/Citrate Noise 
std 
Philips 
Softare 
0.032 0.029 1.09 0.073 0.43 0.83  
jMRUI 4.487e-
5 
5.323e-5 0.84 8.796e-
5 
0.51 1.11 1.87e-
5 
jMRUI with 
Apodization 
Lorentzian 
5 Hz 
3.876e-
5 
5.081e-5 0.76 9.009e-
5 
0.43 0.99 1.69e-
6 
 
Results from AMARES and Philips software show differences above 20% in the 
estimated ratio. (Ch+Cr)/Citrate >0.5, so this can be considered a “positive” case. Errors 
from fitting have been estimated as Ch 12%, Cr 12%, Citrate 7%, so the error in the ratio is 
about 30%. Then in this case Philips and jMRUI give the same estimation. 
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9.1.5 - Patient 5: Prostata SV2 
 
Figure 16: Patient 5 spectrum. jMRUI software. 
Table 5: AMARES results for Patient 5. 
 Choline Creatine Ch/Cr Citrate Ch/Citrate (Ch+Cr)/Citrate Noise std 
jMRUI 4.985e-5 7.181e-5 0.69 1.506e-
4 
0.33 0.807 1.63e-5 
jMRUI with 
Apodization 
Lorentzian 5 
Hz 
4.516e-5 6.124e-5 0.74 1.444e-
4 
0.31 0.74 1.44e-6 
 
9.1.6 - Patient 6: MA5/03 
 
Figure 17: Patient 6. jMRUI software. 
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Table 6: AMARES results for Patient 6. 
 Choline Creatine Ch/Cr Citrate Ch/Citrate (Ch+Cr)/Citrate Noise 
std 
jMRUI 6.281e-5 7.997e-5 0.78 1.208e-4 0.52 1.18 1.72e-5 
 
 
9.1.7 - Patient 7: SS, positive case post-operative. 
 
Description: “Positivo. Prostata operata, con recidiva, si vede solo tumore.” Visible 
only Choline peak. 
 
 
Figure 18: Patient 7. Positive case, only Choline peak is visible. jMRUI software. 
 
9.1.8 - Patient Head 1: an example of brain spectroscopy 
 
This is an example of brain spectroscopy performed at S.M.N. Hospital. 
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Figure 19: Patient Head 1. Spectrum demonstrates major metabolites, such as NAA peak at 2.02, Cho peak at 
3.22, and Cr, which has peaks at 3 and 3.9 ppm. At short TE, metabolites with shorter T2 decays will be demon-
strated, such as Myo at 3.6 ppm, Glx at 2.05 e 2.5 ppm, and sometimes some lipid peaks at 0.9 and 1.3 ppm. 
 
   
Chapter 10 
 
FUTURE DEVELOPMENTS: 
NANOPARTICLES FOR THERANOSTIC APPLICATIONS IN MAGNETIC 
RESONANCE IMAGING 
 
 
In this chapter, we aim to introduce some application of nanoparticles in MRI. In 
particular we will introduce Gold Nanoparticles (GNP) and PMMA-nanoparticles (PMMA-
NP) which are already used at “Nello Carrara” Institute of Applied Physics, IFAC-CNR (via 
Madonna del Piano 10, Sesto Fiorentino, Firenze), Italy, for Biophotonics applications. 
My idea is to use this type of nanoparticles for magnetic resonance imaging, 
exploring their potential as a theranostic agent. We will explore their effects in diffusion and 
spectroscopy, trying to characterize their behavior, opening a new scenario for their 
applications. 
This part of my thesis has been developed in collaboration with Francesco Baldini, 
Ambra Giannetti, Sara Tombelli, Barbara Adinolfi, Roberto Pini, Fulvio Ratto, Sonia Centi, 
Lucia Cavigli, all from IFAC-CNR. 
PMMA nanoparticles were supplied by ISOF-CNR (Istituto per la Sintesi Organica e la 
Fotoreattività, Area della Ricerca di Bologna, via P. Gobetti 101, 40129 Bologna, Italy) while 
Gold nanoparticles by Roberto Pini, Fulvio ratto e Lucia Cavigli from IFAC-CNR. 
 
10.1 - Brief  introduction to nanoparticles 
 
Nanoparticles (NPs) are promising tools for applications in biology. Many innovative 
techniques using nanoparticles are being developed for the detection of low levels of 
analytes, pathogens, and cells. Nanoparticles are also being explored as delivery vehicles, 
imaging agents, and to better understand biology at the molecular, cellular, and tissue level. 
The integration of nanotechnology with biology offers many advantages that can help 
stimulate further biological and biomedical studies. 
NPs can be engineered to possess unique compositions and functionalities to enable 
novel tools and techniques that have not existed previously in biomedical research.  
Nanoparticles are defined as structures that are nanometers in size [Ref. 157-160]. 
In contrast to atoms and molecules, nanomaterials have an extensive available surface area 
per unit of volume and tunable optical, electronic, magnetic and biologic properties, which 
can be obtained, in some cases, only in nanometer scale. They can be engineered to have 
different sizes, shapes, chemical compositions, chemical surface characteristics, and hollow, 
porous or solid structures [Ref. 161, 162].  
Nanoparticles can be made of materials of diverse chemical nature, the most 
common being metals, metal oxides, silicates, polymers, carbon, lipids and biomolecules. 
Nanoparticles exist in several different morphologies such as spheres, cylinders, platelets, 
tubes, etc. When used in living organisms, the study of these structures is known as 
nanomedicine. Thus, nanomedicine can be defined as the use of nanoparticles for diagnosis, 
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monitoring of physical and pathologic processes, for therapy and for control of biological 
systems [Ref. 157].  
Over the last years, many studies have been reported in order to describe novel drug 
delivery systems. In fact, nanotechnology can be used to prepare nanostructures that will 
present advantages over regular chemotherapeutic agents, especially against cancer. For 
instance, drug carriers can be tailored to overcome some of the mechanisms conferring drug 
resistance to multidrug resistant cancer cells [Ref. 163]. Long-circulating nanocarriers, such 
as lipossomes, micells, lipid solid nanoparticles, and polymeric nanoparticles can 
accumulate in several affected areas where vasculature is somehow abnormal, by the EPR 
(Enhanced Permeability and Retention) effect. These particles, typically, display higher 
bioavailability and concentration in targeted tissues. Furthermore, reduced side effects 
compared with free drug were observed [Ref. 164].  
Along with drug delivery researches other studies have been done to develop new 
tracers for diagnostic applications. Based on advances in molecular imaging, nanoparticles 
can be used to visualize, characterize and measure biological process at molecular and 
cellular level. Molecular imaging takes advantage of the traditional diagnostic imaging 
techniques and introduces molecular imaging probes to measure the expression of 
indicative molecular markers at different stages of diseases [Ref. 165].  
Radiotracer-based imaging either using single-photon emission computed 
tomography (SPECT) or positron-emission tomography (PET) is particularly suited for 
targeted in vivo molecular imaging. The major advantages of SPECT or PET molecular 
imaging techniques over other approaches include high sensitivity, the ability to make 
quantitative measurements, and the absence of a tissue penetration limit [Ref. 166]. In 
addition, multimodality imaging (such as, PET/SPECT, MRI, CT, NIRF) can allow detecting 
the nanoparticle with various imaging techniques, providing more accurate and dependable 
data than SPECT or PET alone [Ref. 165].  
Currently, many efforts have been made to conciliate both therapy and diagnosis 
properties in just one particle, leading to advantages over single approaches. The word 
“theranostics” refers to the simultaneous integration of diagnosis and therapy approaches 
[Ref. 167]. Therefore, the purpose is to diagnose and treat the diseases at their earliest 
stage, when the diseases are most likely curable or at least treatable. Theranostic 
nanomedicine shows better characteristics than other theranostics agents since they have 
advanced capabilities in an all-in-one single platform, which include sustained/controlled 
release, targeted delivery, and multimodality diagnosis and/or therapies.  
Other interesting approach aims to develop multimodal nanotheranostics systems 
that use co-encapsulation of multiple different diagnostic modalities and therapeutic in 
targeting nanomedicine platforms.  
As an example of studies published in recent years, we highlight the combination of a 
therapeutic effect of a traditional chemotherapeutic drug (i.e. paclitaxel, doxorubicin) and 
an excitable probes agent for imaging (i.e quantum dots, gold or metals) [Ref. 168]. In this 
sense, a work, conducted by Bae et al. [Ref. 169], quantum dots and paclitaxel were 
incorporated in solid lipid nanoparticles functionalized with siRNA aiming anticancer 
theranostics. The prepared solid lipid nanoparticles/siRNA complexes was efficiently 
delivered both paclitaxel and Bcl-2 targeting siRNA into human lung carcinoma cells and 
exhibited synergistic anticancer activities triggered by apoptotic mechanisms. Furthermore, 
the intense fluorescence of quantum dots within solid lipid nanoparticles enabled in situ 
visualization and intracellular translocation of solid lipid nanoparticles in cancer cells.  
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Another example of multimodality nanotheranostic system was created by Chen et 
al. [Ref. 170]. Nanoparticles were prepared with Doxorrubicin (DOX) conjugated to gold 
nanoparticles through Au-S bond by using a peptide Cys-Pro-Leu-Gly-Leu-Ala-Gly-Gly 
(CPLGLAGG), which is specifically cleaved by the protease. Studies conducted in tumor-
bearing mice showed that after injection of the functionalized gold nanoparticles, the over-
expressed protease in tumor tissue and intracellular glutathione conducted to a fast release 
of DOX from the functionalized gold nanoparticles, leading to enhanced efficacy on tumor 
growth inhibition and fluorescent imaging simultaneously.  
Saho et al. [Ref. 171] introduced the concept of synergy of photothermally- activated 
physical and biological effects in nanoparticle-drug conjugates for theranostic objectives. 
The authors utilized tumor necrosis factor- alpha coated gold nanospheres (Au-TNF) heated 
by laser pulses. In vivo studies demonstrated higher therapeutic efficacy in mice, over action 
of laser at wavelength of 690 nm with Au–TNF conjugates. In addition, according to the 
authors, the photothermal activation of low toxicity Au-TNF conjugates, which are in phase 
II trials in humans, with a laser approved for medical applications, opens new possibilities 
for the development of platforms for clinically relevant nanodrugs with synergistic 
antitumor theranostic action.  
A multifunctional pH-sensitive polymeric nanoparticle system for simultaneous 
tumor magnetic resonance imaging (MRI) and therapy was developed by Liu et al. [Ref. 
172]. The nanoparticles were self-assembled using the multi-block polymer poly(lactic 
acid)-poly(ethylene glycol)- poly(L-lysine)-diethylenetriamine penta acetic acid and the pH- 
sensitive material poly(L-histidine)-poly(ethylene glycol)-biotin. The anti-hepatocellular 
carcinoma (HCC) drug sorafenib was incorporated inside the nanoparticles. Gd-DTPA 
complexes were distributed on the nanoparticle surface and vascular endothelial growth 
factor receptor (VEGFR) antibodies were linked to the surface biotin groups of 
nanoparticles to form the target pH-sensitive theranostic nanoparticles (TPTN). In in vivo 
anti-tumor studies, TPTN showed significantly higher antitumor effect in H22 tumor 
(VEGFR overexpressed cell line) bearing mice compared to free sorafenib and a positive 
contrast agent, with higher resolution and longer imaging time (more than 90 min) in the 
MRI diagnosis of tumor-bearing mice compared to Magnevist, indicated that TPTN was a 
promising theranostic carrier which could be a platform for the development of novel 
multifunctional theranostic agents.  
 
10.2 - Types of nanoparticles 
 
There are many types of NP platforms with differing size, shape, composition, and 
functionality. Furthermore, each type of NP can potentially be fabricated using different 
techniques, such as both nanoprecipitation and lithography for polymeric NPs. While it is 
not within this thesis’s scope to discuss the differences in NP platforms and their fabrication 
in detail, we will discuss the major characteristics and functionalities of each NP that are 
relevant for biological research [Ref. 173], focusing on Gold and PMMA nanoparticles which 
are available at our research Institute.  
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 Liposomes  
 
Liposomes were one of the first NP platforms. Liposomes were first described in 
1965 as a model of cellular membranes. Since then, liposomes have moved from a model in 
biophysical research to one of the first NP platforms to be applied for gene and drug 
delivery.  
Liposomes are spherical vesicles that contain a single or multiple bilayered structure 
of lipids that self-assemble in aqueous systems. Unique advantages imparted by liposomes 
are their diverse range of compositions, ability to carry and protect many types of 
biomolecules, as well as their biocompatibility and biodegradability. These advantages have 
led to the well-characterized and wide use of liposomes as transfection agents of genetic 
material into cells (lipofection) in biology research.  
Lipofection generally uses a cationic lipid to form an aggregate with the anionic 
genetic material. Another major application of liposomes is their use as therapeutic carriers 
since their design can allow for entrapment of hydrophilic compounds within the core and 
hydrophobic drugs in the lipid bilayer itself. To enhance their circulation half-life and 
stability in vivo, liposomes have been conjugated with biocompatible polymers such as 
polyethylene glycol (PEG).  
Liposomes can also be functionalized with targeting ligands to increase the 
accumulation of diagnostic and therapeutic agents within desired cells. Today, there are 
twelve clinically approved liposome-based therapeutic drugs.  
 Albumin-bound NPs  
 
Albumin-bound NPs (nab) use the endogenous albumin pathways to carry 
hydrophobic molecules in the bloodstream. Albumin naturally binds to the hydrophobic 
molecules with non-covalent reversible binding, avoiding solvent-based toxicity of 
therapeutics. As a result, this platform has been successfully adapted as a drug delivery 
vehicle. Abraxane, a 130 nm nab paclitaxel, was approved by the FDA in 2005 for the 
treatment of metastatic breast cancer. Abraxane concentrates in cells through albumin 
receptor (gp60)- mediated transport in endothelial cells. It may also target the albumin-
binding protein SPARC (secreted protein acidic and rich in cysteine), which is 
overexpressed in certain tumors. Further understanding of the mechanism of action may 
lead to better targeting and development of novel therapeutics using the nab platform.  
 Polymeric NPs  
 
Polymeric NPs formed from biocompatible and biodegradable polymers have been 
extensively investigated as therapeutic carriers and contrast agent [Ref. 174 – 182, 185]. 
Polymeric NPs are formulated through block-copolymers of different hydrophobicity. These 
copolymers spontaneously assemble into a core–shell micelle formation in an aqueous 
environment. Polymeric NPs have been formulated to encapsulate hydrophilic and/or 
hydrophobic small molecule drugs, as well as proteins and nucleic acid macromolecules. 
The NP design can allow for slow and controlled release of drug at target sites. Polymeric 
NPs are usually able to improve the safety and efficacy of the drugs they carry. 
Functionalizing polymeric NPs with targeting ligands for improved drug delivery has been 
an important area of investigation since polymeric NPs are unique in their ability to be 
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tailored prior to particle assembly. The incorporation of targeting ligands on the NPs can 
lead to their increased uptake along with their cargo, leading to enhanced therapeutic 
outcomes.  
Another type of polymeric NP is dendrimers. Dendrimers are regularly branched 
macromolecules made from synthetic or natural elements including amino acids, sugars, 
and nucleotides. They have a central core, interior layers of branches, and an exterior 
surface. The varied combination of these components can yield dendrimers of well-defined 
size, shape, and branching length/ density. As a result of their unique design, dendrimers 
can be developed as sensors as well as drug and gene delivery carriers. Dendrimers can be 
loaded with small molecules in the cavities of the cores through chemical linkage, hydrogen 
bond, and/or hydrophobic interaction. The exterior surface can also be readily modified to 
produce chemical functional groups for the attachment of molecular targeting groups, 
detection and imaging agents, and therapeutic agents. 
 PMMA nanoparticles in collaboration with IFAC and ISOF 
 
The nanoparticles used in this study consist of a core of polymethylmethacrylate 
surrounded by a shell bearing cationic groups (-NH4+) and amine groups with fluoresceine 
covalently immobilized inside the nanoparticles. NPs were kindly donated by the group of 
Dott. G. Varchi (ISOF, CNR, Bologna, Italy).  
 Iron oxide  
 
Iron oxide NPs are widely studied as passive and active targeting imaging agents 
since they are mainly superparamagnetic [Ref. 183 - 184]. The superparamagnetic iron 
oxide NPs (SPIONs) generally have an iron oxide core with a hydrophilic coat of dextran or 
other biocompatible compound to increase their stability. The most widely used SPIONs 
consist of a magnetite (Fe3O4) and/or maghemite (Fe2O3) core. These NPs exhibit size-
dependent superparamagnetism, which allows them to become magnetized with the 
application of an external magnetic field and exhibit zero net magnetization upon removal of 
the magnetic field. SPIONs have been successfully used as T2-weighted magnetic resonance 
(MR) contrast agents to track and monitor cells. SPIONs have several advantages over 
conventional gadolinium-chelate contrast agents including decreased toxicity and increased 
imaging sensitivity and specificity. SPIONs can also be degraded to iron and iron oxide 
molecules that are metabolized, stored in cells as ferritin, and incorporated into 
hemoglobin. Currently, two SPIO agents, ferumoxides (120–180 nm) and ferucarbotran (60 
nm), are clinically approved for MRI. SPIONs have also been used in molecular imaging 
applications such as the detection of apoptosis and gene expression. SPIONs can be 
functionalized with optical and radionuclide targeting ligands for multimodal imaging. They 
can also potentially be used as non-invasive diagnostic tools and as drug delivery vehicles. 
 Quantum dot  
 
First discovered in 1980, quantum dots (QDs) are semiconductor particles that are 
less than 10 nm in diameter. QDs display unique size-dependent electronic and optical 
properties. Most QDs studied consist of a cadmium selenide (CdSe) core and a zinc selenide 
(ZnS) cap. The absorption spectra of these particles are very broad and emission is confined 
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to a narrow band. QDs can also emit bright colors, have long lifetimes and high efficiencies 
and are stable against photobleaching. They can be generated to have various biochemical 
specificities and can be simultaneously excited and detected. As a result, QDs have several 
significant advantages over many organic fluorophore dyes for optical applications. They 
are widely used in biological research as fluorescence imaging tools for applications such as 
cell labeling and biomolecule tracking. The small size of quantum dots also enables them to 
be suitable for biomedical applications such as medical imaging and diagnostics.  
 Gold  
 
Gold NPs offer many size-and-shape dependent optical and chemical properties, 
biocompatibility, and facile surface modification. Gold NPs can strongly enhance optical 
processes such as light absorption, scattering, fluorescence, and surface-enhanced Raman 
scattering (SERS) due to the unique interaction of the free electrons in the NP with light. 
These properties have enabled the realization of gold NPs in many applications such as 
biochemical sensing and detection, biological imaging, diagnostics, and therapeutic 
applications. Sensing techniques include the use of gold NPs in colorimetric arrays and the 
use of gold NPs as substrates in SERS to significantly enhance Raman scattering, allowing for 
spectroscopic detection and identification of proteins and single molecules at the NP 
surface. Gold NP probes have also been used to detect heart disease and cancer biomarkers. 
They can also transform absorbed light into heat and therefore have high potential for 
infrared phototherapy. 
The intense research activities devoted to the nanotechnology led to the 
development of multifunctional nanoparticles which combine imaging (X-ray, CT, MRI, 
Optical) and therapy (phototherapy, radiotherapy, chemiotherapy, thermal therapy). There 
is in fact a considerable need for new functionalized NP for both imaging and therapy of 
cancer, in particular those that have adequate pharmacokinetic properties and low levels of 
non-specific accumulation in the body. The improvement of the sensitivity of magnetic 
resonance imaging (MRI) requires the development of original contrast agents [Ref. 186 – 
189, 202], while cancer therapy requires novel agents radiosensitisers [Ref. 190 – 194, 197, 
200, 201]. The experimental observation of ferromagnetic moment formation at the 
nanoscale in Au nanoparticles and some considerations on their intrinsic magnetic moments 
ocan be found in [Ref. 195, 196].  
 Gold nanoparticles in collaboration with IFAC 
 
GNPs were kindly donated by the group of Dott. R. Pini (IFAC, CNR, Florence, Italy) 
[Ref. 198, 199].  
10.3 - Diffusion-MRI techniques and nanoparticles 
 
The aim of this part of the thesis is to indroduce diffusion in MRI (d-MRI), trying to 
understand if nanoparticles can be revealed by d-MRI techniques, looking at the change in 
water motion due to the presence of nanoparticles in the environment [Ref. 203]. 
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 Basic diffusion 
 
A complete discussion of diffusion in MRI is beyond the scope of this thesis, so in this 
part i will briefly describe diffusion [Ref. 204, 228]. 
This approach is based on the measurement of Brownian motion of molecules. It has 
been long, but not widely, known that nuclear magnetic resonance is capable of quantifying 
diffusional movement of molecules. In the 1980s, a method that combines this diffusion 
measurement with MRI was introduced, which is now widely called diffusion imaging. This 
technique can characterize water diffusion properties at each pixel of an image. The first 
important application of diffusion MRI emerged at center stage of the MRI community in 
early 1990s when it was discovered that DWI can detect stroke in its acute phase. Around 
the same time, scientists had also noticed that there is a peculiar property of water diffusion 
in highly ordered organs such as brains. In these organs, water does not diffuse equally in all 
direc- tions, a property called anisotropic diffusion. For example, brain water diffuses 
preferentially along axonal fiber directions. Then molecular diffusion in tissues is not free, 
but reflects interactions with many obstacles, such as macromolecules, fibers, and 
membranes. Water molecule diffusion patterns can therefore reveal microscopic details 
about tissue architecture, either normal or in a diseased state. 
10.3.1 - Agar Phantom for Diffusion and spectroscopy measurements in MRI 
 
We are working on a agar phantom with some spots of nanoparticles at different 
concentrations. 
We will look at differences in diffusion (using kurtosis too) and T1, T2 in respect to 
agar phantom without NP. We will use different kind of Gold NP and PMMA-NP.  
 
 
Chapter 11 
 
CONCLUSIONS 
 
 
What emerges from this thesis is that there is no “recipe” for magnetic resonance spectroscopy 
data analysis. Sequences parameters must be choose very carefully and data must be analyzed from 
experienced Medical Physicist. Any single spectrum must be analyzed with the best accuracy. No 
automatic procedure is possible at moment. 
At first we focused on water signals coming from different MR scanners and vendors, looking 
for accuracy. Good results have been found on this cases. 
Then, with increasing complexity, we have focused on the Siemens phantom, characterizing its 
behavior at 3T Philips MR scanner, looking for the best sequence parameters and best algorithm. 
Results have shown the importance of the right choice of the sequence parameters in order to have a 
good estimation of T1, T2 and metabolites concentration. E.g. for T1 estimation it is very important to 
have a narrow inversion band centered on the metabolite of interest. The sampling time of the 
sequence must be choose carefully too, bearing in mind a rough estimate of the metabolite relaxation 
times. TI, TE, TR must be choosen very very carefully. E.g. for Lactate at 3T is very important to choose a 
TE of about 288 ms or multiples. In the future we will explore different sequences, e.g. adiabatic, 
looking for the differences in estimated parameters. 
Algorithms for peaks area estimation HLSVD and AMARES have been tested, showing no net 
differences between the two algorithms, although AMARES is more flexible due to the possibility in the 
choice of fitting parameters. About AMARES it is very important to highlight as a very good peaks area 
fitting estimation can be obtained only with the right choice of starting values and prior knowledge 
parameters, with small differences giving results completely differents. 
QUEST algorithm has been tested too, and it is very interesting but it is very useful only when 
the real parameters of the MR scanner sequence are known. 
Fitting procedure for T1, T2 estimation has been tested with different fitting function, showing 
the importance of the right choice of sequence parameters and fitting function. In particular, 
approximated fitting function must be choosen very carefully. Due to the use of non linear least square 
fitting procedure, it is very important to have a prior knowledge very accurate of the estimated 
parameters in order to have a good estimation. 
Quantitation have been performed in detail with 3T Meyer data, showing some ciriticity about 
quantitation of metabolites concentration, with errors even of 40% on the estimation of the known 
concentration. In this case we suspect that the concentration in the Siemens phantom is not accurate, 
because we obtain always an overestimate for Acetate and underestimate for Lactate. In this moment 
we are working on a test phantom with a very accurate metabolites concentration, aimed to test again 
our sequences and algorithms. 
In conclusion a right MRS examination requires a specific protocol for diagnostic requirements 
and must be evaluated patient by patient. All the recommendations discussed in the previous chapters 
must be taken into account too. The literature reference values are not sufficient to estimate 
metabolites concentration with the right precision. 
MRS can become a very important diagnostic instrument for the daily clinical use of 
radiologists only if Medical Physicists will be part of the team. 
 
 
   
Appendix 1 
 
ESTIMATION BY QUEST 
 
 
Acetate estimation by QUEST and NMR-Scope 
In NMR-Scope we need to simulate signals one by one for every TI. An Inversion 
Recovery sequence (180°-TI-90°-AQ) can be simulated with a specific TI and for a specific 
metabolite as shown in Figure 2, Figure 3 for Acetate. It’s very important to choose the right 
parameter for the simulation of the sequence, e.g. there is difference in the choice of the 
Phase of the Detection period. 
 
 
Figure 1: Example of water spectra simulation using QUEST. Scanner 3T, bandwidth 2000 Hz, sampling 0.5 ms.  
Alpha and Beta parameters are for a Voight curve. 
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Figure 2: NMR-scope simulation Inversion Recovery sequence of Acetate at 3T with 170 ms Inversion time.  
Note the phase of the Detection period of 90°. 
 
 
Figure 3: NMR-scope simulation Inversion Recovery sequence of Acetate at 3T with 170 ms Inversion time.  
Note the phase of the Detection period of 270°. 
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Using QUEST we can quantifies the Acetate spectrum using the simulation 
performed with NMR-scope.  
 
 
Figure 4: QUEST quantitation of Acetate. On the left side the QUEST panel, while on the right side the original 
signal. In this case the signal has an Inversion Recovery time of 170 ms. 
 
 
Figure 5: Result of QUEST quantification of the first Inversion Recovery signal obtained with a TI of 170 ms. 
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INVERSION RECOVERY SEQUENCES PARAMETERS FOR T1 ESTIMATION 
 
Table 1: Water sequences parameters. 
7/03/15 1/06/15 - 2/06 – 2/06 2th 2/06/15 3th 
SmartSelect =  
 "yes"; 
Coil 1  (exclude) = 
 "None"; 
VOI orientation = 
 "transverse"; 
VOI size AP (mm) =  20; 
         RL (mm) =  20; 
         FH (mm) =  20; 
Samples =   1024; 
Spectral BW (Hz) =  2000; 
VOI offc. AP (P=+mm) = 
 -5; 
          RL (L=+mm) = 0; 
          FH (H=+mm) = 
 10; 
VOI ang. AP (deg) =  0; 
         RL (deg) =  -0; 
         FH (deg) =  -0; 
Chem. shift Dir AP =  "A"; 
Chem. shift Dir LR =  "L"; 
Chem. shift Dir FH =  "F"; 
Large table movement = 
 "no"; 
REST slabs =  
 0; 
Patient position =  "head 
first"; 
        orientation = 
 "supine"; 
Scan type =  
 "Spectroscopy"; 
Scan mode =  
 "SV"; 
    technique =  
 "ECHO"; 
VOI selection =  
 "volume"; 
    method =  
 "PRESS"; 
Gradient Spoiling =  "no"; 
Fast Imaging mode =  "none"; 
Echo acquisition =  "half"; 
TE =   
 "user defined"; 
    (ms) =   35; 
Flip angle (deg) =  90; 
RF pulse set =  
 "normal"; 
TR =   
 "user defined"; 
    (ms) =   6000; 
RF Shims =  
 "fixed"; 
Shim =   
 "PB-auto"; 
    PB order =  
 "second"; 
Water suppression =  "no"; 
BASING pulse =  
 "no"; 
Research prepulse =  "no"; 
Pre-saturation =  "no"; 
Multi-transmit =  "yes"; 
SmartSelect =  
 "yes"; 
Coil 1  (exclude) = 
 "None"; 
VOI orientation = 
 "transverse"; 
VOI size AP (mm) =  20; 
         RL (mm) =  20; 
         FH (mm) =  20; 
Samples =   1024; 
Spectral BW (Hz) =  2000; 
VOI offc. AP (P=+mm) = 
 0; 
          RL (L=+mm) = 0; 
          FH (H=+mm) = 
 10; 
VOI ang. AP (deg) =  0; 
         RL (deg) =  -0; 
         FH (deg) =  -0; 
Chem. shift Dir AP =  "A"; 
Chem. shift Dir LR =  "L"; 
Chem. shift Dir FH =  "F"; 
Large table movement = 
 "no"; 
REST slabs =  
 0; 
Patient position =  "head 
first"; 
        orientation = 
 "supine"; 
Scan type =  
 "Spectroscopy"; 
Scan mode =  
 "SV"; 
    technique =  
 "ECHO"; 
VOI selection =  
 "volume"; 
    method =  
 "PRESS"; 
Gradient Spoiling =  "no"; 
Fast Imaging mode =  "none"; 
Echo acquisition =  "half"; 
TE =   
 "shortest"; 
Flip angle (deg) =  90; 
RF pulse set =  
 "normal"; 
TR =   
 "user defined"; 
    (ms) =   15000; 
RF Shims =  
 "fixed"; 
Shim =   
 "PB-auto"; 
    PB order =  
 "second"; 
Water suppression =  "no"; 
BASING pulse =  
 "no"; 
Research prepulse =  "no"; 
Pre-saturation =  "no"; 
Multi-transmit =  "yes"; 
Transmit channels =  "both"; 
SmartSelect =  
 "yes"; 
Coil 1  (exclude) = 
 "None"; 
VOI orientation = 
 "transverse"; 
VOI size AP (mm) =  20; 
         RL (mm) =  20; 
         FH (mm) =  20; 
Samples =   1024; 
Spectral BW (Hz) =  2000; 
VOI offc. AP (P=+mm) = 
 0; 
          RL (L=+mm) = 0; 
          FH (H=+mm) = 
 10; 
VOI ang. AP (deg) =  0; 
         RL (deg) =  -0; 
         FH (deg) =  -0; 
Chem. shift Dir AP =  "A"; 
Chem. shift Dir LR =  "L"; 
Chem. shift Dir FH =  "F"; 
Large table movement = 
 "no"; 
REST slabs =  
 0; 
Patient position =  "head 
first"; 
        orientation = 
 "supine"; 
Scan type =  
 "Spectroscopy"; 
Scan mode =  
 "SV"; 
    technique =  
 "ECHO"; 
VOI selection =  
 "volume"; 
    method =  
 "PRESS"; 
Gradient Spoiling =  "no"; 
Fast Imaging mode =  "none"; 
Echo acquisition =  "half"; 
TE =   
 "shortest"; 
Flip angle (deg) =  90; 
RF pulse set =  
 "normal"; 
TR =   
 "user defined"; 
    (ms) =   15000; 
RF Shims =  
 "fixed"; 
Shim =   
 "PB-auto"; 
    PB order =  
 "second"; 
Water suppression =  "no"; 
BASING pulse =  
 "no"; 
Research prepulse =  "no"; 
Pre-saturation =  "no"; 
Multi-transmit =  "yes"; 
Transmit channels =  "both"; 
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Transmit channels =  "both"; 
SAR mode =  
 "high"; 
B1 mode =  
 "default"; 
SAR Patient data =  "auto"; 
PNS mode =  
 "low"; 
Gradient mode =  
 "default"; 
SofTone mode =  
 "no"; 
Cardiac synchronization = "no"; 
Respiratory compensation = "no"; 
Startup acquisitions =  2; 
NSA =   
 16; 
Phase cycles =  
 16; 
Frequency stabilization = "yes"; 
Parameter series =  "TI"; 
   nr TIs =   5; 
   series spacing =  "user 
def."; 
   TI values (ms) =  30, 
250, 
   
 700, 2500, 5400, (123) 0; 
   inv. bw (Hz) =  1500; 
   inv. offset (Hz) =  0; 
   dummy scans =  1; 
Manual start =  
 "no"; 
Dynamic study =  
 "no"; 
Arterial Spin labeling = "no"; 
Preparation phases =  "full"; 
Interactive F0 =  "no"; 
Receiver optimization = 
 "OFF"; 
Receiver attenuation = 
 8; 
Spectral correction =  "yes"; 
    spectral correction NSA = 16; 
    fat supp. on correction = "no"; 
Reference tissue =  "White 
matter"; 
PlanScan metabolite = 
 "H20"; 
Shifted metabolite displayed =
 "NAA"; 
Preset window contrast = "soft"; 
Save raw data =  
 "yes"; 
Hardcopy protocol =  "no"; 
Elliptical k-space shutter =
 "default"; 
IF_info_seperator = 
 1634755923; 
Total scan duration = 
 "18:48.0"; 
Act. TR/TE (ms) =  "6000 / 
35"; 
Min. TR/TE (ms) =  "5969 / 
34"; 
Series TI (ms) = 
 "30/250/700/2500/5400"; 
SPAIR TR (ms) =  
 5983.22266; 
SPAIR inv. delay (ms) = 
 "0.00"; 
Spectral resolution (Hz/point) =
 1.953125; 
Readout duration (ms) = 
 512; 
SAR mode =  
 "high"; 
B1 mode =  
 "default"; 
SAR Patient data =  "auto"; 
PNS mode =  
 "high"; 
Gradient mode =  
 "maximum"; 
SofTone mode =  
 "no"; 
Cardiac synchronization = "no"; 
Respiratory compensation = "no"; 
Startup acquisitions =  2; 
NSA =   
 2; 
Phase cycles =  
 2; 
Frequency stabilization = "yes"; 
Parameter series =  "TI"; 
   nr TIs =   7; 
   series spacing =  "user 
def."; 
   TI values (ms) =  10, 
300, 
   
 1000, 3000, 5000, 8000, 
10000, 
   
 (121) 0; 
   inv. bw (Hz) =  1500; 
   inv. offset (Hz) =  0; 
   dummy scans =  0; 
Manual start =  
 "no"; 
Dynamic study =  
 "no"; 
Arterial Spin labeling = "no"; 
Preparation phases =  "full"; 
Interactive F0 =  "no"; 
Receiver optimization = 
 "ON"; 
Spectral correction =  "yes"; 
    spectral correction NSA = 2; 
    fat supp. on correction = "no"; 
Reference tissue =  "White 
matter"; 
PlanScan metabolite = 
 "H20"; 
Shifted metabolite displayed =
 "Lactate/Lipid"; 
Preset window contrast = "soft"; 
Save raw data =  
 "yes"; 
Hardcopy protocol =  "no"; 
Elliptical k-space shutter =
 "default"; 
IF_info_seperator = 
 1634755923; 
Total scan duration = 
 "10:30.0"; 
Act. TR/TE (ms) =  "15000 
/ 28"; 
Min. TR/TE (ms) =  "10565 
/ 28"; 
Series TI (ms) =   
   
 "10/300/1000/3000/5000/800
0/10000"; 
SPAIR TR (ms) =  
 14983.2227; 
SPAIR inv. delay (ms) = 
 "0.00"; 
Spectral resolution (Hz/point) =
 1.953125; 
SAR mode =  
 "high"; 
B1 mode =  
 "default"; 
SAR Patient data =  "auto"; 
PNS mode =  
 "high"; 
Gradient mode =  
 "maximum"; 
SofTone mode =  
 "no"; 
Cardiac synchronization = "no"; 
Respiratory compensation = "no"; 
Startup acquisitions =  2; 
NSA =   
 2; 
Phase cycles =  
 2; 
Frequency stabilization = "yes"; 
Parameter series =  "TI"; 
   nr TIs =   7; 
   series spacing =  "user 
def."; 
   TI values (ms) =  10, 
300, 
   
 1000, 3000, 5000, 8000, 
10000, 
   
 (121) 0; 
   inv. bw (Hz) =  200; 
   inv. offset (Hz) =  0; 
   dummy scans =  0; 
Manual start =  
 "no"; 
Dynamic study =  
 "no"; 
Arterial Spin labeling = "no"; 
Preparation phases =  "full"; 
Interactive F0 =  "no"; 
Receiver optimization = 
 "ON"; 
Spectral correction =  "yes"; 
    spectral correction NSA = 2; 
    fat supp. on correction = "no"; 
Reference tissue =  "White 
matter"; 
PlanScan metabolite = 
 "H20"; 
Shifted metabolite displayed =
 "Lactate/Lipid"; 
Preset window contrast = "soft"; 
Save raw data =  
 "yes"; 
Hardcopy protocol =  "no"; 
Elliptical k-space shutter =
 "default"; 
Total scan duration = 
 "10:30.0"; 
Act. TR/TE (ms) =  "15000 
/ 28"; 
Min. TR/TE (ms) =  "10617 
/ 28"; 
Series TI (ms) =   
   
 "10/300/1000/3000/5000/800
0/10000"; 
SPAIR TR (ms) =  
 14983.2227; 
SPAIR inv. delay (ms) = 
 "0.00"; 
Spectral resolution (Hz/point) =
 1.953125; 
Readout duration (ms) = 
 512; 
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SAR / head =  
 "<  4 %"; 
Whole body / level =  "0.0 
W/kg / normal"; 
SED =   
 "  0.0 kJ/kg"; 
B1+rms / Coil Power = 
 "0.46 uT / 4 %"; 
Max B1+rms =  
 "0.56 uT"; 
PNS / level =  
 "33 % / normal"; 
dB/dt =   "17.0 
T/s"; 
Sound Pressure Level (dB) = 0; 
 
Readout duration (ms) = 
 512; 
SAR / head =  
 "<  2 %"; 
Whole body / level =  "0.0 
W/kg / normal"; 
SED =   
 "  0.0 kJ/kg"; 
B1+rms / Coil Power ="0.29 uT / 2 %"; 
Max B1+rms =  "1.19 
uT"; 
PNS / level = "67 % / normal"; 
dB/dt =   "37.6 
T/s"; 
Sound Pressure Level (dB) = 0; 
SAR / head =  
 "<  1 %"; 
Whole body / level =  "0.0 
W/kg / normal"; 
SED =   
 "  0.0 kJ/kg"; 
B1+rms / Coil Power = 
 "0.24 uT / 1 %"; 
Max B1+rms =  "1.19 
uT"; 
PNS / level = "67 % / normal"; 
dB/dt =   "37.6 
T/s"; 
Sound Pressure Level (dB) = 0; 
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Table 2: Acetate and Lactate doublet sequences parameters. 
7/03/15 20/05/15 1/06 – 2/06 – 2/06 2th 2/06 3th 2/06 4th – 2/06 5th 
SmartSelect = 
 
 "yes"; 
Coil 1  (exclude) = 
 "None"; 
VOI orientation = 
 "transverse"; 
VOI size AP (mm) = 
 20; 
         RL (mm) = 
 20; 
         FH (mm) = 
 20; 
Samples =  
 1024; 
Spectral BW (Hz) = 
 2000; 
VOI offc. AP (P=+mm) =
  -5; 
          RL (L=+mm) = 
 0; 
          FH (H=+mm) =
  10; 
VOI ang. AP (deg) = 
 0; 
         RL (deg) = 
 -0; 
         FH (deg) = 
 -0; 
Chem. shift Dir AP = 
 "A"; 
Chem. shift Dir LR = 
 "L"; 
Chem. shift Dir FH = 
 "F"; 
Large table movement =
  "no"; 
REST slabs = 
  0; 
Patient position = 
 "head first"; 
        orientation = 
 "supine"; 
Scan type = 
 
 "Spectroscopy"; 
Scan mode = 
 
 "SV"; 
    technique = 
 
 "ECHO"; 
VOI selection = 
 
 "volume"; 
    method = 
 
 "PRESS"; 
Gradient Spoiling = 
 "no"; 
Fast Imaging mode = 
 "none"; 
Echo acquisition = 
 "half"; 
TE =  
  "user 
defined"; 
    (ms) =  
 35; 
Flip angle (deg) = 
 90; 
RF pulse set = 
 
SmartSelect = 
 
 "yes"; 
Coil 1  (exclude) = 
 "None"; 
VOI orientation = 
 "transverse"; 
VOI size AP (mm) = 
 20; 
         RL (mm) = 
 20; 
         FH (mm) = 
 20; 
Samples =  
 1024; 
Spectral BW (Hz) = 
 2000; 
VOI offc. AP (P=+mm) =
  0; 
          RL (L=+mm) = 
 0; 
          FH (H=+mm) =
  0; 
VOI ang. AP (deg) = 
 0; 
         RL (deg) = 
 -0; 
         FH (deg) = 
 -0; 
Chem. shift Dir AP = 
 "A"; 
Chem. shift Dir LR = 
 "L"; 
Chem. shift Dir FH = 
 "F"; 
Large table movement =
  "no"; 
REST slabs = 
  0; 
Patient position = 
 "head first"; 
        orientation = 
 "supine"; 
Scan type = 
 
 "Spectroscopy"; 
Scan mode = 
 
 "SV"; 
    technique = 
 
 "ECHO"; 
VOI selection = 
 
 "volume"; 
    method = 
 
 "PRESS"; 
Gradient Spoiling = 
 "no"; 
Fast Imaging mode = 
 "none"; 
Echo acquisition = 
 "half"; 
TE =  
 
 "shortest"; 
Flip angle (deg) = 
 90; 
RF pulse set = 
 
 "normal"; 
TR =  
SmartSelect = 
 
 "yes"; 
Coil 1  (exclude) = 
 "None"; 
VOI orientation = 
 "transverse"; 
VOI size AP (mm) = 
 20; 
         RL (mm) = 
 20; 
         FH (mm) = 
 20; 
Samples =  
 1024; 
Spectral BW (Hz) = 
 2000; 
VOI offc. AP (P=+mm) =
  0; 
          RL (L=+mm) = 
 0; 
          FH (H=+mm) =
  10; 
VOI ang. AP (deg) = 
 0; 
         RL (deg) = 
 -0; 
         FH (deg) = 
 -0; 
Chem. shift Dir AP = 
 "A"; 
Chem. shift Dir LR = 
 "L"; 
Chem. shift Dir FH = 
 "F"; 
Large table movement =
  "no"; 
REST slabs = 
  0; 
Patient position = 
 "head first"; 
        orientation = 
 "supine"; 
Scan type = 
 
 "Spectroscopy"; 
Scan mode = 
 
 "SV"; 
    technique = 
 
 "ECHO"; 
VOI selection = 
 
 "volume"; 
    method = 
 
 "PRESS"; 
Gradient Spoiling = 
 "no"; 
Fast Imaging mode = 
 "none"; 
Echo acquisition = 
 "half"; 
TE =  
 
 "shortest"; 
Flip angle (deg) = 
 90; 
RF pulse set = 
 
 "normal"; 
TR =  
SmartSelect = 
 
 "yes"; 
Coil 1  (exclude) = 
 "None"; 
VOI orientation = 
 "transverse"; 
VOI size AP (mm) = 
 20; 
         RL (mm) = 
 20; 
         FH (mm) = 
 20; 
Samples =  
 1024; 
Spectral BW (Hz) = 
 2000; 
VOI offc. AP (P=+mm) =
  0; 
          RL (L=+mm) = 
 0; 
          FH (H=+mm) =
  10; 
VOI ang. AP (deg) = 
 0; 
         RL (deg) = 
 -0; 
         FH (deg) = 
 -0; 
Chem. shift Dir AP = 
 "A"; 
Chem. shift Dir LR = 
 "L"; 
Chem. shift Dir FH = 
 "F"; 
Large table movement =
  "no"; 
REST slabs = 
  0; 
Patient position = 
 "head first"; 
        orientation = 
 "supine"; 
Scan type = 
 
 "Spectroscopy"; 
Scan mode = 
 
 "SV"; 
    technique = 
 
 "ECHO"; 
VOI selection = 
 
 "volume"; 
    method = 
 
 "PRESS"; 
Gradient Spoiling = 
 "no"; 
Fast Imaging mode = 
 "none"; 
Echo acquisition = 
 "half"; 
TE =  
 
 "shortest"; 
Flip angle (deg) = 
 90; 
RF pulse set = 
 
 "normal"; 
TR =  
SmartSelect = 
 
 "yes"; 
Coil 1  (exclude) = 
 "None"; 
VOI orientation = 
 "transverse"; 
VOI size AP (mm) = 
 20; 
         RL (mm) = 
 20; 
         FH (mm) = 
 20; 
Samples =  
 1024; 
Spectral BW (Hz) = 
 2000; 
VOI offc. AP (P=+mm) =
  0; 
          RL (L=+mm) = 
 0; 
          FH (H=+mm) =
  10; 
VOI ang. AP (deg) = 
 0; 
         RL (deg) = 
 -0; 
         FH (deg) = 
 -0; 
Chem. shift Dir AP = 
 "A"; 
Chem. shift Dir LR = 
 "L"; 
Chem. shift Dir FH = 
 "F"; 
Large table movement =
  "no"; 
REST slabs = 
  0; 
Patient position = 
 "head first"; 
        orientation = 
 "supine"; 
Scan type = 
 
 "Spectroscopy"; 
Scan mode = 
 
 "SV"; 
    technique = 
 
 "ECHO"; 
VOI selection = 
 
 "volume"; 
    method = 
 
 "PRESS"; 
Gradient Spoiling = 
 "no"; 
Fast Imaging mode = 
 "none"; 
Echo acquisition = 
 "half"; 
TE =  
  "user 
defined"; 
    (ms) =  
 288; 
Flip angle (deg) = 
 90; 
RF pulse set = 
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 "normal"; 
TR =  
  "user 
defined"; 
    (ms) =  
 6000; 
RF Shims = 
 
 "fixed"; 
Shim =  
  "PB-
auto"; 
    PB order = 
 
 "second"; 
Water suppression = 
 "excitation"; 
    window (Hz) = 
 140; 
    second pulse angle =
 300; 
WS prescan = 
 
 "auto"; 
BASING pulse = 
  "no"; 
Research prepulse = 
 "no"; 
Pre-saturation = 
 "no"; 
Multi-transmit = 
 "yes"; 
Transmit channels = 
 "both"; 
SAR mode = 
 
 "high"; 
B1 mode = 
 
 "default"; 
SAR Patient data = 
 "auto"; 
PNS mode = 
 
 "low"; 
Gradient mode = 
 
 "default"; 
SofTone mode = 
  "no"; 
Cardiac synchronization =
 "no"; 
Respiratory compensation 
= "no"; 
Startup acquisitions = 
 2; 
NSA =  
  16; 
Phase cycles = 
  16; 
Frequency stabilization =
 "yes"; 
Parameter series = 
 "TI"; 
   nr TIs =  
 5; 
   series spacing = 
 "user def."; 
   TI values (ms) = 
 170, 250, 
  
  700, 
2500, 5400, (123) 0; 
   inv. bw (Hz) = 
 1500; 
 
 "shortest"; 
RF Shims = 
 
 "fixed"; 
Shim =  
  "PB-
auto"; 
    PB order = 
 
 "second"; 
Water suppression = 
 "excitation"; 
    window (Hz) = 
 140; 
    second pulse angle =
 300; 
WS prescan = 
 
 "auto"; 
BASING pulse = 
  "no"; 
Research prepulse = 
 "no"; 
Pre-saturation = 
 "no"; 
Multi-transmit = 
 "yes"; 
Transmit channels = 
 "both"; 
SAR mode = 
 
 "high"; 
B1 mode = 
 
 "default"; 
SAR Patient data = 
 "auto"; 
PNS mode = 
 
 "high"; 
Gradient mode = 
 
 "maximum"; 
SofTone mode = 
  "no"; 
Cardiac synchronization =
 "no"; 
Respiratory compensation 
= "no"; 
Startup acquisitions = 
 2; 
NSA =  
  4; 
Phase cycles = 
  4; 
Frequency stabilization =
 "yes"; 
Parameter series = 
 "TI"; 
   nr TIs =  
 7; 
   series spacing = 
 "user def."; 
   TI values (ms) = 
 170, 1000, 
  
 
 2000, 3000, 
5000, 8000, 10000, 
  
 
 (121) 0; 
   inv. bw (Hz) = 
 1500; 
  "user 
defined"; 
    (ms) =  
 15000; 
RF Shims = 
 
 "fixed"; 
Shim =  
  "PB-
auto"; 
    PB order = 
 
 "second"; 
Water suppression = 
 "excitation"; 
    window (Hz) = 
 140; 
    second pulse angle =
 300; 
WS prescan = 
 
 "auto"; 
BASING pulse = 
  "no"; 
Research prepulse = 
 "no"; 
Pre-saturation = 
 "no"; 
Multi-transmit = 
 "yes"; 
Transmit channels = 
 "both"; 
SAR mode = 
 
 "high"; 
B1 mode = 
 
 "default"; 
SAR Patient data = 
 "auto"; 
PNS mode = 
 
 "high"; 
Gradient mode = 
 
 "maximum"; 
SofTone mode = 
  "no"; 
Cardiac synchronization =
 "no"; 
Respiratory compensation 
= "no"; 
Startup acquisitions = 
 2; 
NSA =  
  4; 
Phase cycles = 
  4; 
Frequency stabilization =
 "yes"; 
Parameter series = 
 "TI"; 
   nr TIs =  
 7; 
   series spacing = 
 "user def."; 
   TI values (ms) = 
 170, 1000, 
  
 
 2000, 3000, 
5000, 8000, 10000, 
  
 
 (121) 0; 
  "user 
defined"; 
    (ms) =  
 15000; 
RF Shims = 
 
 "fixed"; 
Shim =  
  "PB-
auto"; 
    PB order = 
 
 "second"; 
Water suppression = 
 "excitation"; 
    window (Hz) = 
 140; 
    second pulse angle =
 300; 
WS prescan = 
 
 "auto"; 
BASING pulse = 
  "no"; 
Research prepulse = 
 "no"; 
Pre-saturation = 
 "no"; 
Multi-transmit = 
 "yes"; 
Transmit channels = 
 "both"; 
SAR mode = 
 
 "high"; 
B1 mode = 
 
 "default"; 
SAR Patient data = 
 "auto"; 
PNS mode = 
 
 "high"; 
Gradient mode = 
 
 "maximum"; 
SofTone mode = 
  "no"; 
Cardiac synchronization =
 "no"; 
Respiratory compensation 
= "no"; 
Startup acquisitions = 
 2; 
NSA =  
  4; 
Phase cycles = 
  4; 
Frequency stabilization =
 "yes"; 
Parameter series = 
 "TI"; 
   nr TIs =  
 7; 
   series spacing = 
 "user def."; 
   TI values (ms) = 
 170, 1000, 
  
 
 2000, 3000, 
5000, 8000, 10000, 
  
 
 (121) 0; 
 "normal"; 
TR =  
  "user 
defined"; 
    (ms) =  
 15000; 
RF Shims = 
 
 "fixed"; 
Shim =  
  "PB-
auto"; 
    PB order = 
 
 "second"; 
Water suppression = 
 "excitation"; 
    window (Hz) = 
 140; 
    second pulse angle =
 300; 
WS prescan = 
 
 "auto"; 
BASING pulse = 
  "no"; 
Research prepulse = 
 "no"; 
Pre-saturation = 
 "no"; 
Multi-transmit = 
 "yes"; 
Transmit channels = 
 "both"; 
SAR mode = 
 
 "high"; 
B1 mode = 
 
 "default"; 
SAR Patient data = 
 "auto"; 
PNS mode = 
 
 "high"; 
Gradient mode = 
 
 "maximum"; 
SofTone mode = 
  "no"; 
Cardiac synchronization =
 "no"; 
Respiratory compensation 
= "no"; 
Startup acquisitions = 
 2; 
NSA =  
  4; 
Phase cycles = 
  4; 
Frequency stabilization =
 "yes"; 
Parameter series = 
 "TI"; 
   nr TIs =  
 7; 
   series spacing = 
 "user def."; 
   TI values (ms) = 
 170, 1000, 
  
 
 2000, 3000, 
5000, 8000, 10000, 
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   inv. offset (Hz) = 
 0; 
   dummy scans = 
 1; 
Manual start = 
  "no"; 
Dynamic study = 
  "no"; 
Arterial Spin labeling =
 "no"; 
Preparation phases = 
 "full"; 
Interactive F0 = 
 "no"; 
Receiver optimization =
 
 "OFF"; 
Receiver attenuation =
  8; 
Spectral correction = 
 "yes"; 
    spectral correction NSA 
= 16; 
    fat supp. on correction =
 "no"; 
Reference tissue = 
 "White matter"; 
PlanScan metabolite =
 
 "NAA"; 
Shifted metabolite 
displayed =
 "H20"; 
Preset window contrast =
 "soft"; 
Save raw data = 
 
 "yes"; 
Hardcopy protocol = 
 "no"; 
Elliptical k-space shutter =
 "default"; 
IF_info_seperator = 
 1634755923; 
Total scan duration = 
 "18:48.0"; 
Act. TR/TE (ms) = 
 "6000 / 35"; 
Min. TR/TE (ms) = 
 "5973 / 34"; 
Series TI (ms) = 
 "170/250/700/2
500/5400"; 
SPAIR TR (ms) = 
 
 5983.22266; 
SPAIR inv. delay (ms) =
 
 "0.00"; 
Spectral resolution 
(Hz/point) =
 1.953125; 
Readout duration (ms) =
  512; 
SAR / head = 
  "<  4 
%"; 
Whole body / level = 
 "0.0 W/kg / 
normal"; 
SED =  
  "  
0.0 kJ/kg"; 
B1+rms / Coil Power =
 
   inv. offset (Hz) = 
 0; 
   dummy scans = 
 0; 
Manual start = 
  "no"; 
Dynamic study = 
  "no"; 
Arterial Spin labeling =
 "no"; 
Preparation phases = 
 "full"; 
Interactive F0 = 
 "no"; 
Receiver optimization =
 
 "ON"; 
Spectral correction = 
 "yes"; 
    spectral correction NSA 
= 4; 
    fat supp. on correction =
 "no"; 
Reference tissue = 
 "White matter"; 
PlanScan metabolite =
 
 "NAA"; 
Shifted metabolite 
displayed =
 "H20"; 
Preset window contrast =
 "soft"; 
Save raw data = 
 
 "yes"; 
Hardcopy protocol = 
 "no"; 
Elliptical k-space shutter =
 "default"; 
IF_info_seperator = 
 1634755923; 
Total scan duration = 
 "12:19.6"; 
Act. TR/TE (ms) = 
 "10565 / 28"; 
Min. TR/TE (ms) = 
 "10565 / 28"; 
Series TI (ms) = 
  
  
 
 "170/1000/2000
/3000/5000/8000/10000"; 
SPAIR TR (ms) = 
 
 10548.4795; 
SPAIR inv. delay (ms) =
 
 "0.00"; 
Spectral resolution 
(Hz/point) =
 1.953125; 
Readout duration (ms) =
  512; 
SAR / head = 
  "<  2 
%"; 
Whole body / level = 
 "0.0 W/kg / 
normal"; 
SED =  
  "  
0.0 kJ/kg"; 
B1+rms / Coil Power =
   inv. bw (Hz) = 
 1500; 
   inv. offset (Hz) = 
 0; 
   dummy scans = 
 0; 
Manual start = 
  "no"; 
Dynamic study = 
  "no"; 
Arterial Spin labeling =
 "no"; 
Preparation phases = 
 "full"; 
Interactive F0 = 
 "no"; 
Receiver optimization =
 
 "ON"; 
Spectral correction = 
 "yes"; 
    spectral correction NSA 
= 4; 
    fat supp. on correction =
 "no"; 
Reference tissue = 
 "White matter"; 
PlanScan metabolite =
 
 "NAA"; 
Shifted metabolite 
displayed =
 "Lactate/Lipid"; 
Preset window contrast =
 "soft"; 
Save raw data = 
 
 "yes"; 
Hardcopy protocol = 
 "no"; 
Elliptical k-space shutter =
 "default"; 
IF_info_seperator = 
 1634755923; 
Total scan duration = 
 "17:30.0"; 
Act. TR/TE (ms) = 
 "15000 / 28"; 
Min. TR/TE (ms) = 
 "10565 / 28"; 
Series TI (ms) = 
  
  
 
 "170/1000/2000
/3000/5000/8000/10000"; 
SPAIR TR (ms) = 
 
 14983.2227; 
SPAIR inv. delay (ms) =
 
 "0.00"; 
Spectral resolution 
(Hz/point) =
 1.953125; 
Readout duration (ms) =
  512; 
SAR / head = 
  "<  2 
%"; 
Whole body / level = 
 "0.0 W/kg / 
normal"; 
SED =  
  "  
   inv. bw (Hz) = 
 300; 
   inv. offset (Hz) = 
 400; 
   dummy scans = 
 0; 
Manual start = 
  "no"; 
Dynamic study = 
  "no"; 
Arterial Spin labeling =
 "no"; 
Preparation phases = 
 "full"; 
Interactive F0 = 
 "no"; 
Receiver optimization =
 
 "ON"; 
Spectral correction = 
 "yes"; 
    spectral correction NSA 
= 4; 
    fat supp. on correction =
 "no"; 
Reference tissue = 
 "White matter"; 
PlanScan metabolite =
 
 "NAA"; 
Shifted metabolite 
displayed =
 "Lactate/Lipid"; 
Preset window contrast =
 "soft"; 
Save raw data = 
 
 "yes"; 
Hardcopy protocol = 
 "no"; 
Elliptical k-space shutter =
 "default"; 
Total scan duration = 
 "17:30.0"; 
Act. TR/TE (ms) = 
 "15000 / 28"; 
Min. TR/TE (ms) = 
 "10597 / 28"; 
Series TI (ms) = 
  
  
 
 "170/1000/2000
/3000/5000/8000/10000"; 
SPAIR TR (ms) = 
 
 14983.2227; 
SPAIR inv. delay (ms) =
 
 "0.00"; 
Spectral resolution 
(Hz/point) =
 1.953125; 
Readout duration (ms) =
  512; 
SAR / head = 
  "<  1 
%"; 
Whole body / level = 
 "0.0 W/kg / 
normal"; 
SED =  
  "  
0.0 kJ/kg"; 
B1+rms / Coil Power =
 
 (121) 0; 
   inv. bw (Hz) = 
 1500; 
   inv. offset (Hz) = 
 0; 
   dummy scans = 
 0; 
Manual start = 
  "no"; 
Dynamic study = 
  "no"; 
Arterial Spin labeling =
 "no"; 
Preparation phases = 
 "full"; 
Interactive F0 = 
 "no"; 
Receiver optimization =
 
 "ON"; 
Spectral correction = 
 "yes"; 
    spectral correction NSA 
= 4; 
    fat supp. on correction =
 "no"; 
Reference tissue = 
 "White matter"; 
PlanScan metabolite =
 
 "Lactate/Lipid"; 
Shifted metabolite 
displayed =
 "NAA"; 
Preset window contrast =
 "soft"; 
Save raw data = 
 
 "yes"; 
Hardcopy protocol = 
 "no"; 
Elliptical k-space shutter =
 "default"; 
Total scan duration = 
 "17:30.0"; 
Act. TR/TE (ms) = 
 "15000 / 288"; 
Min. TR/TE (ms) = 
 "10825 / 28"; 
Series TI (ms) = 
  
  
 
 "170/1000/2000
/3000/5000/8000/10000"; 
SPAIR TR (ms) = 
 
 14983.2227; 
SPAIR inv. delay (ms) =
 
 "0.00"; 
Spectral resolution 
(Hz/point) =
 1.953125; 
Readout duration (ms) =
  512; 
SAR / head = 
  "<  2 
%"; 
Whole body / level = 
 "0.0 W/kg / 
normal"; 
SED =  
  "  
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 "0.46 uT / 4 
%"; 
Max B1+rms = 
 
 "0.58 uT"; 
PNS / level = 
  "33 
% / normal"; 
dB/dt =  
 
 "17.0 T/s"; 
Sound Pressure Level (dB) 
= 0; 
 
 
 "0.35 uT / 2 
%"; 
Max B1+rms = 
 
 "1.04 uT"; 
PNS / level = 
  "67 
% / normal"; 
dB/dt =  
 
 "37.6 T/s"; 
Sound Pressure Level (dB) 
= 0; 
 
0.0 kJ/kg"; 
B1+rms / Coil Power =
 
 "0.29 uT / 2 
%"; 
Max B1+rms = 
 
 "1.04 uT"; 
PNS / level = 
  "67 
% / normal"; 
dB/dt =  
 
 "37.6 T/s"; 
Sound Pressure Level (dB) 
= 0; 
 
 
 "0.25 uT / 1 
%"; 
Max B1+rms = 
 
 "1.04 uT"; 
PNS / level = 
  "67 
% / normal"; 
dB/dt =  
 
 "37.6 T/s"; 
Sound Pressure Level (dB) 
= 0; 
 
0.0 kJ/kg"; 
B1+rms / Coil Power =
 
 "0.29 uT / 2 
%"; 
Max B1+rms = 
 
 "0.90 uT"; 
PNS / level = 
  "65 
% / normal"; 
dB/dt =  
 
 "37.6 T/s"; 
Sound Pressure Level (dB) 
= 0; 
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Table 3: Lactate doublet and quadrouplet sequences parameters. 
20/05/15 1/06 – 2/06 – 2/06 2th 2/06 3th - 2/06 4th 
SmartSelect =  
 "yes"; 
Coil 1  (exclude) =  "None"; 
VOI orientation = 
 "transverse"; 
VOI size AP (mm) =  20; 
         RL (mm) =  20; 
         FH (mm) =  20; 
Samples =   1024; 
Spectral BW (Hz) =  2000; 
VOI offc. AP (P=+mm) = 
 0; 
          RL (L=+mm) = 0; 
          FH (H=+mm) = 
 0; 
VOI ang. AP (deg) =  0; 
         RL (deg) =  -0; 
         FH (deg) =  -0; 
Chem. shift Dir AP =  "A"; 
Chem. shift Dir LR =  "L"; 
Chem. shift Dir FH =  "F"; 
Large table movement = 
 "no"; 
REST slabs =  
 0; 
Patient position =  "head 
first"; 
        orientation =  "supine"; 
Scan type =  
 "Spectroscopy"; 
Scan mode =  
 "SV"; 
    technique =  
 "ECHO"; 
VOI selection =  
 "volume"; 
    method =  
 "PRESS"; 
Gradient Spoiling =  "no"; 
Fast Imaging mode =  "none"; 
Echo acquisition =  "half"; 
TE =   
 "shortest"; 
Flip angle (deg) =  90; 
RF pulse set =  
 "normal"; 
TR =   
 "shortest"; 
RF Shims =  
 "fixed"; 
Shim =   
 "PB-auto"; 
    PB order =  
 "second"; 
Water suppression = 
 "excitation"; 
    window (Hz) =  140; 
    second pulse angle = 300; 
WS prescan =  
 "auto"; 
BASING pulse =  
 "no"; 
Research prepulse =  "no"; 
Pre-saturation =  "no"; 
Multi-transmit =  "yes"; 
Transmit channels =  "both"; 
SAR mode =  
 "high"; 
B1 mode =  
 "default"; 
SAR Patient data =  "auto"; 
PNS mode =  
 "high"; 
SmartSelect =  
 "yes"; 
Coil 1  (exclude) =  "None"; 
VOI orientation = 
 "transverse"; 
VOI size AP (mm) =  20; 
         RL (mm) =  20; 
         FH (mm) =  20; 
Samples =   1024; 
Spectral BW (Hz) =  2000; 
VOI offc. AP (P=+mm) = 
 0; 
          RL (L=+mm) = 0; 
          FH (H=+mm) = 
 10; 
VOI ang. AP (deg) =  0; 
         RL (deg) =  -0; 
         FH (deg) =  -0; 
Chem. shift Dir AP =  "A"; 
Chem. shift Dir LR =  "L"; 
Chem. shift Dir FH =  "F"; 
Large table movement = 
 "no"; 
REST slabs =  
 0; 
Patient position =  "head 
first"; 
        orientation =  "supine"; 
Scan type =  
 "Spectroscopy"; 
Scan mode =  
 "SV"; 
    technique =  
 "ECHO"; 
VOI selection =  
 "volume"; 
    method =  
 "PRESS"; 
Gradient Spoiling =  "no"; 
Fast Imaging mode =  "none"; 
Echo acquisition =  "half"; 
TE =   
 "shortest"; 
Flip angle (deg) =  90; 
RF pulse set =  
 "normal"; 
TR =   
 "user defined"; 
    (ms) =   15000; 
RF Shims =  
 "fixed"; 
Shim =   
 "PB-auto"; 
    PB order =  
 "second"; 
Water suppression = 
 "excitation"; 
    window (Hz) =  140; 
    second pulse angle = 300; 
WS prescan =  
 "auto"; 
BASING pulse =  
 "no"; 
Research prepulse =  "no"; 
Pre-saturation =  "no"; 
Multi-transmit =  "yes"; 
Transmit channels =  "both"; 
SAR mode =  
 "high"; 
B1 mode =  
 "default"; 
SAR Patient data =  "auto"; 
PNS mode =  
SmartSelect =  
 "yes"; 
Coil 1  (exclude) =  "None"; 
VOI orientation = 
 "transverse"; 
VOI size AP (mm) =  20; 
         RL (mm) =  20; 
         FH (mm) =  20; 
Samples =   1024; 
Spectral BW (Hz) =  2000; 
VOI offc. AP (P=+mm) = 
 0; 
          RL (L=+mm) = 0; 
          FH (H=+mm) = 
 10; 
VOI ang. AP (deg) =  0; 
         RL (deg) =  -0; 
         FH (deg) =  -0; 
Chem. shift Dir AP =  "A"; 
Chem. shift Dir LR =  "L"; 
Chem. shift Dir FH =  "F"; 
Large table movement = 
 "no"; 
REST slabs =  
 0; 
Patient position =  "head 
first"; 
        orientation =  "supine"; 
Scan type =  
 "Spectroscopy"; 
Scan mode =  
 "SV"; 
    technique =  
 "ECHO"; 
VOI selection =  
 "volume"; 
    method =  
 "PRESS"; 
Gradient Spoiling =  "no"; 
Fast Imaging mode =  "none"; 
Echo acquisition =  "half"; 
TE =   
 "user defined"; 
    (ms) =   288; 
Flip angle (deg) =  90; 
RF pulse set =  
 "normal"; 
TR =   
 "user defined"; 
    (ms) =   15000; 
RF Shims =  
 "fixed"; 
Shim =   
 "PB-auto"; 
    PB order =  
 "second"; 
Water suppression = 
 "excitation"; 
    window (Hz) =  140; 
    second pulse angle = 300; 
WS prescan =  
 "auto"; 
BASING pulse =  
 "no"; 
Research prepulse =  "no"; 
Pre-saturation =  "no"; 
Multi-transmit =  "yes"; 
Transmit channels =  "both"; 
SAR mode =  
 "high"; 
B1 mode =  
 "default"; 
SAR Patient data =  "auto"; 
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Gradient mode =  
 "maximum"; 
SofTone mode =  
 "no"; 
Cardiac synchronization = "no"; 
Respiratory compensation = "no"; 
Startup acquisitions =  2; 
NSA =   
 4; 
Phase cycles =  
 4; 
Frequency stabilization = "yes"; 
Parameter series =  "TI"; 
   nr TIs =   7; 
   series spacing =  "user 
def."; 
   TI values (ms) =  170, 
1000, 
   
 2000, 3000, 5000, 8000, 10000, 
   
 (121) 0; 
   inv. bw (Hz) =  1500; 
   inv. offset (Hz) =  0; 
   dummy scans =  0; 
Manual start =  
 "no"; 
Dynamic study =  
 "no"; 
Arterial Spin labeling = "no"; 
Preparation phases =  "full"; 
Interactive F0 =  "no"; 
Receiver optimization = 
 "ON"; 
Spectral correction =  "yes"; 
    spectral correction NSA = 4; 
    fat supp. on correction = "no"; 
Reference tissue =  "White 
matter"; 
PlanScan metabolite = 
 "NAA"; 
Shifted metabolite displayed = "H20"; 
Preset window contrast = "soft"; 
Save raw data =  "yes"; 
Hardcopy protocol =  "no"; 
Elliptical k-space shutter = "default"; 
IF_info_seperator = 
 1634755923; 
Total scan duration = 
 "12:19.6"; 
Act. TR/TE (ms) =  "10565 / 
28"; 
Min. TR/TE (ms) =  "10565 / 
28"; 
Series TI (ms) =   
 "170/1000/2000/3000/5000/800
0/10000"; 
SPAIR TR (ms) = 
 10548.4795; 
SPAIR inv. delay (ms) = "0.00"; 
Spectral resolution (Hz/point) = 1.953125; 
Readout duration (ms) = 512; 
SAR / head =  
 "<  2 %"; 
Whole body / level =  "0.0 
W/kg / normal"; 
SED =   
 "  0.0 kJ/kg"; 
B1+rms / Coil Power ="0.35 uT / 2 %"; 
Max B1+rms =  "1.04 
uT"; 
PNS / level =  
 "67 % / normal"; 
dB/dt =  "37.6 T/s"; 
Sound Pressure Level (dB) = 0; 
 "high"; 
Gradient mode =  
 "maximum"; 
SofTone mode =  
 "no"; 
Cardiac synchronization = "no"; 
Respiratory compensation = "no"; 
Startup acquisitions =  2; 
NSA =   
 4; 
Phase cycles =  
 4; 
Frequency stabilization = "yes"; 
Parameter series =  "TI"; 
   nr TIs =   7; 
   series spacing =  "user 
def."; 
   TI values (ms) =  170, 
1000, 
   
 2000, 3000, 5000, 8000, 10000, 
   
 (121) 0; 
   inv. bw (Hz) =  1500; 
   inv. offset (Hz) =  0; 
   dummy scans =  0; 
Manual start =  
 "no"; 
Dynamic study =  
 "no"; 
Arterial Spin labeling = "no"; 
Preparation phases =  "full"; 
Interactive F0 =  "no"; 
Receiver optimization = 
 "ON"; 
Spectral correction =  "yes"; 
    spectral correction NSA = 4; 
    fat supp. on correction = "no"; 
Reference tissue =  "White 
matter"; 
PlanScan metabolite = 
 "NAA"; 
Shifted metabolite displayed =
 "Lactate/Lipid"; 
Preset window contrast = "soft"; 
Save raw data =  "yes"; 
Hardcopy protocol =  "no"; 
Elliptical k-space shutter = "default"; 
IF_info_seperator = 
 1634755923; 
Total scan duration = 
 "17:30.0"; 
Act. TR/TE (ms) =  "15000 / 
28"; 
Min. TR/TE (ms) =  "10565 / 
28"; 
Series TI (ms) =   
 "170/1000/2000/3000/5000/800
0/10000"; 
SPAIR TR (ms) = 
 14983.2227; 
SPAIR inv. delay (ms) = "0.00"; 
Spectral resolution (Hz/point) = 1.953125; 
Readout duration (ms) = 512; 
SAR / head =  
 "<  2 %"; 
Whole body / level =  "0.0 
W/kg / normal"; 
SED =  "  0.0 kJ/kg"; 
B1+rms / Coil Power ="0.29 uT / 2 %"; 
Max B1+rms = "1.04 uT"; 
PNS / level ="67 % / normal"; 
dB/dt =  "37.6 T/s"; 
Sound Pressure Level (dB) = 0; 
PNS mode =  
 "high"; 
Gradient mode =  
 "maximum"; 
SofTone mode =  
 "no"; 
Cardiac synchronization = "no"; 
Respiratory compensation = "no"; 
Startup acquisitions =  2; 
NSA =   
 4; 
Phase cycles =  
 4; 
Frequency stabilization = "yes"; 
Parameter series =  "TI"; 
   nr TIs =   7; 
   series spacing =  "user 
def."; 
   TI values (ms) =  170, 
1000, 
   
 2000, 3000, 5000, 8000, 10000, 
   
 (121) 0; 
   inv. bw (Hz) =  1500; 
   inv. offset (Hz) =  0; 
   dummy scans =  0; 
Manual start =  
 "no"; 
Dynamic study =  
 "no"; 
Arterial Spin labeling = "no"; 
Preparation phases =  "full"; 
Interactive F0 =  "no"; 
Receiver optimization = 
 "ON"; 
Spectral correction =  "yes"; 
    spectral correction NSA = 4; 
    fat supp. on correction = "no"; 
Reference tissue =  "White 
matter"; 
PlanScan metabolite = 
 "Lactate/Lipid"; 
Shifted metabolite displayed = "NAA"; 
Preset window contrast = "soft"; 
Save raw data =  "yes"; 
Hardcopy protocol =  "no"; 
Elliptical k-space shutter = "default"; 
Total scan duration = 
 "17:30.0"; 
Act. TR/TE (ms) =  "15000 / 
288"; 
Min. TR/TE (ms) =  "10825 / 
28"; 
Series TI (ms) =   
 "170/1000/2000/3000/5000/800
0/10000"; 
SPAIR TR (ms) = 
 14983.2227; 
SPAIR inv. delay (ms) = "0.00"; 
Spectral resolution (Hz/point) = 1.953125; 
Readout duration (ms) = 512; 
SAR / head =  "<  2 %"; 
Whole body / level = "0.0 W/kg / normal"; 
SED =  "  0.0 kJ/kg"; 
B1+rms / Coil Power ="0.29 uT / 2 %"; 
Max B1+rms =  "0.90 
uT"; 
PNS / level = "65 % / normal"; 
dB/dt =   "37.6 
T/s"; 
Sound Pressure Level (dB) = 0; 
 
  
 
Appendix 3 
 
SPIN-ECHO SEQUENCES PARAMETERS FOR T2 ESTIMATION 
 
Table 1: Water T2 sequences parameters. 
7/03/15 20/05/15 1/06-2/06-2/06 2th 
SmartSelect = "yes"; 
Coil 1  (exclude) = "None"; 
VOI orientation = "transverse"; 
VOI size AP (mm) =  20; 
         RL (mm) =  20; 
         FH (mm) =  20; 
Samples =  1024; 
Spectral BW (Hz) = 2000; 
VOI offc. AP (P=+mm) = -5; 
          RL (L=+mm) = 0; 
          FH (H=+mm) =10; 
VOI ang. AP (deg) =  0; 
         RL (deg) =  -0; 
         FH (deg) =  -0; 
Chem. shift Dir AP = "A"; 
Chem. shift Dir LR = "L"; 
Chem. shift Dir FH = "F"; 
Large table movement = "no"; 
REST slabs = 0; 
Patient position = "head first"; 
        orientation = "supine"; 
Scan type ="Spectroscopy"; 
Scan mode = "SV"; 
    technique = "ECHO"; 
VOI selection = "volume"; 
    method ="PRESS"; 
Gradient Spoiling = "no"; 
Fast Imaging mode = "none"; 
Echo acquisition = "half"; 
Flip angle (deg) =  90; 
RF pulse set = "normal"; 
TR ="user defined"; 
    (ms) = 4000; 
RF Shims ="fixed"; 
Shim = "PB-auto"; 
    PB order ="second"; 
Water suppression = "no"; 
BASING pulse = "no"; 
Fat suppression = "no"; 
Research prepulse = "no"; 
Pre-saturation = "no"; 
Multi-transmit = "yes"; 
Transmit channels = "both"; 
SAR mode = "high"; 
B1 mode = "default"; 
SAR Patient data = "auto"; 
PNS mode = "low"; 
Gradient mode = "default"; 
SofTone mode = "no"; 
Cardiac synchronization ="no"; 
Respiratory compensation ="no"; 
Startup acquisitions =  2; 
NSA =   16; 
Phase cycles =  16; 
Frequency stabilization ="yes"; 
Parameter series = "TE"; 
   nr TEs =   6; 
   series spacing = "user def."; 
   TE values (ms) =  35, 
100,150, 300, 400, 700, (122) 0; 
   dummy scans =  0; 
Manual start = "no"; 
Dynamic study = "no"; 
Arterial Spin labeling ="no"; 
Preparation phases = "full"; 
SmartSelect =  "yes"; 
Coil 1  (exclude) =  "None"; 
VOI orientation =  "transverse"; 
VOI size AP (mm) =  20; 
         RL (mm) =  20; 
         FH (mm) =  20; 
Samples =   1024; 
Spectral BW (Hz) =  2000; 
VOI offc. AP (P=+mm) =  0; 
          RL (L=+mm) = 0; 
          FH (H=+mm) =  0; 
VOI ang. AP (deg) =  0; 
         RL (deg) =  -0; 
         FH (deg) =  -0; 
Chem. shift Dir AP =  "A"; 
Chem. shift Dir LR =  "L"; 
Chem. shift Dir FH =  "F"; 
Large table movement = "no"; 
REST slabs =   0; 
Patient position =  "head first"; 
        orientation =  "supine"; 
Scan type = "Spectroscopy"; 
Scan mode =  "SV"; 
    technique =  "ECHO"; 
VOI selection =  "volume"; 
    method =  "PRESS"; 
Gradient Spoiling =  "no"; 
Fast Imaging mode =  "none"; 
Echo acquisition =  "half"; 
Flip angle (deg) =  90; 
RF pulse set =  "normal"; 
TR = "user defined"; 
    (ms) = 3000; 
RF Shims = "fixed"; 
Shim = "PB-auto"; 
    PB order = "second"; 
Water suppression =  "no"; 
BASING pulse = "no"; 
Fat suppression =  "no"; 
Research prepulse =  "no"; 
Pre-saturation =  "no"; 
Multi-transmit =  "yes"; 
Transmit channels =  "both"; 
SAR mode =  "high"; 
B1 mode =  "default"; 
SAR Patient data =  "auto"; 
PNS mode = "high"; 
Gradient mode =  "maximum"; 
SofTone mode =  "no"; 
Cardiac synchronization = "no"; 
Respiratory compensation = "no"; 
Startup acquisitions =  2; 
NSA =    2; 
Phase cycles =   2; 
Frequency stabilization = "yes"; 
Parameter series =  "TE"; 
   nr TEs =   8; 
   series spacing =  "user def."; 
   TE values (ms) = 30, 100, 200, 400, 800, 
1200, 1600, 2000, (120) 0; 
   dummy scans =  0; 
Manual start =  "no"; 
Dynamic study =  "no"; 
Arterial Spin labeling = "no"; 
Preparation phases =  "auto"; 
SmartSelect =   "yes"; 
Coil 1  (exclude) =  "None"; 
VOI orientation =  "transverse"; 
VOI size AP (mm) =  20; 
         RL (mm) =  20; 
         FH (mm) =  20; 
Samples =   1024; 
Spectral BW (Hz) =  2000; 
VOI offc. AP (P=+mm) =  0; 
          RL (L=+mm) = 0; 
          FH (H=+mm) =  10; 
VOI ang. AP (deg) =  0; 
         RL (deg) =  -0; 
         FH (deg) =  -0; 
Chem. shift Dir AP =  "A"; 
Chem. shift Dir LR =  "L"; 
Chem. shift Dir FH =  "F"; 
Large table movement =  "no"; 
REST slabs =   0; 
Patient position =  "head first"; 
        orientation =  "supine"; 
Scan type =  
 "Spectroscopy"; 
Scan mode =   "SV"; 
    technique =   "ECHO"; 
VOI selection =   "volume"; 
    method =   "PRESS"; 
Gradient Spoiling =  "no"; 
Fast Imaging mode =  "none"; 
Echo acquisition =  "half"; 
Flip angle (deg) =  90; 
RF pulse set =   "normal"; 
TR =    "user 
defined"; 
    (ms) =   6000; 
RF Shims =   "fixed"; 
Shim =    "PB-auto"; 
    PB order =   "second"; 
Water suppression =  "no"; 
BASING pulse =   "no"; 
Fat suppression =  "no"; 
Research prepulse =  "no"; 
Pre-saturation =  "no"; 
Multi-transmit =  "yes"; 
Transmit channels =  "both"; 
SAR mode =   "high"; 
B1 mode =   "default"; 
SAR Patient data =  "auto"; 
PNS mode =   "high"; 
Gradient mode =  
 "maximum"; 
SofTone mode =   "no"; 
Cardiac synchronization = "no"; 
Respiratory compensation = "no"; 
Startup acquisitions =  2; 
NSA =    2; 
Phase cycles =   2; 
Frequency stabilization = "yes"; 
Parameter series =  "TE"; 
   nr TEs =   9; 
   series spacing =  "user def."; 
   TE values (ms) = 30, 100, 200, 400, 800, 1200, 
1600, 2000, 3000, (119) 0; 
   dummy scans =  0; 
Manual start =   "no"; 
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Interactive F0 = "no"; 
Receiver optimization ="OFF"; 
Receiver attenuation = 8; 
Spectral correction = "yes"; 
    spectral correction NSA = 16; 
    fat supp. on correction ="no"; 
Reference tissue ="White matter"; 
PlanScan metabolite ="H20"; 
Shifted metabolite displayed =
 "NAA"; 
Preset window contrast ="soft"; 
Save raw data = "yes"; 
Hardcopy protocol = "no"; 
Elliptical k-space shutter ="default"; 
IF_info_seperator = 1634755923; 
Total scan duration = "13:36.0"; 
Act. TR/TE (ms) = "4000 / 35"; 
Min. TR/TE (ms) = "1236 / 34"; 
Series TE (ms) 
="35/100/150/300/400/700"; 
Spectral resolution (Hz/point) 
=1.953125; 
Readout duration (ms) =512; 
SAR / head = "<  4 %"; 
Whole body / level = "0.0 W/kg / 
normal"; 
SED =  "  0.0 kJ/kg"; 
B1+rms / Coil Power ="0.45 uT / 4 
%"; 
Max B1+rms = "0.45 uT"; 
PNS / level ="33 % / normal"; 
dB/dt = "17.0 T/s"; 
Sound Pressure Level (dB) = 0; 
Interactive F0 =  "no"; 
Receiver optimization = "ON"; 
Spectral correction =  "yes"; 
    spectral correction NSA = 2; 
    fat supp. on correction = "no"; 
Reference tissue =  "White matter"; 
PlanScan metabolite = "H20"; 
Shifted metabolite displayed = "none"; 
Preset window contrast = "soft"; 
Save raw data =  "yes"; 
Hardcopy protocol =  "no"; 
Elliptical k-space shutter = "default"; 
IF_info_seperator =  1634755923; 
Total scan duration =  "02:24.0"; 
Act. TR/TE (ms) =  "3000 / 30"; 
Min. TR/TE (ms) =  "2536 / 28"; 
Series TE (ms) =   
"30/100/200/400/800/1200/1600/2000"; 
Spectral resolution (Hz/point) = 1.953125; 
Readout duration (ms) = 512; 
SAR / head = "<  5 %"; 
Whole body / level = "0.0 W/kg / normal"; 
SED = "  0.0 kJ/kg"; 
B1+rms / Coil Power ="0.52 uT / 5 %"; 
Max B1+rms = "0.53 uT"; 
PNS / level ="66 % / normal"; 
dB/dt = "37.6 T/s"; 
Sound Pressure Level (dB) = 0; 
Dynamic study =   "no"; 
Arterial Spin labeling = "no"; 
Preparation phases =  "full"; 
Interactive F0 =  "no"; 
Receiver optimization =  "ON"; 
Spectral correction =  "yes"; 
    spectral correction NSA = 2; 
    fat supp. on correction = "no"; 
Reference tissue =  "White matter"; 
PlanScan metabolite =  "H20"; 
Shifted metabolite displayed = "Lactate/Lipid"; 
Preset window contrast = "soft"; 
Save raw data =   "yes"; 
Hardcopy protocol =  "no"; 
Elliptical k-space shutter = "default"; 
IF_info_seperator =  1634755923; 
Total scan duration =  "05:24.0"; 
Act. TR/TE (ms) =  "6000 / 30"; 
Min. TR/TE (ms) =  "3536 / 28"; 
Series TE (ms) =   
 "30/100/200/400/800/1200/1600/2000/3000"; 
Spectral resolution (Hz/point) = 1.953125; 
Readout duration (ms) =  512; 
SAR / head =   "<  2 %"; 
Whole body / level =  "0.0 W/kg / normal"; 
SED =    "  0.0 
kJ/kg"; 
B1+rms / Coil Power = "0.37 uT / 2 %"; 
Max B1+rms =   "0.37 uT"; 
PNS / level =  "66 % / normal"; 
dB/dt =    "37.6 T/s"; 
Sound Pressure Level (dB) = 0; 
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Table 2: Acetate and Lactate sequences parameters. 
7/03 20/05 1/06- 2/06 – 2/06 2th 2/06 3th-2/06 4th, Lactate specific 
sequence 
SmartSelect =  
 "yes"; 
Coil 1  (exclude) = 
 "None"; 
VOI orientation = 
 "transverse"; 
VOI size AP (mm) = 
 20; 
         RL (mm) = 
 20; 
         FH (mm) = 
 20; 
Samples =  
 1024; 
Spectral BW (Hz) = 
 2000; 
VOI offc. AP (P=+mm) = 
 -5; 
          RL (L=+mm) = 
 0; 
          FH (H=+mm) = 
 10; 
VOI ang. AP (deg) = 
 0; 
         RL (deg) =  -
0; 
         FH (deg) =  -
0; 
Chem. shift Dir AP = 
 "A"; 
Chem. shift Dir LR = 
 "L"; 
Chem. shift Dir FH = 
 "F"; 
Large table movement ="no"; 
REST slabs =0; 
Patient position ="head first"; 
        orientation = 
 "supine"; 
Scan type ="Spectroscopy"; 
Scan mode ="SV"; 
    technique = 
 "ECHO"; 
VOI selection = 
 "volume"; 
    method ="PRESS"; 
Gradient Spoiling = 
 "no"; 
Fast Imaging mode = 
 "none"; 
Echo acquisition = 
 "half"; 
Flip angle (deg) = 
 90; 
RF pulse set ="normal"; 
TR ="user defined"; 
    (ms) = 4000; 
RF Shims ="fixed"; 
Shim = "PB-auto"; 
    PB order = 
 "second"; 
Water suppression ="excitation"; 
    window (Hz) = 
 140; 
    second pulse angle =
 300; 
WS prescan = 
 "auto"; 
BASING pulse = 
 "no"; 
Fat suppression = 
 "no"; 
Research prepulse = 
 "no"; 
SmartSelect =  
 "yes"; 
Coil 1  (exclude) = 
 "None"; 
VOI orientation = 
 "transverse"; 
VOI size AP (mm) = 
 20; 
         RL (mm) = 
 20; 
         FH (mm) = 
 20; 
Samples =  
 1024; 
Spectral BW (Hz) = 
 2000; 
VOI offc. AP (P=+mm) = 
 0; 
          RL (L=+mm) = 
 0; 
          FH (H=+mm) = 
 0; 
VOI ang. AP (deg) = 
 0; 
         RL (deg) =  -
0; 
         FH (deg) =  -
0; 
Chem. shift Dir AP = 
 "A"; 
Chem. shift Dir LR = 
 "L"; 
Chem. shift Dir FH = 
 "F"; 
Large table movement = 
 "no"; 
REST slabs =  
 0; 
Patient position = 
 "head first"; 
        orientation = 
 "supine"; 
Scan type =  
 "Spectroscopy"; 
Scan mode =  
 "SV"; 
    technique =  
 "ECHO"; 
VOI selection =  
 "volume"; 
    method =  
 "PRESS"; 
Gradient Spoiling = 
 "no"; 
Fast Imaging mode = 
 "none"; 
Echo acquisition = 
 "half"; 
Flip angle (deg) = 
 90; 
RF pulse set =  
 "normal"; 
TR =   
 "user defined"; 
    (ms) =  
 3000; 
RF Shims =  
 "fixed"; 
Shim =   
 "PB-auto"; 
    PB order =  
 "second"; 
Water suppression = 
 "excitation"; 
SmartSelect =  
 "yes"; 
Coil 1  (exclude) = 
 "None"; 
VOI orientation = 
 "transverse"; 
VOI size AP (mm) = 
 20; 
         RL (mm) = 
 20; 
         FH (mm) = 
 20; 
Samples =  
 1024; 
Spectral BW (Hz) = 
 2000; 
VOI offc. AP (P=+mm) = 
 0; 
          RL (L=+mm) = 
 0; 
          FH (H=+mm) = 
 10; 
VOI ang. AP (deg) = 
 0; 
         RL (deg) =  -
0; 
         FH (deg) =  -
0; 
Chem. shift Dir AP = 
 "A"; 
Chem. shift Dir LR = 
 "L"; 
Chem. shift Dir FH = 
 "F"; 
Large table movement = 
 "no"; 
REST slabs =  
 0; 
Patient position = 
 "head first"; 
        orientation = 
 "supine"; 
Scan type =  
 "Spectroscopy"; 
Scan mode =  
 "SV"; 
    technique =  
 "ECHO"; 
VOI selection =  
 "volume"; 
    method =  
 "PRESS"; 
Gradient Spoiling = 
 "no"; 
Fast Imaging mode = 
 "none"; 
Echo acquisition = 
 "half"; 
Flip angle (deg) = 
 90; 
RF pulse set =  
 "normal"; 
TR =   
 "user defined"; 
    (ms) =  
 6000; 
RF Shims =  
 "fixed"; 
Shim =   
 "PB-auto"; 
    PB order =  
 "second"; 
Water suppression = 
 "excitation"; 
SmartSelect =  
 "yes"; 
Coil 1  (exclude) = 
 "None"; 
VOI orientation = 
 "transverse"; 
VOI size AP (mm) = 
 20; 
         RL (mm) = 
 20; 
         FH (mm) = 
 20; 
Samples =  
 1024; 
Spectral BW (Hz) = 
 2000; 
VOI offc. AP (P=+mm) = 
 0; 
          RL (L=+mm) = 
 0; 
          FH (H=+mm) = 
 10; 
VOI ang. AP (deg) = 
 0; 
         RL (deg) =  -
0; 
         FH (deg) =  -
0; 
Chem. shift Dir AP = 
 "A"; 
Chem. shift Dir LR = 
 "L"; 
Chem. shift Dir FH = 
 "F"; 
Large table movement = 
 "no"; 
REST slabs =  
 0; 
Patient position = 
 "head first"; 
        orientation = 
 "supine"; 
Scan type =  
 "Spectroscopy"; 
Scan mode =  
 "SV"; 
    technique =  
 "ECHO"; 
VOI selection =  
 "volume"; 
    method =  
 "PRESS"; 
Gradient Spoiling = 
 "no"; 
Fast Imaging mode = 
 "none"; 
Echo acquisition = 
 "half"; 
Flip angle (deg) = 
 90; 
RF pulse set =  
 "normal"; 
TR =   
 "user defined"; 
    (ms) =  
 6000; 
RF Shims =  
 "fixed"; 
Shim =   
 "PB-auto"; 
    PB order =  
 "second"; 
Water suppression = 
 "excitation"; 
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Pre-saturation = 
 "no"; 
Multi-transmit = 
 "yes"; 
Transmit channels = 
 "both"; 
SAR mode ="high"; 
B1 mode = 
 "default"; 
SAR Patient data = 
 "auto"; 
PNS mode ="low"; 
Gradient mode = 
 "default"; 
SofTone mode ="no"; 
Cardiac synchronization =
 "no"; 
Respiratory compensation ="no"; 
Startup acquisitions = 
 2; 
NSA = 16; 
Phase cycles =16; 
Frequency stabilization =
 "yes"; 
Parameter series = 
 "TE"; 
   nr TEs = 6; 
   series spacing = 
 "user def."; 
   TE values (ms) =35, 100,150, 
300, 400, 700, (122) 0; 
   dummy scans =0; 
Manual start ="no"; 
Dynamic study ="no"; 
Arterial Spin labeling =
 "no"; 
Preparation phases = 
 "full"; 
Interactive F0 ="no"; 
Receiver optimization =
 "OFF"; 
Receiver attenuation =
 8; 
Spectral correction = 
 "yes"; 
    spectral correction NSA =
 16; 
    fat supp. on correction ="no"; 
Reference tissue ="White matter"; 
PlanScan metabolite =
 "NAA"; 
Shifted metabolite displayed 
="H20"; 
Preset window contrast =
 "soft"; 
Save raw data = 
 "yes"; 
Hardcopy protocol = 
 "no"; 
Elliptical k-space shutter =
 "default"; 
IF_info_seperator =1634755923; 
Total scan duration ="13:36.0"; 
Act. TR/TE (ms) ="4000 / 35"; 
Min. TR/TE (ms) ="1396 / 34"; 
Series TE (ms) =
 "35/100/150/300/400/7
00"; 
Spectral resolution (Hz/point) 
=1.953125; 
Readout duration (ms) =
 512; 
SAR / head ="<  4 %"; 
Whole body / level ="0.0 W/kg / 
normal"; 
SED ="  0.0 kJ/kg"; 
B1+rms / Coil Power ="0.46 uT / 
    window (Hz) = 
 140; 
    second pulse angle =
 300; 
WS prescan =  
 "auto"; 
BASING pulse =  
 "no"; 
Fat suppression = 
 "no"; 
Research prepulse = 
 "no"; 
Pre-saturation = 
 "no"; 
Multi-transmit = 
 "yes"; 
Transmit channels = 
 "both"; 
SAR mode =  
 "high"; 
B1 mode =  
 "default"; 
SAR Patient data = 
 "auto"; 
PNS mode =  
 "high"; 
Gradient mode =  
 "maximum"; 
SofTone mode =  
 "no"; 
Cardiac synchronization =
 "no"; 
Respiratory compensation =
 "no"; 
Startup acquisitions = 
 2; 
NSA =   
 8; 
Phase cycles =  
 8; 
Frequency stabilization =
 "yes"; 
Parameter series = 
 "TE"; 
   nr TEs =  
 8; 
   series spacing = 
 "user def."; 
   TE values (ms) = 
 30, 100, 
   
 200, 400, 800, 1200, 
1600, 
   
 2000, (120) 0; 
   dummy scans = 
 0; 
Manual start =  
 "no"; 
Dynamic study =  
 "no"; 
Arterial Spin labeling =
 "no"; 
Preparation phases = 
 "full"; 
Interactive F0 = 
 "no"; 
Receiver optimization = 
 "ON"; 
Spectral correction = 
 "yes"; 
    spectral correction NSA =
 8; 
    fat supp. on correction =
 "no"; 
Reference tissue = 
 "White matter"; 
    window (Hz) = 
 140; 
    second pulse angle =
 300; 
WS prescan =  
 "auto"; 
BASING pulse =  
 "no"; 
Fat suppression = 
 "no"; 
Research prepulse = 
 "no"; 
Pre-saturation = 
 "no"; 
Multi-transmit = 
 "yes"; 
Transmit channels = 
 "both"; 
SAR mode =  
 "high"; 
B1 mode =  
 "default"; 
SAR Patient data = 
 "auto"; 
PNS mode =  
 "high"; 
Gradient mode =  
 "maximum"; 
SofTone mode =  
 "no"; 
Cardiac synchronization =
 "no"; 
Respiratory compensation =
 "no"; 
Startup acquisitions = 
 2; 
NSA =   
 16; 
Phase cycles =  
 16; 
Frequency stabilization =
 "yes"; 
Parameter series = 
 "TE"; 
   nr TEs =  
 9; 
   series spacing = 
 "user def."; 
   TE values (ms) = 
 30, 100, 
   
 200, 400, 800, 1200, 
1600, 
   
 2000, 3000, (119) 0; 
   dummy scans = 
 0; 
Manual start =  
 "no"; 
Dynamic study =  
 "no"; 
Arterial Spin labeling =
 "no"; 
Preparation phases = 
 "full"; 
Interactive F0 = 
 "no"; 
Receiver optimization = 
 "ON"; 
Spectral correction = 
 "yes"; 
    spectral correction NSA =
 16; 
    fat supp. on correction =
 "no"; 
Reference tissue = 
 "White matter"; 
    window (Hz) = 
 140; 
    second pulse angle =
 300; 
WS prescan =  
 "auto"; 
BASING pulse =  
 "no"; 
Fat suppression = 
 "no"; 
Research prepulse = 
 "no"; 
Pre-saturation = 
 "no"; 
Multi-transmit = 
 "yes"; 
Transmit channels = 
 "both"; 
SAR mode =  
 "high"; 
B1 mode =  
 "default"; 
SAR Patient data = 
 "auto"; 
PNS mode =  
 "high"; 
Gradient mode =  
 "maximum"; 
SofTone mode =  
 "no"; 
Cardiac synchronization =
 "no"; 
Respiratory compensation =
 "no"; 
Startup acquisitions = 
 2; 
NSA =   
 16; 
Phase cycles =  
 16; 
Frequency stabilization =
 "yes"; 
Parameter series = 
 "TE"; 
   nr TEs =  
 9; 
   series spacing = 
 "user def."; 
   TE values (ms) = 
 29, 288, 
   
 576, 864, 1152, 1440, 
1728, 
   
 2304, 2880, (119) 0; 
   dummy scans = 
 0; 
Manual start =  
 "no"; 
Dynamic study =  
 "no"; 
Arterial Spin labeling =
 "no"; 
Preparation phases = 
 "full"; 
Interactive F0 = 
 "no"; 
Receiver optimization = 
 "ON"; 
Spectral correction = 
 "yes"; 
    spectral correction NSA =
 16; 
    fat supp. on correction =
 "no"; 
Reference tissue = 
 "White matter"; 
Spin-echo sequences parameters for T2 estimation                                                                                                                                                                    133
 
4 %"; 
Max B1+rms ="0.46 uT"; 
PNS / level ="33 % / normal"; 
dB/dt = "17.0 T/s"; 
Sound Pressure Level (dB) =
 0; 
 
PlanScan metabolite = 
 "NAA"; 
Shifted metabolite displayed =
 "H20"; 
Preset window contrast =
 "soft"; 
Save raw data =  
 "yes"; 
Hardcopy protocol = 
 "no"; 
Elliptical k-space shutter =
 "default"; 
IF_info_seperator = 
 1634755923; 
Total scan duration = 
 "07:12.0"; 
Act. TR/TE (ms) = 
 "3000 / 30"; 
Min. TR/TE (ms) = 
 "2696 / 28"; 
Series TE (ms) =   
   
 "30/100/200/400/800/1
200/1600/2000"; 
Spectral resolution (Hz/point) =
 1.953125; 
Readout duration (ms) =512; 
SAR / head = 
 "<  5 %"; 
Whole body / level = 
 "0.0 W/kg / normal"; 
SED =  "  0.0 
kJ/kg"; 
B1+rms / Coil Power = 
 "0.53 uT / 5 %"; 
Max B1+rms = "0.53 uT"; 
PNS / level ="66 % / normal"; 
dB/dt =  "37.6 T/s"; 
Sound Pressure Level (dB) =
 0; 
 
PlanScan metabolite = 
 "NAA"; 
Shifted metabolite displayed =
 "Lactate/Lipid"; 
Preset window contrast =
 "soft"; 
Save raw data =  
 "yes"; 
Hardcopy protocol = 
 "no"; 
Elliptical k-space shutter =
 "default"; 
IF_info_seperator = 
 1634755923; 
Total scan duration = 
 "30:36.0"; 
Act. TR/TE (ms) = 
 "6000 / 30"; 
Min. TR/TE (ms) = 
 "3696 / 28"; 
Series TE (ms) =   
   
 "30/100/200/400/800/1
200/1600/2000/3000"; 
Spectral resolution (Hz/point) =
 1.953125; 
Readout duration (ms) = 
 512; 
SAR / head =  
 "<  3 %"; 
Whole body / level = 
 "0.0 W/kg / normal"; 
SED =   
 "  0.0 kJ/kg"; 
B1+rms / Coil Power = 
 "0.37 uT / 3 %"; 
Max B1+rms =  
 "0.37 uT"; 
PNS / level =  
 "66 % / normal"; 
dB/dt =   
 "37.6 T/s"; 
Sound Pressure Level (dB) =
 0; 
 
PlanScan metabolite = 
 "Lactate/Lipid"; 
Shifted metabolite displayed =
 "NAA"; 
Preset window contrast =
 "soft"; 
Save raw data =  
 "yes"; 
Hardcopy protocol = 
 "no"; 
Elliptical k-space shutter =
 "default"; 
Total scan duration = 
 "30:36.0"; 
Act. TR/TE (ms) = 
 "6000 / 29"; 
Min. TR/TE (ms) = 
 "3576 / 28"; 
Series TE (ms) =   
   
 "29/288/576/864/1152/
1440/1728/2304/2880"; 
Spectral resolution (Hz/point) =
 1.953125; 
Readout duration (ms) = 
 512; 
SAR / head =  
 "<  3 %"; 
Whole body / level = 
 "0.0 W/kg / normal"; 
SED =   
 "  0.0 kJ/kg"; 
B1+rms / Coil Power = 
 "0.37 uT / 3 %"; 
Max B1+rms =  
 "0.37 uT"; 
PNS / level =  
 "66 % / normal"; 
dB/dt =   
 "37.6 T/s"; 
Sound Pressure Level (dB) =
 0; 
 
 
 
 
Appendix 4 
 
SEQUENCES PARAMETERS FOR METABOLITES QUANTITATION 
OF SIEMENS PHANTOM AT MEYER 
 
Table 1: PRESS sequences for quantitation of metabolites in the Siemens phantom. 
Water  Metabolites 
Data file name: DBIEX_6_2_RAW_act.sdat 
SmartSelect =   "yes"; 
Coil 1  (exclude) =  "None"; 
VOI orientation =  "transverse"; 
VOI size AP (mm) =  20; 
         RL (mm) =  20; 
         FH (mm) =  20; 
Samples =   1024; 
Spectral BW (Hz) =  2000; 
VOI offc. AP (P=+mm) =  -5; 
          RL (L=+mm) = 0; 
          FH (H=+mm) =  10; 
VOI ang. AP (deg) =  0; 
         RL (deg) =  -0; 
         FH (deg) =  -0; 
Chem. shift Dir AP =  "A"; 
Chem. shift Dir LR =  "L"; 
Chem. shift Dir FH =  "F"; 
Large table movement =  "no"; 
REST slabs =   0; 
Patient position =  "head first"; 
        orientation =  "supine"; 
Scan type =   "Spectroscopy"; 
Scan mode =   "SV"; 
    technique =   "ECHO"; 
VOI selection =   "volume"; 
    method =   "PRESS"; 
Gradient Spoiling =  "no"; 
Fast Imaging mode =  "none"; 
Echo acquisition =  "half"; 
TE =    "user defined"; 
    (ms) =   35; 
Flip angle (deg) =  90; 
RF pulse set =   "normal"; 
TR =    "user defined"; 
    (ms) =   4000; 
RF Shims =   "fixed"; 
Shim =    "PB-auto"; 
    PB order =   "second"; 
Water suppression =  "no"; 
BASING pulse =   "no"; 
Fat suppression =  "no"; 
Research prepulse =  "no"; 
Pre-saturation =  "no"; 
Multi-transmit =  "yes"; 
Transmit channels =  "both"; 
SAR mode =   "high"; 
B1 mode =   "default"; 
SAR Patient data =  "auto"; 
PNS mode =   "low"; 
Gradient mode =   "default"; 
SofTone mode =   "no"; 
Cardiac synchronization = "no"; 
Respiratory compensation = "no"; 
Startup acquisitions =  2; 
NSA =    16; 
Phase cycles =   16; 
Frequency stabilization = "yes"; 
Parameter series =  "no"; 
Manual start =   "no"; 
Dynamic study =   "no"; 
Arterial Spin labeling = "no"; 
Preparation phases =  "full"; 
Data file name: DBIEX_7_2_RAW_act.sdat 
SmartSelect =   "yes"; 
Coil 1  (exclude) =  "None"; 
VOI orientation =  "transverse"; 
VOI size AP (mm) =  20; 
         RL (mm) =  20; 
         FH (mm) =  20; 
Samples =   1024; 
Spectral BW (Hz) =  2000; 
VOI offc. AP (P=+mm) =  -5; 
          RL (L=+mm) = 0; 
          FH (H=+mm) =  10; 
VOI ang. AP (deg) =  0; 
         RL (deg) =  -0; 
         FH (deg) =  -0; 
Chem. shift Dir AP =  "A"; 
Chem. shift Dir LR =  "L"; 
Chem. shift Dir FH =  "F"; 
Large table movement =  "no"; 
REST slabs =   0; 
Patient position =  "head first"; 
        orientation =  "supine"; 
Scan type =   "Spectroscopy"; 
Scan mode =   "SV"; 
    technique =   "ECHO"; 
VOI selection =   "volume"; 
    method =   "PRESS"; 
Gradient Spoiling =  "no"; 
Fast Imaging mode =  "none"; 
Echo acquisition =  "half"; 
TE =    "user defined"; 
    (ms) =   35; 
Flip angle (deg) =  90; 
RF pulse set =   "normal"; 
TR =    "user defined"; 
    (ms) =   4000; 
RF Shims =   "fixed"; 
Shim =    "PB-auto"; 
    PB order =   "second"; 
Water suppression =  "excitation"; 
    window (Hz) =  140; 
    second pulse angle = 300; 
WS prescan =   "auto"; 
BASING pulse =   "no"; 
Fat suppression =  "no"; 
Research prepulse =  "no"; 
Pre-saturation =  "no"; 
Multi-transmit =  "yes"; 
Transmit channels =  "both"; 
SAR mode =   "high"; 
B1 mode =   "default"; 
SAR Patient data =  "auto"; 
PNS mode =   "low"; 
Gradient mode =   "default"; 
SofTone mode =   "no"; 
Cardiac synchronization = "no"; 
Respiratory compensation = "no"; 
Startup acquisitions =  2; 
NSA =    16; 
Phase cycles =   16; 
Frequency stabilization = "yes"; 
Parameter series =  "no"; 
Manual start =   "no"; 
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Interactive F0 =  "no"; 
Receiver optimization =  "OFF"; 
Receiver attenuation =  8; 
Spectral correction =  "yes"; 
    spectral correction NSA = 16; 
    fat supp. on correction = "no"; 
Reference tissue =  "White matter"; 
PlanScan metabolite =  "H20"; 
Shifted metabolite displayed = "NAA"; 
Preset window contrast = "soft"; 
Save raw data =   "yes"; 
Hardcopy protocol =  "no"; 
Elliptical k-space shutter = "default"; 
IF_info_seperator =  1634755923; 
Total scan duration =  "02:16.0"; 
Act. TR/TE (ms) =  "4000 / 35"; 
Min. TR/TE (ms) =  "571 / 34"; 
Spectral resolution (Hz/point) = 1.953125; 
Readout duration (ms) =  512; 
SAR / head =   "<  4 %"; 
Whole body / level =  "0.0 W/kg / normal"; 
SED =    "  0.0 kJ/kg"; 
B1+rms / Coil Power =  "0.45 uT / 4 %"; 
Max B1+rms =   "0.45 uT"; 
PNS / level =   "33 % / normal"; 
dB/dt =    "17.0 T/s"; 
Sound Pressure Level (dB) = 0; 
Dynamic study =   "no"; 
Arterial Spin labeling = "no"; 
Preparation phases =  "full"; 
Interactive F0 =  "no"; 
Receiver optimization =  "OFF"; 
Receiver attenuation =  8; 
Spectral correction =  "yes"; 
    spectral correction NSA = 16; 
    fat supp. on correction = "no"; 
Reference tissue =  "White matter"; 
PlanScan metabolite =  "NAA"; 
Shifted metabolite displayed = "H20"; 
Preset window contrast = "soft"; 
Save raw data =   "yes"; 
Hardcopy protocol =  "no"; 
Elliptical k-space shutter = "default"; 
IF_info_seperator =  1634755923; 
Total scan duration =  "02:16.0"; 
Act. TR/TE (ms) =  "4000 / 35"; 
Min. TR/TE (ms) =  "731 / 34"; 
Spectral resolution (Hz/point) = 1.953125; 
Readout duration (ms) =  512; 
SAR / head =   "<  4 %"; 
Whole body / level =  "0.0 W/kg / normal"; 
SED =    "  0.0 kJ/kg"; 
B1+rms / Coil Power =  "0.46 uT / 4 %"; 
Max B1+rms =   "0.46 uT"; 
PNS / level =   "33 % / normal"; 
dB/dt =    "17.0 T/s"; 
Sound Pressure Level (dB) = 0; 
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